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Abstract 
 
Coronaviruses are enveloped, positive sense, RNA viruses that infect many 
species of animals, including humans. Of the six coronaviruses that can infect 
humans, SARS-CoV and MERS-CoV are the etiological agents of most concern 
currently. Coronaviruses possess the most complex and largest RNA genomes 
among all RNA viruses. The genome contains up to 15 genes with multiple open 
reading frames (ORFs) encoding both structural and non-structural proteins. 
Coronaviruses encode about 30 proteins that play specific, and often essential, 
roles in viral replication and assembly.  
 
This thesis presents work done to express Murine hepatitis virus strain A59 (MHV-
A59) proteins such as Nucleoprotein and membrane genes, non-structural proteins 
(5,6,7,8,9,10,16) from gene1, part of non-structural proteins (Plpro, Y-domain from 
nsp3 and N-terminal from nsp12) and RdRp from C-terminal part of nsp12 in E. coli 
BL21 cells and mammalian 17clone-1 cells, the latter of which are permissive for 
MHV-A59. The efficiency of transfection and expression of the proteins in 
mammalian cells was evaluated. SUMOStar (small ubiquitin-like modifier) fusion 
technology was used to enhance protein expression in the eukaryotic system. 
Expressed proteins were detected by Western blot with an anti-His tag antibody. 
The ability of virus-expressed proteins to interfere with virus infection was tested 
and an inhibitory effect was detected by plaque assay.  
 
The coronavirus nucleoprotein (N) is an important component for both viral 
replication and transcription. Error-prone PCR (ep-PCR) was used with the N 
protein as template to introduce random error and the number of mutations 
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introduced was calculated after 100 random colonies were sequenced to validate 
the mutagenesis. Transient expression of N protein was shown to increase the 
efficiency of infection and virus yield.  The function of N was investigated by 
screening for dominant-negative N mutants, using a library of N variants 
constructed using ep-PCR. The cytotoxicity of N variants was tested by MTT 
assay. Expressed N variants showed a range of effects ranging from a 10-fold 
increase in virus yield associated with the wild type N to 10-fold inhibition of virus 
growth. One particular N variant, mut38, was non-toxic, but reproducibly inhibited 
virus growth.  The potential to screen for dominant-negative N variants using cell 
survival was also assessed using different N libraries. The thesis also investigated 
different strategies aimed at purification of non-structural protein 16 (nsp16). The 
overall findings suggest an ability of virus-expressed proteins in eukaryotic cells to 
interfere with virus infection and demonstrate that such antiviral activity can be 
generated by mutating an important viral protein. 
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1 Introduction 
1.1 Coronaviruses 
 
Coronaviruses are a group of important pathogens that infect both humans and a 
variety of domesticated animals. Infections caused by this group have resulted in 
significant economic losses for the domestic animal industry worldwide and has 
recently threatened human health with multiple outbreaks, becoming potentially 
pandemic. Coronaviruses have been studied since the 1930’s; the first described 
virus was called avian infectious bronchitis virus (IBV) followed by murine hepatitis 
virus (MHV) and transmissible gastroenteritis virus (TGEV) (Beaudette and 
Hudson, 1937; Doyle and Hutchings, 1946; JB, 1949; Schalk and Hawn, 1931). 
However, the relationships between these viruses was not clearly realized until the 
1960’s when the human coronaviruses HCoV-229E and HCoV-OC43 were 
described (Hamre and Procknow, 1966). All of these viruses possessed a distinct 
morphology of a crown-like appearance and so were called coronaviruses (Tyrell et 
al., 1968). Coronaviruses (CoVs) may infect and cause diseases in a wide variety 
of animals, including bats, birds, cats, dogs, pigs, mice, horses and whales in 
addition to humans (De Groot,RJ et al., 2012). They can cause respiratory, enteric, 
hepatic, and neurological diseases with highly variable severity and cause acute or 
persistent infections.  
The first human coronavirus epidemic occurred in 2003 with the outbreak of severe 
acute respiratory syndrome (SARS) caused by SARS-CoV (Marra et al., 2003; 
Rota et al., 2003). Then, in 2012 a novel coronavirus emerged in the Middle East 
(Zaki et al., 2012). The novel Middle East Respiratory Syndrome coronavirus 
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(MERS-CoV) causes severe pneumonia as well as renal failure, with a high fatality 
rate.  
Over the past ten years significant effort has resulted in the discovery of new 
additional human coronaviruses such as HCoV-NL63 and HCoV-HKU1 (van der 
Hoek et al., 2004; Woo et al., 2005b) and in the development of effective therapies 
by both the academic sector and pharmaceutical industries. Despite this and 
although more than 10 years have passed since the SARS-CoV outbreak, there 
are presently still no available approved vaccines or antiviral drugs for human 
coronavirus infection. Therefore, revealing any undiscovered aspects of the 
coronavirus genome and it’s replication might help improve our understanding of 
the role of each gene and suggest useful antiviral drug targets. 
1.2 Taxonomy 
 
Coronaviruses are a group of enveloped complex ssRNA viruses that belong to the 
order Nidovirales. The order Nidovirales is a large group of RNA viruses that 
posses the largest genomes known to date. The phylogenetic analysis of nidovirus 
members shows a great genetic distance, which is almost equivalent to that of the 
archaea, eubacteria and eukaryote combined Figure 1.1, and due to the extremely 
high mutation rates and lack of fossil records this group remains difficult to study. 
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Figure 1.1. Phylogeny of nidoviruses in comparison to the Tree of life (ToL). 
Bayesian phylogenies of nidoviruses (A) and ToL (B) are drawn to a common scale of 0.1 
amino acid substitutions per position. Major lineages are indicated by vertical bars and 
names; arteri: Arteriviridae, mesoni: Mesoniviridae, roni: Roniviridae, toro: Torovirinae, 
corona: Coronavirinae. Rooting was according to either (A) domain- specific outgroups 
(Nga et al., 2011) or (B) as described (Boussau et al., 2008). A common normalized scale 
of (0,1) is used. Posterior probability support values and fixed basal branch points (*) are 
indicated. The nidovirus and ToL alignments include, respectively, three enzymes and 56 
single-gene protein families, 604 and 3336 columns, 2.95% and 2.8% gaps. Taken from 
(Lauber et al., 2013). 	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Nidoviruses are named for their eminent feature of a set of multiple 3’-nested 
subgenomic RNAs (nidus = nest). Nidoviruses possess a linear 5'-capped positive 
sense single stranded, non-segmented RNA with two large open reading frames 
(ORFs) 1a and 1b located at the 5’-end of the genome. The order historically 
included three families, which are coronaviridae, roniviridae and arteriviridae, the 
first two families with large genome size (26.3-31.3 kb) and the third one with 
smaller genome sizes (12.7-15.7 kb) (De Groot,RJ et al., 2012). Recently a fourth 
family Mesonviridae joined the previous three families with an intermediate genome 
size between those of the coronaviridae and arteriviridae (Gorbalenya et al., 2006; 
Lauber et al., 2012; Nauwynck et al., 2012). Coronavirinae and torovirinae are two 
subfamilies of coronaviridae. Until a few years ago the coronavirinae family was 
divided into three groups (I, II and III) based on genotypic and serological 
differences. However these groups have since been elevated to genus level and 
named alphacoronavirus, betacoronavirus and gammacoronavirus, which 
respectively represent groups I, II and III (Gonzalez et al., 2003) and a new genus, 
deltacoronavirus, was added recently (King et al., 2011). The genus 
alphacoronavirus is further separated into a and b clades while betacoronavirus are 
subdivided into clades a to d. The alphacoronavirus genus is exclusively found in 
mammalian hosts, and includes the human pathogens HCoV-229E and HCoV-
NL63, in addition to porcine Epidemic Diarrhea Virus (PEDV) and Transmissible 
Gastroenteritis Virus (TGEV) in pigs Figure 1.2. 
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Figure 1.2. Schematic representation of the taxonomy of coronaviridae according 
to the International Committee on Taxonomy of Viruses. Human coronavirus-NL63 
(HCoV-NL63), Human coronavirus-229E (HCoV-229E), Murine hepatitis virus (MHV), 
Severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), 
Avian infectious bronchitis virus (IBV), Bulbul coronavirus HKU11 (HKU11). 
 
 
 
Betacoronaviruses are also associated exclusively with mammalian hosts.  
Examples of pathogenic betacoronaviruses include the human pathogen HCoV-
OC43, murine hepatitis virus (MHV) and SARS-CoV, which causes severe acute 
respiratory syndrome. Intensive studies led to the finding of several more novel 
coronavirus in human and animals after the 2003 SARS-CoV epidemic outbreak 
(Poon et al., 2005). New studies indicate that bats are the natural reservoirs of 
these two genera and suggest that bats are likely to play an important role in the 
introduction of coronaviruses to other species as well as the evolution and 
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dissemination of coronaviruses (Tong et al., 2009). Conversely, the majority of 
gammacoronavirus are isolated from birds such as Infectious Bronchitis Virus (IBV) 
in chickens and Grey Goose coronavirus (GCoV) in geese. A new genus, 
deltacoronavirus, was detected in pigs and birds, and includes Bulbul coronavirus 
HKU11, Thrush coronavirus HKU12 and Munia coronavirus HKU13 (Chu et al., 
2011). Both gammacoronavirus and deltacoronavirus reservoirs are birds (Woo et 
al., 2012). 
1.3 Morphology 
 
The virion of coronavirus is spherical or pleomorphic, approximately 50-150nm in 
diameter (Neuman, 2008). The virion membrane as shown in Figure 1.3 contains 
three viral proteins, the spike protein (S) which gives the virus it’s crown shape 
under the electron microscope and plays a role in viral attachment to the cell and 
the subsequent fusion process, the membrane protein (M) with multi spanning 
membrane domains, large carboxy terminus and small amino terminus, and the 
envelope protein (E) with highly hydrophobic amino and carboxy-terminal regions 
(Bond et al., 1979). Both E protein and M proteins are involved in the virus 
assembly process (Hsieh et al., 2005). Some coronaviruses from the 
betacoronavirus group also contain a hemagglutinin esterase (HE) protein on the 
virion surface that may serve as another protein for binding or release from the 
host cell. Moreover, SARS-CoV contains accessory proteins such as 3a, 6 and 7a, 
that are involved in cellular processes or modulating virus-host interactions 
(McBride and Fielding, 2012). Inside the virion there is a helical nucleocapsid that 
contains the largest known viral RNA genome associated with the nucleoprotein 
(N) (Lai and Anderson, 2007). 
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Figure 1.3. (A) Electron microscopy image of coronavirus. Adapted from (Davies and 
Macnaughton, 1979). (B) Schematic diagram of a coronavirus particle. The viral RNA 
is associated with the nucleocapsid protein (N). The lipid bilayer includes the spike protein 
(S), the membrane protein (M) and the envelope protein (E) (Figure is adapted from 
(Stadler et al., 2003)). 
 
1.4 Coronavirus life cycle 
 
The first step of the coronavirus life cycle starts by interaction of the spike protein 
with a specific receptor on the host cell surface. There are different receptors 
across the coronavirus family: carcinoembryonic antigen 1 (CEACAM1) for MHV 
(Tan et al., 2002), human angiotensin converting enzyme 2 (hACE2) for SARS-
CoV (Li, 2013) and NL63 (Glowacka et al., 2010; Wu et al., 2009), dipeptidyl 
peptidase 4 (DPP4) for MERS-CoV (Wang et al., 2013) and aminopeptidase N 
(APN) for TGEV (Shahwan et al., 2013). After attachment and uptake into a 
vesicle, a major conformational change occurs in the spike protein (S) (Gallagher 
and Buchmeier, 2001). The spike glycoprotein typically can be divided into the S1 
domain (the amino-proximal half), which contains the receptor-binding domain and 
the S2 domain (the carboxyl- proximal half), which contains elements involved in 
membrane fusion (Heald-Sargent & Gallagher, 2012). The two domains are 
cleaved from each other by the activity of a cellular furin-like enzyme (de Haan et 
A B 
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al., 2004). Like most RNA viruses, coronaviruses replicate in the cytoplasm of an 
infected cell. Once the genome has entered the cytoplasm it serves as an mRNA 
since it has a 5’-methyl cap structure and a polyadenylated tail, which mimics 
mRNAs of eukaryotes. Two thirds of the genome at the 5’ end is occupied by the 
two large open reading frames (ORFs 1a and 1b) which together encode the 
replicase gene while the rest of the genome encodes structural and accessory 
genes in the 3’ one-third. A frame shift region in the replicase gene connects 
ORF1a and ORF1b and will direct the expression of ORF1b to facilitate the 
formation of an ORF1ab polyprotein (pp1ab) (Bredenbeek et al., 1990; Brian and 
Baric, 2005; Brierley and Dos Ramos, 2006) Figure 1.4. 
 
 
Figure 1.4. A schematic representation of MHV-A59 genome organization and 
expression. Replicase components are processed from two forms of polyprotein 
translated from the genomic RNA into non-structural proteins (nsp1- nsp16) by 
autoproteolytic processing. Nested sets of positive sense sub-genomic sized mRNAs are 
translated by host ribosomes into viral structural (S, E, M, N) and accessory proteins. 
Figure adapted from (Sawicki et al., 2005). 
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After translation, the papain-like protease(s) (PlPro) and main protease (MPro) 
proteins, which are encoded in ORF1ab, cleave the replicase polyprotein into 15 to 
16 non-structural proteins (nsps) (Woo et al., 2007, 2005a). The non-structural 
proteins are anchored onto double membrane vesicles (DMVs) to make up the bulk 
of the replication/transcription complex (RTC) and this is the site where all events 
for virus transcription/replication take place (Brockway et al., 2003; Gosert et al., 
2002; Snijder et al., 2006). A full-length negative-stranded RNA intermediate 
serves as template for the synthesis of more full-length positive sense RNA 
(Sawicki et al., 2007). While not completely understood, subgenomic mRNA 
synthesis in the nidovirales involves a unique discontinuous transcription 
mechanism which produces a 3’ co-terminal nested set of mRNAs (La Monica et 
al., 1992). The mRNA synthesis is regulated by transcription-regulating sequences 
(TRSs) present in the genomic RNA upstream of most open reading frames (La 
Monica et al., 1992). Both new copies of the complete genome and sub-genomic 
mRNA species, which are synthesized from the negative strand RNA intermediate 
later, are translated into structural and accessory proteins. After translation of the 
structural proteins, the N protein wraps the genomic RNA to form the nucleocapsid 
(a helical structure). All structural proteins, and the HE protein in some species, are 
located in the endoplasmic reticulum (ER) and aggregate with the nucleocapsid in 
the endoplasmic reticulum Golgi intermediate compartment (ERGIC) for virion 
assembly, which is driven by M and E proteins (Hsieh et al., 2005; Neuman et al., 
2011; Tseng et al., 2005). Later, virions are released extracellularly either from the 
basolateral and apical surfaces for MHV (Rossen et al., 1996) or from the apical 
surface of the host cell for TGEV and SARS-CoV (Rossen et al., 1994; Tseng et 
al., 2005) Figure 1.5.  
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Figure 1.5. Life cycle of SARS-CoV. First spike protein binds to the specific receptor 
(ACE2) to form ACE2-virus complex. Then the complex is translocated to endosomes in 
which S protein is cleaved by the endosomal acid protease (cathepsin L) for activation of 
it’s fusion activity. The viral genome is released inside the cell, and then replicase gene is 
translated to polyproteins pp 1a and 1ab, which is cleaved into small products by viral 
proteinases. Subgenomic negative-strand templates are synthesized from discontinuous 
transcription on the plus-strand genome and act as templates for mRNA synthesis to 
produce negative-sens RNA and subgenomic RNAs. Nucleocapsid is assembled from 
genomic RNA and N protein in the cytoplasm. The structural proteins S, E, M are 
translated and inserted in the endoplasmic reticulum (ER) to meet nuclecapsid in the 
endoplasmic reticulum (ER)-Golgi intermediate compartment ERGIC. Virions are released 
from the cell by exocytosis. Figure adapted from (Du et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   30 
1.5 Coronavirus genome 
 
Coronaviruses possess the largest and most complex RNA genome among all 
RNA viruses ranging from 26.4 kb - 31.7 kb (Woo et al., 2009). The genome 
contains up to 15 genes with multiple open reading frames (ORFs) encoding both 
structural and non-structural proteins (Sawicki et al., 2005; Ziebuhr, 2005). The 
RNA genome comprises a 5’ leader sequence (60-80 nucleotides), followed by an 
un-translated region (UTR) (200-600 nucleotides). The first gene (replicase) 
comprises two-thirds of the genome with the two large ORFs (ORF 1a and ORF 
1b) translated to give polyprotein 1a and polyprotein 1ab, the latter via a frameshift 
mechanism. Despite it’s positive strand nature the replicase is the only translated 
product derived from the genome. The last third of the genome is occupied by 
genes for structural proteins with the order S-E-M-N, all of which are expressed 
following the production of several subgenomic RNAs. Between these genes there 
are a variable numbers of ORFs encoding accessory proteins (Sawicki et al., 
2007). The transcriptional regulatory sequences (TRSs) that are present at the 3’ 
end of each gene represent a signal for subgenomic RNA transcription of the 
following gene. At the 3’ end of the genome, there are 270-500 nucleotides of UTR 
followed by the poly A tail Figure 1.6.  
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Figure 1.6. Coronavirus genome organization. ORF1a and ORF1b are located at the 5’ 
two thirds and encode two polyproteins, namely pp1a and pp1ab which include 16 
nonstructural proteins (nsp1 to nsp16) contain ubiquitin-like (Ub1), hypervariable region 
(HVR), papain-like protease (Pl1pro), ADP-ribose 1″ phosphatase (ADRP), papain-like 
protease (Plpro2) Y-domain, 3C-like main proteinase (MPro), single-strand RNA binding 
protein (ssRDP), RNA-dependent RNA polymerase (RDRP), replicase, exonuclease 
(ExoN), N7 methyltransferase (NMT), endoribonuclease (Endo), 2′-O-methyltransferase 
(2′-O-MTase). The first 3 non-structural proteins are cleaved by viral papin-like 
proteinase(s) (PLpro), the other 13 non-structural proteins are cleaved by the 3C-like main 
proteinase (MPro). The four structural proteins are coded by the remaining one third of the 
genome in coronaviruses and include the spike (S) protein, envelope (E) protein, 
membrane (M) protein, nuclepcapsid (N) protein and HE (hemagglutinin) is found on some 
betacoronaviruses. 
 
1.5.1 Non structural proteins 
 
The nonstructural proteins required for the replication/transcription complex (RTC) 
are encoded by the replicase gene, which is expressed from two overlapping 
ORFs. The first three non structural proteins in ORF1a are released by cleavage by 
a viral papin-like proteinase(s) (Plpro) while the 3C-like main proteinase (Mpro) 
cleaves 11 sites in polyprotein 1ab to release 13 non-structural proteins (Denison 
et al., 1992; Namy et al., 2006; Prentice et al., 2004; Snijder et al., 2003; Ziebuhr et 
al., 2000). The second ORF, 1b, is translated via a ribosomal frameshift signal 
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which is stimulated by a slippery sequence (UUUAAAC) and a pseudoknot 
structure, resulting in higher levels of the truncated ORF1a product relative to the 
larger protein 1ab which contains 5 additional non-structural proteins (nsp12-
nsp16) (Subissi et al., 2014). ORF1a includes the viral proteinase, anti-host 
activities, membrane-anchoring domains, RNA-binding and RNA-modifying 
activities while ORF1b encodes enzymes required in RNA replication, transcription, 
proofreading and capping (Decroly et al., 2008). 
The first region (ORF1a) of the replicase gene encodes non-structural proteins 
(nsp) 1-11. The first mature protein released is nsp1. This protein is ~110 residues 
in betacoronaviruses and can be used as a group specific marker due to it’s high 
sequence variability and the absence of nsp1 in both gammacoronaviruses and 
deltacoronaviruses. Nsp1 has been reported to inhibit host gene expression most 
likely by promoting host mRNA degradation as described for SARS-CoV (Kamitani 
et al., 2006; Narayanan et al., 2008; Züst et al., 2007), it also prevents type I 
interferon production in infected cells (Wathelet et al., 2007). The nsp2 possesses 
a highly divergent sequence across the coronaviruses and it’s function remains 
unknown. Nsp3 is the largest coronavirus-encoded protein. It is a glycosylated, 
transmembrane, multidomain protein that interacts with several proteins involved in 
the replication and transcription processes (Barretto et al., 2005; Imbert et al., 
2008; Kanjanahaluethai et al., 2007; Neuman et al., 2008; von Brunn et al., 2007). 
Nsp3 proteins in coronavirus contain 10-16 domains (Neuman, 2016). Some of the 
nsp3 domains are duplicated and are conserved in all coronaviruses. The N-
terminal region of nsp3 contains ubiquitin (Ub1), a hypervariable region (HVR) and 
a papain-like protease (PLP) domain PL1Pro
 
(Neuman, 2016). In MHV, Ub1 initiates 
viral RNA synthesis by interacting with the N protein (Hurst et al., 2013; Hurst-Hess 
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et al., 2015) while PL1Pro is responsible for the 3 cleavage sites at the N-terminal 
sites in the replicase to release nsp1, nsp2 and nsp3 respectively. However, there 
are different mechanisms of processing in different coronaviruses (Gadlage and 
Denison, 2010; Ziebuhr et al., 2007). In some cases one PLP is sufficient while in 
others two active PLP may have specialized or overlapping functions (Baker et al., 
1993; Bonilla et al., 1997; Graham and Denison, 2006). The ADRP like domain is a 
conserved domain in coronavirus and is associated with proteins involved in ADP-
ribosylation or poly (ADP-ribose) polymerization and ATP-dependent chromatin re-
modeling (Egloff et al., 2004; Saikatendu et al., 2005). Many coronaviruses encode 
two papain-like proteases, however SARS-CoV has only a single copy of a papain-
like cysteine protease (PL2
pro
), which cleaves polyprotein 1a at three sites to 
release the three non-structural proteins (Harcourt et al., 2004; Thiel et al., 2003). 
The Y domain at the C-terminus of nsp3 is highly conserved in all coronaviruses, 
but the function of this domain is unclear (Neuman et al., 2008). Nsp4 is about 500 
amino acids in length, contains four transmembrane helices and a carboxy-terminal 
domain (Oostra et al., 2008). This protein is fundamental for cytoplasmic 
membrane modification with the assistance of nsp3 and nsp6 (Angelini et al., 
2013). Nsp5 is the 3C-like main protease (Mpro) which has a three-domain structure 
that mediates maturation cleavages of nsp4 to nsp16 (Perlman and Netland, 2009; 
Ziebuhr et al., 2000). Nsp6 is involved in the activation of autophagy which induces 
vesicles that contain Atg5 and LC3-II (Cottam et al., 2011). LC3 is present in the 
cell in a cytoplasmic form (LC3-I) that is converted into an active lipidated form 
(LC3-II) by specific covalent linkage upon autophagy induction (Mizushima et al., 
2004). The conversion of LC3-I into LC3-II requires several proteins including Atg5 
(Mizushima et al., 2001; Yoshimori and Noda, 2008) and Atg7 (Komatsu et al., 
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2005). Furthermore, nsp6 interacts with other proteins such as nsp2, nsp3, nsp4, 
nsp8 and nsp9 (Krogh et al., 2001; von Brunn et al., 2007). In SARS-CoV, the 
crystal structure of the nsp7 (12kDa) and nsp8 (22-kDa) complex revealed a 
hollow, cylindrical hexadecamer composed of eight copies of nsp7 and eight copies 
of nsp8. This complex might provide a platform which improves the processivity of 
RNA synthesis by nsp12 and the increased binding of nsp12 to RNA (Zhai et al., 
2005). However the role of nsp8 is not yet clear despite some studies indicating 
that nsp8 may act as an RNA primase for nsp12 in SARS-CoV, since it 
polymerizes small oligomers via it’s C-terminal domain, similar to those that can 
bind the palm subdomain of RNA dependent RNA polymerase (RdRp) (Subissi et 
al., 2014). Nsp9 is possibly involved in binding single stranded RNA as part of the 
viral replication complex as well as other proteins required for this complex (Sutton 
et al., 2004).  
Nsp10 represents a novel fold that consists of a pair of antiparallel N-terminal 
helices, ß-strand, a loop at C-terminus, and two zinc fingers (Krishna et al., 2003). 
Studies proposed that nsp10 might play important roles in the synthesis of the viral 
RNA and in polyprotein processing through interaction with the nsp5 (Donaldson et 
al., 2007). Recently, studies proposed that it may act as a co-factor for nsp16 2`-O-
Meythyltransferase activity for the regulation of viral RNA capping (Bouvet et al., 
2010) and/or enhancing ExoN activity by interaction with nsp14 (Bouvet et al., 
2012; Chen et al., 2011; Decroly et al., 2011). Nsp10 is followed by nsp11, a short 
peptide of highly variable sequence that is not conserved in different coronavirus 
genomes (Neuman et al., 2014). Nsp11 of SARS-CoV is attached to nsp10 but 
appears not to cause a significant difference in the core nsp10 structure (Su et al., 
2006) and there is no indication of nsp11 interaction with nsp10 or any other 
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protein.  
The second region of gene1 (ORF1b) encodes non-structural proteins 12-16. 
Nsp12 is about 102 kDa (932 amino acid residues), and is the most conserved 
protein in coronavirus, produced by Mpro (nsp5) action to result in pp1ab cleavage. 
The C-terminal domain of nsp12 contains the canonical RNA-dependent RNA 
polymerase (RdRp) motifs. RdRp is the core catalytic subunit that synthesizes 
negative strand RNA, new genome molecules and subgenomic messenger RNAs 
(mRNA) in many groups of RNA viruses (Ahlquist et al., 2003; Miller and Koev, 
2000). Nsp12 therefore plays a key role in the viral replication/transcription 
complex. This enzyme carries a conserved active site (Ser-Asp-Asp - motif C) that 
is conserved in all nidovirales. Another motif, G, has a SXGXP conserved 
sequence and is consistently followed by a conserved basic residue (Gorbalenya et 
al., 2002). Motif G in SARS-CoV RdRp has also been shown to initiate RNA 
synthesis in a primer-dependent manner (te Velthuis et al., 2010). Several studies 
have shown a validated direct interaction between nsp8 and nsp12 (Imbert et al., 
2006; von Brunn et al., 2007), while new studies indicate that nsp7/nsp8 
complexes increase binding of nsp12 to RNA as a result of a major increase in the 
number of nucleotides synthesized per binding event. Nsp8 carries a second, non-
canonical RdRp activity (Imbert et al., 2006; te Velthuis et al., 2012; Xiao et al., 
2012). The ability of nsp8 to polymerize small oligomers in a sequence-specific 
manner suggests it acts as an RNA primase for nsp12. The interaction of RdRp 
with other viral proteins could be either directly or indirectly. Taken together, these 
data suggest nsp12 as a good candidate for the development of an antiviral drug. 
Nsp13 (66.5kDa) is a multi-functional protein that contains a zinc-binding domain at 
the amino-terminus and a helicase at the carboxy-terminus (Gorbalenya et al., 
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1989) and unwinds both dsDNA and dsRNA in a 5’ to 3’ direction (Ivanov and 
Ziebuhr, 2004; Ivanov et al., 2004a; Lee et al., 2010; Tanner et al., 2003). This 
protein is essential for viral replication (Fang et al., 2007) and the presence of 
nsp12 stimulates helicase activity (2-fold) through the direct interaction of both 
proteins (Adedeji et al., 2012). Nsp13 has been also shown to exhibit RNA 
triphosphatase (TPase) activity in vitro and may be involved in the RNA capping 
reaction (Ivanov and Ziebuhr, 2004; Ivanov et al., 2004b), however, this proposed 
role requires further experimental evidence. Nsp14 is a N-terminal 3’-
5’exonuclease domain (ExoN) which is unique to nidoviruses (Minskaia et al., 
2006). This enzyme is capable of hydrolyzing single-stranded and double-stranded 
RNAs to final products of 8-12 and 5-7 nucleotides respectively and acts as a 
proofreading system that is involved in improving the fidelity of the large 
coronavirus genome during replication (Lauber et al., 2013). Furthermore, the 
presence of nsp10 was found to stimulate the activity of nsp14 in vitro by more 
than 35-fold (Bouvet et al., 2012) in a reaction which appears to be dsRNA-specific 
and is able to excise one 3´ mismatched nucleotide, mimicking a polymerase-
mediated misincorporation product, which strongly indicates a role for the 5’-
exonuclease activity in RNA synthesis proofreading. The nsp15 is a uridine-specific 
endoribonuclease (Snijder et al., 2003) and forms a hexamer (Guarino et al., 2005; 
Ricagno et al., 2006) with the active site at the C-terminus. Neither the exact 
function of nsp15 in viral replication nor the stimulating effect of Mn2+ on nsp15 
activity is well understood. Finally, nsp16 is a 2´-O-methyltransferase (Chen et al., 
2011; Decroly et al., 2008) that plays a key role in the coronavirus life cycle by 
preventing virus detection by the cell innate sensing mechanisms. In MERS-CoV, 
2′O-methyltransferase is an S-adenosyl-L-methionine (SAM)-dependent 2′-O-
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methyltransferase (2′-O-MTase) which is stimulated by nsp10 which acts as an 
allosteric activator of the nsp16 2′-O-methyltransferase activity (Aouadi et al., 
2017a). This protein is expected to be involved in the final step in cap synthesis by 
adding the final methyl group to complete the cap structure (Bouvet et al., 2010; 
Chen et al., 2011). The cap structure is a distinct feature of eukaryotic mRNAs, 
essential for it’s translation and stability (Cougot et al., 2004; Furuichi and Shatkin, 
2000; Lewis and Izaurflde, 1997; Schwer et al., 1998). Uncapped virus RNAs may 
be detected as ‘non-self’ by the host cell, triggering an antiviral innate immune 
response through the production of interferons (Züst et al., 2011). Therefore, many 
viruses that replicate in the cytoplasm of eukaryotes have evolved the means to 
mimic host mRNA by modifying their mRNA through capping. Capping involves the 
sequential activity of three enzymes. First, an RNA triphosphatase (TPase) will 
remove the γ- phosphate group from the 5’-triphosphate end (pppN) of the nascent 
mRNA chain to generate the diphosphate 5’-ppN. The second step, a RNA 
guanylyltransferase (GTase) transfers a GMP to the 5’-diphosphate end to yield the 
cap core structure (GpppN). The cap is then methylated at the N-7 position of it’s 
guanine by a N7-methyltransferase (MTase) to produce a cap-0 structure 
(m7GpppN) (Furuichi and Shatkin, 2000). 
1.5.2 Structural proteins 
1.5.2.1 Spike protein (S) 
 
The first step in viral infection of host cells is receptor recognition (Baranowski et 
al., 2001). Coronavirus entry into host cells is mediated by the envelope-anchored 
spike protein, first by binding to a specific receptor on the host cell surface and 
then by fusing viral and host membranes (Bosch et al., 2003; Spaan et al., 1988). 
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The spike protein is the largest of the coronavirus structural proteins (Dye and 
Siddell, 2005) and is a member of the class 1 fusion proteins (Eckert and Kim, 
2001; Harrison, 2008; Skehel and Wiley, 2000; Wilson et al., 1981). The spike 
varies from 1,160 to 1,450 amino acids in length and is heavily glycosylated with 21 
to 35 N-glycosylation sites (Belouzard et al., 2012). The spike protein is a trimer 
located at the surface of the virion and gives the distinctive corona shape 
recognized by EM (Xu et al., 2004), consists of three segments; a large 
ectodomain, a single-pass transmembrane anchor, and a short intracellular tail 
(Beniac et al., 2006; Li et al., 2006). The ectodomain of coronavirus S protein can 
be further divided into two domains, binding S1 subunit (variable domain) and a 
membrane-fusion S2 subunit (more conserved domain) Figure 1.7. 
	  
Figure 1.7. Schematic of the S protein domains. Domain structure of MHV spike 
protein. NTD: N-terminal domain; FB: fusion protein; HR: Heptad repeat; TM: 
transmembrane domain. 
 
The globular S1 gives the virus it’s crown-like appearance and is exposed on the 
outside the virus. It contains the receptor binding domain (RBD) within the first 330 
amino acids at the amino terminus that binds to a variety of proteins and sugars, 
responsible for cellular attachment and therefore cell tropism. In coronaviruses, the 
interaction between the RBD and it’s receptor is one of the most important 
determinants of host range and cross-species infection (Li, 2013; Li et al., 2006). 
Furthermore, RBDs contain major neutralization epitopes, which induce most of the 
host immune response and may serve as subunits for vaccine development 
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against coronavirus infections (Du et al., 2014, 2009; He et al., 2005; Jiang et al., 
2014; Sui et al., 2004; Ying et al., 2014). The S2 subunit forms the stalk region of 
the spike protein that is anchored in the membrane and contains two heptad 
repeats HR1 and HR2, a typical feature of class I viral fusion proteins, a putative 
fusion peptide (FP) and one short transmembrane domain (Chambers et al., 1990). 
The S2 domain mediates fusion of the viral and host membranes. In addition, cell-
cell fusion is activated by the expressed viral fusion proteins to form giant 
multinucleated cell named syncytia (Belouzard et al., 2012; Bosch et al., 2003; Luo 
and Weiss, 1998). Some betacoronavirus and gammacoronavirus groups also 
posses a small hemagglutinin-esterase (HE) protein, standing 5-7 nm on the 
envelope along with the S protein (Kienzle et al., 1990). The HE protein contains a 
disulfide link to form a homodimer with both hemagglutinating and esterase activity 
(Brian et al., 1995; Kienzle et al., 1990). The HE protein is believed to have been 
gained from Influenza C virus, where it is the sole glycoprotein, as a result of 
recombination with a coronavirus ancestor (Vlasak et al., 1988). This protein may 
play a role in the entry and/or release of the virus. However, it doesn’t appear to be 
essential for viral replication or virulence (Kazi et al., 2005; Popova and Zhang, 
2002).  
Since the S protein plays an essential role in virus entry and determines tissue and 
cell tropism as well as host range (Lu et al., 2015), this is deemed an excellent 
target for the development of vaccines and antiviral drugs. The S protein proves an 
important target for T cell responses and epitopes located in it’s N- terminal portion 
trigger the production of virus-neutralizing antibodies. The coronavirus S protein, 
when inoculated alone, can induce protective immunity for a number of viruses 
(Cavanagh, 2005). For example, studies on SARS-CoV revealed that vaccines 
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based on the S protein could induce antibodies to block virus binding and fusion to 
neutralize virus infection (Du et al., 2009). For therapeutic targeting, the S protein 
RBD or S2 regions so far appear to be the most investigated targets to identify 
various specific antivirals (Du et al., 2014; Gao et al., 2013; Jiang et al., 2014; Li et 
al., 2015; Lu et al., 2014; Pascal et al., 2015). 
1.5.2.2 Membrane protein (M) 
 
The membrane protein (M) is about 25-30 kDa in size (221-262 amino acids) and is 
the most abundant protein embedded within the coronavirus envelope. M contains 
a short amino terminus located outside the virion, followed by three 
transmembrane domains (Tm), and a large carboxy-terminal domain that is usually 
located inside the virion (Hogue and Machamer, 2008) Figure 1.8. 
	   	  
 
 
Figure 1.8. Coronavirus M protein structure. A schematic representation of MHV-A59 M 
protein domains. Ecto: ectodomain; TM: transmembrane domain; endo: endodomain.  
 
As yet, studies have revealed limited structural information for the M protein, it’s 
transmembrane nature making it difficult to express and purify. The protein is 
moderately well conserved within each group but completely divergent across the 
three groups (Den Boon et al., 1991). M proteins of coronavirus exclusively localize 
to the ER/Golgi area with the exception of SARS-CoV, TGEV and Feline Infectious 
Peritonitis virus, where it is capable of reaching the plasma membrane (Jacobse-
Geels and Horzinek, 1983; Krijnse-Locker et al., 1994; Laviada et al., 1990; To et 
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al., 1991; Tooze and Tooze, 1985; Tooze et al., 1984; Voß et al., 2006). 
Alphacoronavirus and gammacoronavirus M proteins are believed to be O-
glycosylated, while M is N-glycosylated in betacoronavirus (de Haan et al., 2003). 
Glycosylation may play a role in virus-host interaction but does not appear to be 
important for virus assembly or infectivity (de Haan et al., 2003). M protein is 
involved directly in viral assembly and budding in addition to it’s functions in host 
interaction, along with E, S and N (de Haan et al., 1999; Haan et al., 1998; 
Neuman et al., 2011). Studies showed that the endodomain is the locus for M-N 
(Escors et al., 2001; Fang et al., 2005; Hurst et al., 2005; Kuo and Masters, 2002; 
Luo et al., 2006a; Verma et al., 2007, 2006) and S-M interaction (de Haan et al., 
1999; McBride and Machamer, 2010). Cryo-electron micrographic (cryo-EM) and 
tomographic reconstructions (Neuman et al., 2011) and inferences drawn from a 
genetic study of evolved M mutants (Kuo and Masters, 2010) indicate that M-M 
monomer interactions occur via the transmembrane (Tm) domains, whilst higher-
order oligomerization of M dimers is predominatly driven by the endodomain. In 
innate antiviral responses, type I interferons (IFNs) are the prime effector 
cytokines. IFN production is induced by pathogen-associated molecular patterns 
such as viral double-stranded RNA, which are sensed by host pattern recognition 
receptors. M protein is postulated to suppress type I IFN production potently by 
preventing the formation of a functional TRAF3–TANK–TBK1/IKKe complex which 
signals IFN gene expression downstream of interaction of virus RNA with innate 
sensors such as RIG-I or MDA-5 (Siu et al., 2009). A study suggested that 
interaction between the domain N3 of N protein and endodomain of M protein is 
involved in the gRNA packaging process (Kuo et al., 2016). For these reasons, the 
M protein could be an attractive target for development as an antiviral.  
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1.5.2.3 N protein (N) 
 
N protein (N) protein is one of the most abundant coronavirus structural proteins, 
located inside the virus particle. The N protein’s primary function is to enclose the 
viral RNA genome in a helically symmetric ribonucleoprotein (RNP) (Masters and 
Sturman, 1990; Masters et al., 1990). The RNP complex is important to maintain 
the RNA genome in an ordered conformation for replication and transcription. N 
protein is a helical, highly basic and phosphorylated protein, about 50-60 kDa in 
size. Based on MHV strain sequence comparisons, the N protein has three 
conserved domains with a high serine content (7-11%) (Tan et al., 2006). The N 
protein consists of two structural domains: N-terminal domain (NTD) and C-
terminal domain (CTD) linked by a poorly structured linkage region (Linker) 
containing a serine/arginine- rich (S/R) domain (SRD) (Chang et al., 2006; Q. 
Huang et al., 2004; Luo et al., 2006a, 2005) Figure 1.9. The NTD domain of the N 
protein in coronaviruses is involved in RNA binding while the CTD domain is 
involved in RNA binding and self-association of the protein to form higher-order 
oligomers (Chang et al., 2014, 2013; Lo et al., 2013; Ma et al., 2010; Yu et al., 
2006). A critical determinant for recognition of the genomic RNA packaging signal 
has been mapped to the NTD of the N protein in MHV (Kuo et al., 2014). A domain 
called N3 can be found at the carboxy terminus of the N protein and has been 
reported in many studies, but not all, to be a locus for N-M interaction (Fang et al., 
2006; Hatakeyama et al., 2008; He et al., 2004; Hurst et al., 2005; Kuo and 
Masters, 2002; Luo et al., 2006b; Verma et al., 2007, 2006). In addition to it’s 
primary function in packaging the RNA genome in a helical nucleocapsid structure 
during the encapsidation process, N protein plays a role in viral replication and 
discontinuous transcription (Baric et al., 1988; Compton et al., 1987). The N protein 
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of MHV and SARS-CoV posseses chaperone activity (Thiel et al., 2001; Zúñiga et 
al., 2007) that appears important during template switching events. Furthermore, 
the N protein plays a structural role in virus assembly (Hurst et al., 2005). 
 
Figure 1.9. Domain organization of coronavirus nucleocapsid protein. Schematic of 
the coronavirus N protein divided into domains: N1a, NTD: N-terminal RNA-binding 
domain, SR: serine/ arginine region, CTD: C-terminal dimerization domain, N3: N3 domain.  
 
Development of antiviral drugs traditionally targets enzymatic proteins such as 
proteases, polymerases and helicases. However, the multifunctional and crucial 
role of N protein during the viral life cycle could make it an attractive target for 
antiviral design. In addition, detailed high-resolution structural information about N 
proteins from various coronavirus species provides a good starting point for 
structure-based drug discovery, while most replicase protein structures are still 
unknown. For instance, mutations in the center of the NTD domain in HCoV-OC43 
significantly decreased the RNA-binding affinity of the N protein and subsequently 
decreased viral replication which is consistent with it being considered a target for 
the development of RNA-binding inhibitors (Lin et al., 2014). Removal of 40 amino 
acids from the C-terminal tail of the SARS-CoV N protein decreased protein 
oligomerization (Luo et al., 2006a). N protein has been also considered an eligible 
target for DNA or recombinant-protein-mediated vaccination. N protein does not 
elicit neutralizing antibodies because it resides inside the virus particle so the goal 
of N based vaccines is to induce the generation of cytotoxic T lymphocytes (CTLs) 
capable of destroying infected cells. Studies reported that SARS-CoV N protein 
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could induce high CTL activity when introduced into mice (Zhao et al., 2005; Zhu et 
al., 2004).  
1.5.2.4 Envelope protein (E) 
 
The envelope protein (E) is the smallest structural protein. Envelope protein is a 
small monomeric, non-glycosylated protein of 76-109 amino acids with a single 
hydrophobic domain (HD). This protein is usually encoded either by the second or 
third ORF in a bi- or tri cistronic mRNA (Boursnell et al., 1985; Budzilowicz and 
Weiss, 1987) and plays an important role in viral assembly. However, recent 
studies indicate that E protein is also essential for efficient trafficking of the virions 
through the secretory pathway, which may be due to an ion channel activity (Nieto-
Torres et al., 2011; Ruch and Machamer, 2012). The expression of E protein only 
or together with M protein can induce virus like particle synthesis (VLP) but some 
reports indicate that M and N (Y. Huang et al., 2004), M and E (Hsieh et al., 2005) 
or only M protein are able to drive the production of released vesicles (Tseng et al., 
2010), all effectively enabling study of virus-like particle production in different cell 
types and expression systems. E protein is not the best target for development as 
an antiviral as it is the smallest and least abundant of the coronavirus structural 
proteins. It is also poorly conserved across the coronavirus genera (Masters, 2006) 
and lacks confirmed direct interactions with the other structural proteins. 
1.6 Antiviral drugs 
 
Since the SARS-CoV outbreak and it’s worldwide spread, intensified research 
efforts targeting the coronavirus group have resulted in the discovery of two new 
human coronaviruses, and most recently the discovery of MERS-CoV. However, 
high throughput screening is still ongoing for the discovery of antivirals targeting 
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coronavirus proteins. In fact, most known inhibitors are focusing on the main 
antiviral drug targets and are designed on the basis of the structural knowledge of 
these targets. Based on their broad mechanism of action, antiviral therapeutics can 
be divided into three groups: virucides, biological response modifiers, or direct 
acting antivirals. The first group includes chemical or physical agents that are 
capable of physically inactivating a virus. However, owing to toxicity problems, 
agents in this group are used primarily as disinfectants for inanimate objects. The 
second group is a diverse group of agents with the common property of modulating 
the host immune response. They include substances produced naturally in the 
body, like cytokines and synthetically produced compounds (Ford, 1986), or non-
endogenous biological components such as bacterial cell wall extracts. Drugs in 
this group can have an indirect antiviral effect by stimulating the host’s innate or 
adaptive immune response (Bergman et al., 2011). The third group is the direct 
acting antivirals, which is the largest and most important group of antiviral 
therapeutics. Drugs in this group exert their antiviral effect by targeting essential 
viral or cellular factors involved in replication. As mentioned previously, 
coronaviruses have the largest RNA genome known and encode a large number of 
proteins that are involved in viral replication and assembly - about 30 different 
proteins for each virus. Each protein has a specific function or functions. Most of 
the viral proteins are associated with other proteins or with themselves to carry out 
their functions and the interaction between viral proteins plays a crucial role during 
the viral infection cycle. Due to the large genome and high diversity among 
coronaviruses, there are no effective structure based pan-coronavirus drug 
inhibitors. Even if there were, all designed drugs would need further optimization 
and validation before they could be approved (Barnard and Kumaki, 2011). For 
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example, despite the fact that SARS-CoV emerged over a decade ago and over 
3500 publications have been published on it since 2002, the FDA has not yet 
approved an antiviral agent for the treatment of SARS-CoV infection. 
Understanding the etiology, pathology, and possible therapeutic targets of 
coronaviruses will improve the development of an effective antiviral, which may be 
important for future outbreak control.  
There are many challenges in the development of anti-coronavirus therapeutics. 
One of the challenges is the lack of natural infection models that makes it hard to 
evaluate any proposed drug efficiency. Another challenge is to make the availability 
of any broad-spectrum anti-coronavirus drugs and/or vaccines beneficial if a new 
coronavirus with pandemic potential emerges at any time. This complexity makes 
the development of any antiviral a difficult process. On the other hand, many of the 
proteins involved directly in the virus life cycle have been shown to be valid targets 
for antivirals (Mielech et al., 2014). 
There are many factors to bear in mind before considering any coronavirus protein 
as a potential target for rational drug design. Firstly, the specificity of the protein(s) 
(i.e. non-existence of a similar cellular target) is one of the most important 
requirements because a similar cellular target could be affected by any antiviral 
drug and cause serious side effects. Fortunately, most viral enzymes are unique in 
their folding, organization and mechanisms of action and that provides a large 
space for drug design and drug selectivity. Secondly, the potency of the expected 
outcome of viral target inhibition is another important parameter. Lastly, an 
amplifying mechanism means the number of events that the protein is involved in 
during the virus replication cycle. For example, RNA capping events can vary from 
a single capping event to many RNA capping events in nidovirales. In contrast, 
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RdRp enzymatic action incorporates several thousand nucleotides to produce a 
single RNA genome and inhibition of the viral RdRp at each nucleotide 
incorporation step should exhibit a powerful antiviral effect. As noted the large CoV 
genome contains two open reading frames, connected by a ribosomal frame shift 
that encodes two large overlapping replicase polyproteins from which the functional 
proteins are produced by extensive proteolytic processes (Dougherty and Semler, 
1993; Pillaiyar et al., 2016; Ziebuhr et al., 1997). Coronaviruses utilize from one to 
three proteases for such proteolytic processing (Harcourt et al., 2004; Hilgenfeld, 
2014). These enzymes are indispensable to the viral replication and infection 
process, making them an attractive target for the development of an antiviral drug. 
Targeting the 2′ O-MTase activity and corresponding immune responses has been 
suggested as an approach to ablate the capping process in a variety of 
coronavirus. Cap formation is an important post-transcriptional process in 
coronavirus RNA synthesis to ensure that the viral RNAs can be translated by host 
ribosomes as well as being indistinguishable from host mRNA (Menachery et al., 
2014). The strategy described for development of coronavirus antivirals drug so far 
therefore has good starting points based on sound experimental data. However, to 
be prepared for future zoonotic transmissions of coronaviruses into the human 
population, or in the case of new adpated coronavirus outbreaks, more effort is 
required to explore new targets and to develop a novel strategy for drug design 
against all coronaviruses. 
Mouse hepatitis virus (MHV) is commonly used as a model system to study the 
replication and pathogenesis of coronaviruses (Weiss and Leibowitz, 2011) for 
several reasons. MHV is easy to grow and maintain. MHV causes hepatic and 
central nervous system diseases of varying severity depending on the strain and 
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therefore is used as a model for hepatitis, viral encephalitis, and demyelination 
(Weiss and Navas-Martin, 2005). MHV is used as a model to study the interaction 
of coronaviruses with the alpha/beta interferon response since it induces delayed 
IFN response (Roth-Cross et al., 2007) which help in studying general immune 
response. Another reason is that N protein of MHV is interchangeable with N 
protein of counterpart from the closely related bovine coronavirus, which help to 
study infectivity of coronavirus genomic RNA (Hurst et al., 2010). Both MHV and 
SARS-CoV N proteins share the same IFN-β antagonizing mechanism by having 
the ability to disorganize the function of cellular protein activator of protein kinase R 
(PACT) to abolish the innate antiviral response. However, this strategy does not 
appear to be used by all coronavirus N proteins (Ding et al., 2017). 
1.7 Therapies against coronavirus infection 	  
Therapeutic options for coronavirus infections can be divided to vaccine and 
antiviral drug development. Several strategies have been developed to produce 
effective vaccines against SARS-CoV infection such as recombinant vectored 
SARS-CoV S protein, DNA vaccines, inactivated whole-virus vaccines and 
recombinant-protein vaccines (Gillim-Ross and Subbarao, 2006). However there is 
still no progress towards a credible SARS vaccine and further work is required for 
them to be evaluated for safety profile and treatment effects in patients. In the field 
of developing antiviral drugs, there are many difficulties in developing antiviral 
drugs against coronavirus infection. Three general approaches are used to discover 
potential anti-CoV treatment options for human-pathogenic CoVs. The first 
approach is to test existing broad-spectrum antiviral drugs, which have been used 
to treat infection of other viruses by using standard assays to test effects of these 
drugs on virus yield and plaque formation of live and/or pseudotyped coronaviruses 
	  	   49 
such as interferon alfa, interferon beta, interferon gamma, ribavirin and cyclophilin 
inhibitors (Chan et al., 2013; Cheng et al., 2013, 2007; Cinatl et al., 2003; de Wilde 
et al., 2013; Falzarano et al., 2013; Pfefferle et al., 2011; Tanaka et al., 2013). 
Although these drugs are available with known pharmacokinetic and 
pharmacodynamic properties, side effects and dosing regimens they do not have 
specific anti-CoV effects and may be associated with severe adverse effects. For 
example, the HIV-protease inhibitor lopinavir, often combined with ritonavir, 
appeared to show some benefit for SARS patients (Chu et al., 2004), and the effect 
of these compounds was also observed in cell culture. However the coronavirus 
genome does not code for an aspartic protease related to the HIV protease (Wu et 
al., 2004) but codes for a cysteine protease (3C-like protease). More information on 
the proposed binding mode of lopinavir to the SARS-CoV main protease and 
attempts to improve it’s inhibitory potency might be a good starting point for anti-
SARS drug design. The second approach involves the screening in chemical 
libraries that is compromised from large numbers of existing compounds or 
databases that contain information on transcriptional signatures in different cell 
lines (Chan et al., 2013; de Wilde et al., 2014; Dyall et al., 2014; Elshabrawy et al., 
2014; Kindrachuk et al., 2015; Liu et al., 2015). This approach provides rapid, high-
throughput screening of many readily available compounds that can be further 
evaluated by anti- viral assays. However, most of these drugs are not clinically 
useful because they are either associated with immunosuppressive effects or they 
have high anti-CoV half-maximal effective concentrations (EC50) (J. F.-W. Chan et 
al., 2015; Chan et al., 2003; Chu et al., 2004). The third approach involves the de 
novo development of novel, specific agents based on the genomic and biophysical 
understanding of the individual coronaviruses such as small interfering RNA 
	  	   50 
(siRNA) molecules or inhibitors against specific viral enzymes involved in the viral 
replication cycle, monoclonal antibodies which target the host receptor, inhibitors of 
host cellular proteases, inhibitors of virus endocytosis by the host cell, human or 
humanized monoclonal antibodies that target the S1 subunit RBD and antiviral 
peptides that target the S2 subunit (Lu et al., 2014). 
The main drug targets among the viral nonstructural proteins are the main 
protease, the RdRp (Nsp12) and the helicase (Nsp13). Many inhibitors against 
coronavirus proteins have been designed on the basis of crystal structures. There 
are many inhibitors that have been designed and synthesized targeting the 
coronavirus Mpro, but few of them have undergone systematic toxicity and other 
preclinical studies and are still yet not available for clinical trials (Xue et al., 2008). 
Numerous SARS-CoV PLPro inhibitors belonging to different classes have been 
identified such as small-molecule inhibitors, thiopurine compounds, natural 
products, zinc ion and zinc conjugate inhibitors and naphthalene inhibitors (Báez-
Santos et al., 2015) by using high throughput screening and structure-based 
rational design (Hilgenfeld and Peiris, 2013; Kumar et al., 2013; Kuo and Liang, 
2015; Pillaiyar et al., 2016; Tong, 2009; Zhao et al., 2013) but some of these drugs 
only inhibit the enzymatic activities of PLpro, not viral replication, or vice versa 
(Báez-Santos et al., 2015; Báez-Santos et al., 2014; Ratia et al., 2008) and none 
have been validated in animal or human studies (Báez-Santos et al., 2015; Báez-
Santos et al., 2014). Further animal studies needs to be conducted for developing 
one of these potent inhibitors into an antiviral drug. Another target is RNA-
dependent RNA polymerase (RdRp) and helicase, which are required for the 
transcription and replication of the virus (J. F. Chan et al., 2015; van Boheemen et 
al., 2012). However, obtaining an active form, of RdRp (Nsp12) and the helicase 
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(Nsp13) and many attempts to crystallize them has failed. 
On the other hand, CoV structural proteins have also been the targets for antiviral 
development. The spike protein is of particular interest for antiviral development 
because the spike protein is a major immunogenic antigen and is essential for the 
interaction between the virus and the host cell receptor, which make it a perfect 
target for vaccine and antiviral development. Several monoclonal antibodies have 
been developed which target S1, S2 and the RBD. Most of these monoclonal 
antibodies target specific epitopes on the S1 subunit RBD to inhibit virus–cell 
receptor binding, whereas others bind to the S2 subunit to interrupt virus–cell fusion 
(Coughlin and Prabhakar, 2012). Another strategy is targeting different regions of S 
by antiviral peptides. For example, antiviral peptides analogous to the N terminus, 
pre-transmembrane domain or the loop region separating the HR1 and HR2 
domains of SARS- CoV can inhibit virus plaque formation by 40–80% at micromolar 
concentrations (Sainz et al., 2006; Zheng et al., 2005). 
The N protein of SARS-CoV has been widely used as a diagnostic target of SARS 
infection (Surjit and Lal, 2008). Viral N protein shows genetic stability with the least 
variation in the gene sequence, which is a primary requirement for an efficient drug 
target candidate. The N protein has also become a therapeutic target in antiviral 
therapy by disrupting RNP formation through inhibition of either protein 
oligomerization or nucleic acid binding activity in different viruses. For example, 
inhibition of influenza virus by targeting it’s nucleocapsid protein through nucleozin 
and it’s analogues (Hung et al., 2012; Kao et al., 2010), compounds targeting the 
interaction between N protein and nucleic acids have been developed against HIV-
1 virus (Musah, 2004) and a peptide that interferes with the CTD oligomerization of 
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the HCoV-229E N protein and inhibits virus production have been also discovered 
(Lo et al., 2013).  
E, M and some of the accessory proteins, which are essential for virion assembly, 
also have additional functions like suppressing the host immune response to 
facilitate viral replication, siRNAs were developed against E, M, ORF3a, ORF7a or 
ORF7b of SARS-CoV inhibited viral replication in vitro (AAkerström et al., 2007; He 
et al., 2009), none of these siRNAs is ready for human use until better delivery 
methods become available. Huge progress has been made in the elucidation of the 
functions and structures of coronavirus proteins especially SARS and MERS 
coronavirus and research on vaccine development has also progressed, with a 
number of strategies being developed and evaluated in experimental animal 
models but still more effort is needed to develop effective antivirals against current 
and re-emergence coronavirus infection.   
1.8 Directed evolution 
 
Protein engineering is one of the most popular methods used to improve the 
properties of enzymes or proteins by genetic changes. There is an intimate 
relationship between the amino acid sequence and the structure of a folded protein 
but the relationship between a protein structure and it’s function is less well defined 
and understood. Therefore, manipulating or mutating the sequence of a protein can 
alter proteins function and properties, often in unforeseen ways. A successful and 
widely used example of protein design and engineering is the directed evolution 
method (Otten and Quax, 2005), which has become a powerful approach over the 
last two decades (Yuan et al., 2005). This method is inspired by the Darwinian 
concept of natural evolution by mimicking the process of natural selection on a 
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protein (Romero and Arnold, 2009; Skandalis et al., 1997). In vitro evolution is a 
laboratory method applied to evolve molecules with desired properties in a short 
time and has been used to optimize enzymes, improve drug resistance, and in the 
development of novel pharmaceuticals and vaccines (Arnold, 1998, 1996; Patten et 
al., 1997). Gene recombination and random mutagenesis are the two natural 
evolutionary processes, which have been adapted for in vitro evolution 
experiments. An in vitro evolution experiment firstly requires building a library of 
variants from the protein of interest followed by screening and/or selection of the 
protein products with desired properties. Libraries can be created in vitro either by 
site directed mutagenesis or by random mutagenesis; the latter of which is the most 
popular and widely used method. Random mutagenesis requires no structural or 
mechanistic information of the target and can uncover unexpected beneficial 
mutations. There are several methods to generate genetic diversity by random 
mutagenesis, by using chemical mutagens (Cox, 1976; Kadonaga and Knowles, 
1985; Shortle and Nathans, 1978), passing cloned genes through a mutator strain 
(Cox, 1976; Greener et al., 1996) or by error-prone PCR mutagenesis (Cadwell and 
Joyce, 1992; Leung et al., 1989; Patrick and Firth, 2005; Vartanian et al., 1996). 
Error-prone PCR (ep-PCR) techniques are the most popular due to their low-cost 
and simplicity. Various methods are available to generate random mutations using 
ep-PCR such as using a low-fidelity DNA polymerase such as Taq, which lacks 
proofreading efficiency so that mismatched bases are not removed (Tindall and 
Kunkel, 1988). For higher rates of mutation, Mn2+  ions and/or changes in the Mg2+ 
ion concentration, along with unbalanced available nucleotides pools, can 
effectively increase the rate of mutation (Beckman et al., 1985; Cadwell and Joyce, 
1992; El-Deiry et al., 1984). The degree of mutation can be directed by adjusting 
	  	   54 
the number of amplification cycles to allow easy manipulation of the final libaray 
complexity. In the next step, a selection process to be applied to a library of clones 
is required for any directed evolution experiment and again, several methods have 
been developed for screening and selection. For example, libraries of clones may 
be directly separated into individual cultures, expressed, and screened for the 
desired property or whole libraries may be plated and screen en masse. Overall a 
number of available tools required for gene variant generation by directed evolution 
should allow an experimenter to gain results of high impact with moderate effort. 
Directed evolution is commonly used in the field of protein engineering as an 
alternative to rationally designing modified proteins as well as studying fundamental 
evolutionary principles in a controlled, laboratory environment. For example, 
directed evolution-based strategies are most commonly used in protein engineering 
projects, to increase activity, improve stability or provide greater specificity to the 
desired protein, which is an alternative to rational design (Romero and Arnold, 
2009). Computational design has been used in recent years as a promising tool for 
creating protein catalysts with tailored activities and specificities and by using 
directed evolution of a computationally designed enzyme, dramatic molecular 
changes can also drive the optimization of protein active sites with no need to 
understand the mechanism of the desired activity or how mutations would affect it 
(Giger et al., 2013). Another example is directed evolution may also be employed to 
'tune' genetic circuits, or adjust regulatory elements within a stretch of DNA 
incorporating one or more genes (Cobb et al., 2013). 
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1.9 Aims of this research 
 
The aim of this project is to develop small protein inhibitors that interfere with the 
coronavirus replication cycle as a novel mechanism to treat infections caused by 
CoVs. The first aim is to clone several proteins from MHV-A59 in vectors capable 
of protein expression in prokaryotic and eukaryotic cells. For that, protein 
constructs will be expressed in E. coli to confirm correct MHV protein production 
before transfection into a mammalian cell line (17clone-1) which is permissive for 
MHV. The second aim is to examine the effects of expressed non-mutated proteins 
on virus replication based on their ability to protect cells from virus-induced 
cytopathic effects as measured by plaque assay. The third aim is to create a library 
of variants using random mutagenesis via error prone PCR and to optimize the 
library to control the number of mutations generated and to assess the potential of 
the mutated MHV protein varaints as inhibitors of MHV replication. The fourth aim 
is to screen for dominant-negative N variants using cell survival following 
mammalian cell line (17clone-1) transfection with different libraries; variants from 
survivors will be extracted, re-cloned, and transfected again into 17clone-1 and this 
process will be repeated for several rounds. A last aim of this project is to optimize 
purification conditions for difficult to express coronavirus proteins such as nsp16 so 
that they too may be considered as targets. The overall goal of this is to contribute 
to the development a small protein inhibitors using, as exemplars, mutated 
coronavirus proteins that have been selected by directed in vitro evolution. 
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2 Materials and methods  
2.1 Plasmid construction and cloning of desired DNA fragment 
2.1.1 Primers 
The oligonucleotides primers were designed using Gene runner and DNADynamo 
software using the sequence of Murine hepatitis virus strain A59 (GenBank 
accession number AY700211.1). Primers were purchased from Integrated DNA 
Technology (IDT). Forward and reverse primers were reconstituted as 50 µM 
solutions in nuclease-free water and stored at -20°C. All primers used in this study 
are listed below in Tables 2.1– 2.5. Red colour nucleotide in Table 2.3 represents 
nucleotide change for mutation correction. In Table 2.4, red colour represents 
vector sequence. 
 
 
 
 
 
 
 
 
 
	  	   57 
Table 2.1. Oligonucleotides used for cloning in pTriEx1.1 plasmid. Highlight sequence 
represents start codon. 
Primer Sequence bp 
Fw_nsp3_PLPro   AGGAGATATACCATGGCCTCCGAGGCAGATCTTG 34 
Rv_nsp3_ PLPro   GATGGTGGTGCTCGAGCGAAAAAGTTTGCTTTAAATTTT 39 
Fw_nsp5 AGGAGATATACCATGGCCTCTGGTATAGTGAAGATG 36 
Rv_nsp5 GATGGTGGTGCTCGAGCTGTAGCTTGACACCAGC 34 
Fw_nsp6 AGGAGATATACCATGGCCTCAAAGCGCACAAGAG 34 
Rv_nsp6 GATGGTGGTGCTCGAGTTGAATTTGAGATACTTCAATG 38 
Fw_nsp7 AGGAGATATACCATGGCCTCAAGATTGACGGATGT 35 
Rv_nsp7 GATGGTGGTGCTCGAGTTGCAAGACAGTATTGTCG 36 
Fw_nsp8 AGGAGATATACCATGGCCGCCTTACAGAGTGAATT 35 
Rv_nsp8 GATGGTGGTGCTCGAGCTGCAAAACAACAGTAGACA 36 
Fw_nsp9 AGGAGATATACCATGGCCAACAATGAGTTGATGCC 35 
Rv_nsp9 GATGGTGGTGCTCGAGCTGCAATCTCACTGTCGAG 35 
Fw_nsp10 AGGAGATATACCATGGCCGCGGGTACGGCAACTG 34 
Rv_nsp10 GATGGTGGTGCTCGAGGCCTACACAGGAACAGCT 34 
Fw_nsp12C AGGAGATATACCATGGCCAAGGACTTGCTTTTGTAT 36 
Rv_nsp12C GATGGTGGTGCTCGAGTTGCAGCACTGCACTTCTT 35 
Fw_nsp12N AGGAGATATACCATGGCCTCAAAAGACACGAACTTT 36 
Rv_nsp12N GATGGTGGTGCTCGAGAAGAGACAAGCGATAACGAT 36 
Fw_nsp16 AGGAGATATACCATGGCCGCTGCTGCTGACTGGA 34 
Rv_nsp16 GATGGTGGTGCTCGAGTTTGACATTTACTAGGCTATC 37 
Fw_M AGGAGATATACCATGGCCATGAGTAGTACTACTCAG 36 
Rv_M GATGGTGGTGCTCGAGGATTCTCAACAATGCGGTG 35 
Fw_N AGGAGATATACCATGGCCATGTCTTTTGTTCCTGG 35 
Rv_N GATGGTGGTGCTCGAGCACATTAGAGTCATCTTCTAA 37 
Fw_Y AGGAGATATACCATGGCCTGGAGTGCTCGTTTGT  34 
Rv_Y GATGGTGGTGCTCGAGGCCCCCTTTAAGAGAGAAC 35 
 
Table 2.2. Sequencing primers 
Primer Sequence bp 
T7 Forward TAATACGACTCACTATAGGG 20 
TriExUP GGTTATTGTGCTGTCTCATCA 21 
TriExDOWN TCGATCTCAGTGGTATTTGTG 21 
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Table 2.3. Primers used for correction of random mutation in nsp12_N-terminal. Red 
colour nucleotide represents nucleotide change for mutation correction. 
Primer Sequence bp 
Fw_nsp12N-new CACGAACTTTTTAAACCGGATTCGGGGTACA 31 
Rv_nsp12N-new TGTACCCCGAATCCGGTTTAAAAAGTTCGTG  31 
 
 
Table 2.4. Primers used for SUMO cloning in pTriEx1.1 plasmid. Red colour represents 
vector sequence.	  
Primer Sequence bp 
Fw_nsp3_ PlPro _SUMO  CACAGAGAACAGATTGGTGGTTCCGAGGCAGATCTT 36 
Rv_nsp3_ PlPro _SUMO GATGGTGGTGCTCGAGCGAAAAAGTTTGCTTTAAATTTT 39 
Fw_nsp5_SUMO CACAGAGAACAGATTGGTGGTTCTGGTATAGTGAAG 36 
Rv_nsp5_SUMO GATGGTGGTGCTCGAGCTGTAGCTTGACACCAGC 34 
Fw_nsp6_SUMO CACAGAGAACAGATTGGTGGTTCAAAGCGCACAAGA 36 
Rv_nsp6_SUMO GATGGTGGTGCTCGAGTTGAATTTGAGATACTTCAATG 38 
Fw_nsp7_SUMO CACAGAGAACAGATTGGTGGTTCAAGATTGACGGAT 36 
Rv_nsp7_SUMO GATGGTGGTGCTCGAGTTGCAAGACAGTATTGTCG 36 
Fw_nsp8_SUMO CACAGAGAACAGATTGGTGGTGCCTTACAGAGTGAA 36 
Rv_nsp8_SUMO GATGGTGGTGCTCGAGCTGCAAAACAACAGTAGACA 36 
Fw_nsp9_SUMO CACAGAGAACAGATTGGTGGTAACAATGAGTTGATG 36 
Rv_nsp9_SUMO GATGGTGGTGCTCGAGCTGCAATCTCACTGTCGAG 35 
Fw_nsp10_SUMO CACAGAGAACAGATTGGTGGTGCGGGTACGGCAACT 36 
Rv_nsp10_SUMO GATGGTGGTGCTCGAGGCCTACACAGGAACAGCT 34 
Fw_nsp12C_SUMO CACAGAGAACAGATTGGTGGTAAGGACTTGCTTTTG 36 
Rv_nsp12C_SUMO GATGGTGGTGCTCGAGTTGCAGCACTGCACTTCTT 35 
Fw_nsp12N_SUMO CACAGAGAACAGATTGGTGGTTCAAAAGACACGACC 36 
Rv_nsp12N_SUMO GATGGTGGTGCTCGAGAAGAGACAAGCGATAACGAT 36 
Fw_nsp16_SUMO CACAGAGAACAGATTGGTGGTGCTGCTGCTGACTGG 36 
Rv_nsp16_SUMO GATGGTGGTGCTCGAGTTTGACATTTACTAGGCTATC 37 
Fw_M_SUMO CACAGAGAACAGATTGGTGGTAGTAGTACTACTCAG 36 
Rv_M_SUMO GATGGTGGTGCTCGAGGATTCTCAACAATGCGGTG 35 
Fw_N_SUMO CACAGAGAACAGATTGGTGGTATGTCTTTTGTTCCT 36 
Rv_N_SUMO GATGGTGGTGCTCGAGCACATTAGAGTCATCTTCTAA 37 
Fw_Y_SUMO CACAGAGAACAGATTGGTGGTTGGAGTGCTCGTTTG 36 
Rv_Y_SUMO GATGGTGGTGCTCGAGGCCCCCTTTAAGAGAGAAC 35 
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Table 2.5. Primers for SUMOStar cloning 
Primer Sequence bp 
Fw_SacII TGGCTGCGTGAAAGCCTTG 19 
Rv_SacII ACCACCAATCTGTTCTCTGTG 21 
 
2.1.2  pTriEx1.1 vector map 	  
The pTriEx1.1 (Novagen) was kindly provided by Dr. Ian Jones. This vector 
contains mammalian, bacterial and insect promoters upstream of the cloning 
cassette. This vector contains an ampicillin resistance gene for positive colony 
selection, a HSV tag sequence upstream of the cloning site and a 8x His tag 
downstream of the cloning site to enable construction of N-terminal HSV-tagged 
and/or C-terminal His-tagged fusion proteins if desired Figure 2.10. 
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Figure 2.10. Map of the pTriEx1.1 vector showing the cloning sites. 
	  	  	  	  	  
	  	   61 
2.1.3 pTriEx1.1-recombinant map 
All MHV proteins in this study were cloned as C-terminal His-tagged fusion proteins 
by insertion between NcoI and XhoI restriction sites Figure 2.11. 
 
Figure 2.11. Vector map of the pTriEx1.1 vector showing the site of insertion 
 
2.1.4   SUMO-pTriEx1.1 
All MHV proteins in this study were expressed as N-terimal SUMOStar fusion 
proteins by insertion between NcoI and XhoI restriction sites in pTriEx1.1 vector 
Figure 2.12. 
 
pTriEx1.1-recombinant 
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Figure 2.12. Vector map of the pTriEx1.1 vector showing the site of protein and 
SUMO tag insertion. 
 
2.1.5 Amplification of DNA fragments 
The coding sequences of structural proteins N protein and M protein, non structural 
proteins (nsp5, nsp6, nsp7, nsp8, nsp9, nsp10 and nsp16) from gene1, part of nsp 
(Y-domain, PlPro from nsp3 and N-terminal domain from RdRp and the C-terminal 
domain of nsp12 of MHV strain A59 (Accession No. AY700211.1) were amplified 
by polymerase chain reaction (PCR) from cDNA kindly provided by Dr. Volker 
Thiel. The amplification reaction contained the following components 
recommended by the manufacturer’s protocol: CloneAmp HiFi PCR Premix, 100 
µM forward and reverse primers, >100 ng DNA template and volume completed to 
50 µl with dH2O. Placed in PCR machine with the following thermal cycling 
pTriEx1.1-SUMO-recombinant 
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protocol: 
Step Temperature Time No. of cycles 
Initial denaturation 95°C 3:00 1x 
Denaturation 
Annealing 
Extension 
98°C 
55°C 
72°C 
0:10 
0:10 
0:30 
30x 
Final extension 72°C 5:00 1x 
  
For optimal annealing temperature, gradient PCR was applied with the following 
protocol: 98°C for 30 sec, 95°C for 8 sec, 55°C - 65°C for 15 sec, 72°C for 20 sec 
(30x) and 72°C for 5 min. PCR products were purified using cleanup kit according 
to the manufacturer’s protocol (MACHERER NAGEL), eluted in ultra-pure water. 
The concentrations were determined by ND-1000 Nanodrop spectrophotometer 
and stored at -20°C. 
2.1.6  Double digest and gel extraction of pTriEx1.1 vector 
The pTriEx1.1 vector was double digested with NcoI and XhoI (Thermo Fisher 
SCIENTIFIC) restriction enzymes according to the following protocol: 10x Green 
buffer, template (150> ng), (10 U/µl) NcoI, (10 U/µl) XhoI restriction enzymes and 
volume completed to 100 µl, incubated for 30 min at 37°C. After incubation, 100 µl 
was subjected to agarose gel electrophoresis, extracted and purified by cleanup kit 
(MACHERER NAGEL) following the manufacturer’s instructions. The double 
digestion was used for extraction and confirmation of correct clones.    
	  	   64 
2.1.7 In-Fusion cloning of desired proteins to the pTriEx1.1 vector 
Different genes were amplified using primers designed for In-Fusion cloning, as 
listed in Table 1. In a total volume of 10 µl, purified DNA (10-200 ng) was mixed 
with linearized vector (50-200 ng), 2 µl 5X In-Fusion HD Enzyme Premix (Clontech) 
and dH2O following the manufacturer’s protocol. Incubated for 15 min in 50°C. 
2.2 DNA agarose electrophoresis  
Gel electrophoresis was used to visualise DNA fragments and to purify by 
extracting the desired fragment. Agarose was dissolved in 1x TAE (Fisher Thermo 
SCIENTIFIC) buffer by heating in a microwave until boiling. After cooling Gel red 
(Cambridge Bioscience) was added to 1% (w/v). Electrophoresis was carried out at 
120v for 45 min. Gels were imaged using G:BOX Chemi XL (Syngene). The 
approximate size of DNA bands in the agarose gel was determined using 1kb 
HyperLadder (Bioline). Images were photographed and printed. 
2.3 Transformation of E. coli competent cells  
For transformation, 50 µl of Stellar competent cells (Clontech) were thawed on ice 
and 5-50 ng of plasmid DNA was added and gently mixed. The DNA mixture was 
incubated for 30 min on ice.  Next step was a heat shock at 42°C for 45 sec, which 
opens pores of the cell membrane to allow plasmid entry. The cells tube was 
placed back on ice for 1-2 min. Then, 450 µl of pre-warmed SOC (super optimal 
broth) recovery media (Clontech) was added to allow the cells to recover from heat 
shock and to express antibiotic resistance gene. After 1 hr incubation in the shaker 
(225 rpm) at 37°C, 1/5th-1/100 of each transformation reaction were separated and 
volume completed to 100 µl with SOC medium. Later, cells were plated onto Luria- 
Bertani (LB) agar supplemented with 100 µg/ml of ampicillin and incubated at 37°C 
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overnight. Approximately 30 colonies were selected randomly and transferred onto 
LB agar with ampicillin, left for ~5 hours at 37°C. Colonies were then analysed by 
colony PCR. 
2.4 Colony PCR screening of transformant bacteria 
2.4.1  Colony PCR analysis 
Each single colony from LB agar transferred to 30 µl water incubated for 2 min at 
100°C in PCR machine, centrifuged for 2 min and the supernatant (5 µl) used for 
PCR reaction with GoTaq Master mix (promega), (0.5 µM) T7 Forward or TriExUP 
and (0.5 µM) TriExDOWN primers Table 2. The PCR protocol was 1 cycle at 95°C 
for 2 min, 35 cycles with sequential incubation for 30 sec at 95°C, 30 sec at 52°C 
and 1 min at 72°C. Finally, an extension cycle for 10 min at 72°C was used to 
ensure complete extension of all PCR products.  
2.4.2 Plasmid DNA purification and sequencing 
Clones identified by colony PCR as containing the correct size insert were selected 
from LB agar plates and inoculated into LB broth containing 100 µg/ml ampicillin 
and incubated overnight in the shaker (225 rpm) at 37°C. Thermo Fisher 
SCIENTIFIC Miniprep kit was used for isolation of the plasmid DNA from the 10 ml 
cultures according to the manufacturer’s guidelines for plasmid DNA purification. 
The samples concentrations were measured using a NanoDrop ND_1000 
spectrophotometer. Later, pure plasmid DNA samples were sent to Source 
BioScience for sequencing and also double digested with restriction enzymes for 
confirmation. Cell suspension was used to create a stock for each clone in 50% 
glycerol and stored at -80°C. 
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2.5 BL21 (DE3)-pLysS transformation 
Plasmids were transferred in E. coli BL21 (DE3)-pLysS (Invitrogen) competent 
cells. 0.1 µg plasmid DNA mixed gently with 50 µl competent cells, incubated on 
ice for 20-30 min, heat shocked for 45 sec at 42°C water bath, re-placed on ice for 
1-2 min, 450 µl of pre-warmed SOC medium were added to plasmid-cells mixture 
and incubated in the shaker at 37°C for 40-45 min (225 rpm). After incubation, 400 
µl and 100 µl from the total mixture were plated on LB plates containing 100 µg/ml 
ampicillin and incubated overnight at 37°C. The next day 2 transformants were 
grown under the selection of chloramphenicol (34 µg/ml) and 100 µg/ml ampicillin 
in 10 ml LB broth at 37°C in the shaker overnight. The overnight culture was 
inoculated (100 µl) into 10 ml fresh LB broth with ampicillin (100 µg/ml), incubated 
in the shaker at 37°C for 1-3 hr. The expression of MHV fusion proteins was 
induced when cultures had reached an OD600 of 0.3 by adding IPTG (isopropyl-β-
D-thiogalactopyranoside) at a final concentration of 100 mM. For optimal 
expression, 1 ml was taken at time points of 1,2,3, and 4 hr, centrifuged and cells 
pellet were subjected for SDS-PAGE. 
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2.6 Cloning with SUMOStar 
2.6.1 Amplification of SUMOStar and desired protein fragments 
The gene encoding SUMOStar was amplified from the pTriExSUMO plasmid using 
primers listed in Table 5. The reaction contained the following components: 1 x 
phusionR High-Fidelity PCR Master mix (BioLabs), (0.5 µM) forward and reverse 
primers, ~ 500 ng DNA template and dH2O added to a final reaction volume of 50 
µl. PCR products were amplified using method described in section 2.1.5. MHV 
coding sequences of interest were amplified using the same protocol with specific 
primers for each sequence Table 4. Gel electrophoresis was carried out to 
separate and visualise DNA fragments. The PCR products were purified using gel 
extraction kit (Thermo Fisher SCIENTIFIC). The PCR amplified SUMOStar 
fragment was mixed with the MHV PCR products using the following protocol: 1 x 
PhusionR High-Fidelity PCR Master Mix, SUMOStar fragment (0.1 ng/bp) and MHV 
PCR product (0.1 ng/bp) and adjusted to a final volume of 45 µl with dH2O. The 
reactions were placed in a PCR machine and 5 cyles of the program described in 
2.1.5 was used before adding the forward primer Fw_SacII (0.5 µM) and reverse 
primer specific to the MHV coding sequence Table 4 (2.5 µl). The PCR protocol in 
2.1.5 was carried out for a further 30 cycles. The gel extraction kit from (Thermo 
Fisher SCIENTIFIC) was used according to the manufacturer’s instructions to 
purify and extract DNA fragments after gel electrophoresis.  
2.6.2 Restriction digest of pTriEx1.1 plasmid and DNA fragments 
In separate tubes, the plasmid vector and the DNA fragments from 2.6.1 were 
digested first using the restriction endonuclease Cfr421 (SacII) (Thermo Fisher 
SCIENTIFIC) restriction enzyme according to the following protocol: 1x buffer B 
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(Thermo Fisher SCIENTIFIC), 0.5-1 µg/ml DNA template, (10 U/µl) Cfr421 (SacII) 
restriction enzymes and volume adjusted to 50 µl using dH2O, and incubated for 60 
min at 37°C. After incubation, products were purified using a PCR purification kit 
(Thermo Fisher SCIENTIFIC). A second restriction digest was carried out using 
fast digest XhoI (Thermo Fisher SCIENTIFIC) according to the following protocol: 
1x Green buffer, 0.5-1 µg/ml DNA template from first digest, (10 U/µl) XhoI 
restriction enzymes in a final volume of 100 µl adjusted using dH2O, and incubated 
for 30 min at 37°C. Following visualisation by agarose gel electrophoresis, the 
appropriate DNA size was purified using the gel extraction kit (Thermo Fisher 
SCIENTIFIC) according to the manufacturer’s instructions. 
2.6.3 Ligation of PCR fragments in pTriEx1.1 
Ligation reactions were prepared using an approximate 3:1 molar ratio of the insert 
and vector together from 2.6.2 with 1x ligation buffer (Thermo Fisher SCIENTIFIC), 
and 1 unit T4 DNA ligase in a final volume of 10 µl. The reaction was incubated at 
room temperature for 1-3 hours. The ligation mix was then ready for transformation 
into Stellar competent cells (Clontech). 
2.7 Transfection of mammalian cells 
Transfection is a method used to introduce nucleic acids into cells. 17-clone1 were 
cultured in Dulbecco's modified Eagle medium (DMEM) (Sigma Aldrich) 
supplemented with 10% fetal bovine serum (FBS) (GE Healthcare), and antibiotics  
penicillin/streptomycin (penicillin 100 U/ml, streptomycin 0.1 mg/ml; 
Gibco/Invitrogen) in 6 well plate and were transfected with plasmid DNA for the 
expression of viral proteins by using different transfecting reagents to compare 
their efficiency Turbofect (Thermo Fisher SCIENTIFIC), FugeneHD (Promega), 
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Fugene6 (Roche), MirusTransIT-LT1 (Mirus), Lipofectamine2000 (Invitrogen), and  
Lipofectamine3000 (Invitrogen) following the manufacturer’s instructions for each 
reagent. After incubation for 18, 24 and 48 hr, cell culture plates were placed on ice 
and by using a cold plastic cell scraper to scrape adherent cells of each well gently. 
The suspensions were transferred into pre-cooled tubes, centrifuged for 4 min 
(2000 rpm) at 4°C. Finally, the supernatants were aspirated and the pellets re-
suspended with 50 µl ice-cold phosphate-buffered saline (PBS) and stored at -
20°C. 
2.8 Treatment with proteasome inhibitor  
MG132 proteasome inhibitor treatment is performed to determine if coronavirus 
proteins in this study are degraded in mammalian cells. 17 clone-1 cells were 
seeded at 1.9x10
5 in 24 well plates and the next day, cells were transiently 
transfected with plasmid DNA using different transfection reagents. Transfected 
mammalian cells were incubated for 4 hr, and then MG132 (Sigma-Aldrich) was 
added to each well at final concentration of 50 µM. Untreated cells were incubated 
for 24 and 48 hr, and then harvested as described in section 2.7. The MG132 
proteasome inhibitor was added to transfected cells after 20 hr incubation and 
incubated for 4 hr before harvesting. Cell lysates were subjected to 
immunoblotting. Untreated cells were used as a control. 
2.9 SDS Polyacrylamide gel electrophoresis (PAGE)  
The expressed proteins were detected by Western blot. Transfected cells were 
aliquoted in 50 µl chilled PBS, 30 µl of samples were mixed with 10 µl of LDS 
sample buffer (980 µl 4x LDS sample buffer (Novex) and 20 µl β-mercaptoethanol), 
incubated at 100°C for 10 min before being loaded into 4-12% SDS-PAGE gel (Life 
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Technologies). Later, samples were centrifuged for 2 min and 10 µl loaded in mini 
gel tank (Life Technologies). Samples were separated at a constant voltage of 
170v for 30 min in a 1x MES (50 mM MES, 50 mM Tris, 0.1% SDS, 1% EDTA, pH 
7.25) running buffer (Life Technologies). A sample (10 µl) of sharp pre-stained 
protein standard or SeeBlue Plus2 Prestained Standard (Life Technologies) was 
used for molecular size estimation. Once electrophoresed, the gel will be 
transferred either onto PVDF membranes for Western blotting analysis or stained 
with coomassie blue. 
2.10 Protein staining with coomassie blue 
 
Coomassie blue dye was used to visualise proteins separated by SDS PAGE. After 
electrophoresis, the gel was incubated at room temperature on rocking platform (25 
rpm) in a solution of coomassie brilliant blue stain (0.025% coomassie Brillant Blue 
R-250, 45% methanol and 10% glacial acetic acid) for 30 min. The gel was then 
washed with a destaining solution (10% methanol, 10% glacial acetic acid) at room 
temperature on the rocker for 10 minutes. The washing step was repeated three 
times. The gel kept overnight on rocking platform (25 rpm) to enable the 
visualisation of individual protein bands. 
2.11  Western blotting analysis 
Following electrophoresis, SDS-PAGE gels were incubated for 1 min in transfer 
buffer (400 ml 1.5x Tris/glycine (Tris base 25 mM, Glycine 190 mM pH 8.3) buffer, 
20% methanol (Fisher)) for 3 min. The SDS-PAGE gels were transferred onto 
PVDF membranes (Merck) and electroblotted for 1 hour and 20 minutes/ at 150mA 
in transfer buffer using semi-dry Western blotting apparatus (ATTO). Following 
transfer, the membranes were incubated in blocking buffer (5% non-fat milk in 
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TBST buffer (500 ml 1xTBS (50 mM Tris-Cl, 150 mM NaCl, pH 7.6) and 2% 
Tween20 (Fisher BioReagents)), kept in the fridge at 4°C to reduce nonspecific 
binding for overnight. The next day, membranes were washed with TBST buffer 3 
times for 5 min on a rocking platform (25-30 rpm) (Stuart). The primary 6x His tag 
antibody (Abcam) was diluted 1/10,000 in blocking buffer, which was added to the 
membrane in a plastic pouch. Membranes were incubated for 1 hr at room 
temperature on rocking platform (25-30 rpm). After incubation, membranes were 
washed with TBST buffer 3 times for 5 min. Membranes were then incubated for 1 
hr at RT with the secondary antibody (polyclonal Goat Anti-Rabbit Immunoglobulins 
/HRP) dissolved in 1% TBST-milk on rocking platform (25-30 rpm), followed by 3 
times washing steps in TBST as previously described and the protein bands were 
detected using equal volumes of ECL reagents A (0.25 ml) and B (0.25 ml) 
enhanced chemiluminescent substrate (GE healthcare). Luminescence from his-
tag labeled proteins was visualized using a G: BOX Chemi XL(Syngene). 
2.12 Immunoprecipitation 
Cell extracts were prepared on ice by incubating the cell pellets in 500 µl of NP40 
lysis buffer (150 mM sodium chloride, 1.0% NP-40, 50 mM Tris,pH 8.0), vortexed 
and incubated for 30 min on ice. Following centrifugation, clarified lysate were 
ready for immunoprcipitation. 50 µl of Dynabeads protein A (invitrogen) was 
aliquoted into Eppendorfs and placed in a magnetic rack for 1 min and the 
supernatant was removed. Tubes were removed from the rack and the Dynabeads 
re-suspended in 200 µl of PBS with 0.02% Tween20 containing Anti-His tag 
antibody (Ab) (1-10 µg) and incubated for 10 min with slow rotation at 4°C. The 
supernatant was removed after placing in the magnetic rack and Dynabeads-Ab 
copmlex re-suspended in 200 µl PBS with 0.02% Tween20. The supernatant was 
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removed again and 200 µl of the sample containing Ag was added, incubated on 
ice for 30 min to allow antigen (Ag) to bind to the beads-Ab complex. After 
removing supernatant, the beads were washed with wash buffer (PBS and 0.1% 
Tween-20). This wash cycle was repeated 3 times with 200 µl wash buffer and 
each wash included separation by magnet, supernatant removel and resuspention 
by gentle pipetting. Then, beads-Ab-Ag complex were re-suspended in 100 µl of 
washing buffer and placed on magnetic to remove supernatant. Then, 30 µl of 
elution buffer (LDS sample buffer (4X) (novex)) containing loading dye was added 
and incubated at 100°C for 10 min. The supernatant was taken to a new 
microcentrifuge tube after using the magnetic rack and subjected to SDS-PAGE. 
The gel was transferred to PVDF and immunoblotted as described in section 2.10. 
2.13  Error-prone PCR 
Error-prone PCR was performed using two protocols to create a library of variants. 
In the first protocol a 100 µl reaction solution containing 10 mM Tris.Cl (pH 8.3), 50 
mM KCl, 7 mM MgCl2, 1 mM dCTP, 1 mM dTTP, 0.2 mM dATP, 0.2 mM dGTP, 2 
µM Forward and Reverse PCR primers, 20 pg/µl DNA template, 0.5 mM MnCl2 and 
0.05 U/µl Taq DNA polymerase (New England Biolabs). The reaction was placed in 
PCR machine with following thermal cycling conditions: 95°C for 10 min (initial 
denaturation), 94°C for 1 min, 60°C for 1 min, 72°C for 3 min (15 cycle), 72°C for 5 
min (final extension), which will achieve a mutation rate of 0.66% per nucleotide 
position. In the second protocol, a set of 5 tubes prepared and each tube contain: 
PhusionR High-Fidelity PCR (BioLabs), (0.5 µM) forward and reverse primers Table 
1, DNA template and volume completed to 50 µl by dH2O. Different concentrations 
of MnCl2 (50 µl, 100 µl, 200 µl .300 µl, 400 µl) were added to each tube before 
amplification. PCR products were amplified using the protocol described in 2.1.5. 
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The PCR products were analyzed by agarose gel electrophoresis and the correct 
sizes of the PCR products were extracted using a gel extraction kit according to the 
kit manufacturer’s instructions. The products were cloned into pTriEx1.1 vector, 
transformed in Stellar cells (section 2.3) and subsequently plated on solid LB 
medium with 100 µg/ml ampicillin and the mutation rate was confirmed by 
sequencing 10 randomly selected colonies.  
2.14 Directed evolution 
The 17 clone-1 mammalian cells were grown in a T25 tissue culture flask and when 
cells confluence reached ~70%, cells were transfected with a library of variants 
generated by ep-PCR second protocol (50 µl MnCl2) (section 2.13) using Turbofect 
reagent according to the manufacturer’s instructions. After 24 hr incubation, the 
adherent cells were washed with PBS twice and infected with MHV-A59 (MOI=3). 
The flask was incubated at 37°C on a low speed platform rotator (Grant-bio) for 45 
min. After incubation, the inoculum was removed and adherent cells gently washed 
with 2 ml PBS. A fresh 5 ml DMEM media added to the flask and incubated at 37°C 
for 16 hr. The supernatant was collected and kept at -80°C. The flask was washed 
carefully with 2 ml PBS 3 times to eliminate all dead cells. Intact cells were 
recovered by scraping and low speed centrifugation at 4°C and any plasmid DNA 
present in the surviving cells was extracted using a plasmid miniprep kit (Thermo 
Fisher SCIENTIFIC), amplified with specific primers Table 1 using PCR 
amplification protocol described in section 2.1.5. After amplification, gel 
electrophoresis was carried out to visualize DNA fragments. As described 
previously, the PCR reaction products were purified using PCR purification kit 
(Thermo Fisher SCIENTIFIC). The DNA fragments were then inserted in plasmid 
through In-Fusion protocol, transformed in Stellar competent cells and each 100 µl 
	  	   74 
from transformed mixture was placed in 10 ml LB broth with 100µg/ml ampicillin. 
After 16 hr incubation, Miniprep kit (Thermo Fisher SCIENTIFIC) was used for 
isolation of the plasmid DNA from the culture cells according to the manufacturer’s 
instructions and concentration was measured. The library was then ready for 
second round of directed evolution. This process was repeated for several 
passages and the supernatants were collected from each passage and applied for 
plaque assay.  
2.15 Cell culture  
17clone-1 mouse fibroblast cells were grown at 37°C in Dulbecco’s modified Eagle 
medium (DMEM; Gibco/Invitrogen) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), penicillin/streptomycin (penicillin 100 U/ml, streptomycin 0.1 
mg/ml; Gibco/Invitrogen), 1% L-Glutamine (Gibco/Invitrogen) and 1% non-essential 
amino acids 100× concentrate (NEAA; Gibco/Invitrogen). For the maintenance of 
cells, cells were split once they reached ~90% confluence. The media was 
removed and the cells were washed twice with sterile 1x PBS. The cells were 
detached from the plastic using 0.2% Trypsin-EDTA (PAA; Sigma). The cells were 
then suspended in fresh DMEM media to inactivate the trypsin. An aliquot of the 
cell suspension was added to a new flask containing fresh DMEM media and this 
sub-cultivation cycle were routinely repeated.  
2.16 Determination of viral titre by plaque assay 
17clone-1 cells were seeded into 24 well plate (Greiner Bio-one) at approximately 
1.9×105 cells per well, and incubated at 37°C in 5% CO2 for two days, at which a 
monolayer reached ~90-100% confluence. Serial 10-fold dilutions of the MHV-A59 
were prepared in serum free medium (Sigma Aldrich). Following the aspiration of 
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culture media from the wells, 100 µl of each viral dilution was added per well in four 
wells. Plates were incubated at 37°C for 45 min on a low speed platform rotator to 
allow virus to infect the cells and avoid plates drying. 1.4 gm of agarose was 
dissolved in 100 ml distilled water and autoclaved to set agarose medium. Mixing 
2x DMEM (composed of 13.38 gm Dulbecco's modified eagles medium powder 
(gibco), 3.7 gm NaHCo3 (BDH AnalaR) in 500 ml nH2O, Filtered in 0.22 µm filter 
(Sarstedt)) with 4% FBS, 2% penicillin/streptomycin (Gibco, Invitrogen), L-
Glutamine (Invitrogen) and non essential amino acid (Sigma Aldrich) for preparing 
overlay. Equal volumes of agarose and overlay were mixed and kept at 42°C in 
water bath. After incubation, the inoculum was removed and the cells were washed 
with PBS. 1-1.5 ml of agarose overlay media was added in each well, allowed to 
solidified and incubated at 37°C in humidified CO2 (5%) for three days. After 72 hr, 
cells were fixed by adding fixation solution (25 ml 37% formalin (Sigma-Aldrich) 
and 75 ml PBS) for one hour at room temperature. Then, agarose overlay were 
removed by flipping out and monolayers were stained with staining solution (35 ml 
1% crystal violate (ACROS), 35 ml ethanol and volume completed to 100 ml with 
distilled water) for 10 min, washed, and stained plaques of 4 wells of each 
appropriate dilution were counted. PFU/ml were calculated to determine the viral 
infectivity using the following formula: average/dilution factor*volume of diluted 
virus added to the well.  
2.17 Evaluation of cytotoxicity using 3-(4,5-dimethylthiazol-2-yl)-
2,5- diphenyltetrazolium bromide assay (MTT) 
 
The MTT assay method was used to assess the cytotoxicity of wild type and 
mutated proteins in vitro. Cells viability was measured by monitoring the conversion 
of MTT (Sigma) to formazan. 17clone-1 cells were seeded into 24 well plates 
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(Greiner Bio-one)  (100 µl/ well) and allowed to adhere for 24 hr. The next day, 
each well was transfected with a plasmid containing wild type and mutated protein 
in triplicate. After incubation, 20 µl of filter sterilized MTT (5 mg/ml in PBS) was 
added to each well. Following 4 hr incubation period with MTT at 37°C, media was 
removed and 100 µl of sterile DMSO was added to dissolve blue formazan crystals 
trapped inside cells. The absorbance at 595 nm was measured with a plate reader 
(Tecan GENios Microplate Reader) after 1 hour and 24 hours incubation at 37°C.    
2.18 Nsp16 protein purification 
2.18.1  Preparation of LOBSTR E. coli competent cells 
LOBSTR E. coli competent cells was made chemically competent using the 
following protocol; A glycerol stock of LOBSTR E. coli strain was kindly provided 
from Prof. Ian Jones and streaked in fresh LB agar plate to obtain single colonies. 
A single colony was then inoculated into 10 ml of LB medium and grown at 37°C in 
the shaker (225 rpm) overnight. The following day, 1 ml of the starter culture was 
diluted 1/50 to a final volume of 50 ml with fresh LB medium and incubated with 
shaking at 37°C until an OD600 of 0.3- 0.5 was reached. The cells were harvested 
by centrifugation at 4,500 rpm for 20 min at 4°C in falcon tube. The supernatant 
was discarded and the bacterial cell pellet was re-suspended in 5 ml ice-cold sterile 
0.1M CaCl2 and incubated on ice for 3 min. The cells were harvested as above and 
the pellet re-suspended in 5 ml 0.1M CaCl2 containing 15% glycerol (v/v). The cell 
suspension was divided into 50 µl aliquots in sterile 1.5ml eppendorf tubes, snap 
frozen in liquid nitrogen and stored at -80°C. 
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2.18.2   Heat shock transformation of competent LOBSTR E. coli 	  
Chemically competent LOBSTR cells (50 µl) were thawed on ice for 5-10 minutes. 
50-100 ng Plasmid DNA was added and incubated for 25 min on ice. “Heat shock” 
was carried out at 42°C for 45 sec followed by immediate transfer to ice for 2 min. 
450 µl of pre-warmed SOC media was added to allow the bacteria to recover from 
the heat shock. After one hour incubation at 37°C in the shaker (225 rpm), 100 µl 
and 400 µl were plated on LB agar plates containing ampicillin and incubated at 
37°C overnight. After 18 hr incubation, single colonies were inoculated in 10 ml LB 
broth supplemented with 100 µg/ml ampicillin and grown overnight at 37°C in the 
shaker (225 rpm). Glycerol stocks (15% v/v) were prepared and stored at -80°C. 
2.18.3   Small scale protein expression 
Levels of expression and solubilites of nsp16 protein were assessed in different E. 
coli host strains (BL21 (DE3)-pLysS and LOBSTR E. coli) growing in either LB or 
Auto induction media (AIM), with different induction temperatures (16°C and 37°C) 
and different time for induction (3 hours and 16 hours). The expression plasmid 
was transformed into the cloning hosts; BL21 (DE3)-pLysS and LOBSTR E. coli as 
descried in sections 2.3 and 2.18.2, previously. The next day, single colonies were 
inoculated to 10 ml LB with ampicillin, incubated overnight at 37°C in the shaker 
(225 rpm). The following day, the starter culture was diluted 1/1,000 to a final 
volume of 50 ml with fresh LB and AIM media and incubated with shaking until an 
OD600 of 0.6 was reached. For cells in LB media, IPTG was added to a final 
concentration of 1 mM to induce expression. The culture was left to grow at 37°C 
for three hours or overnight at 16°C. Then, the cells were harvested by 
centrifugation (4500 rpm for 45 min at 4°C). The supernatant was discarded and 
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the cell pellets were then re-suspended in 1x binding buffer (50 mM Tris-HCL, 150 
mM NaCl, 40 mM imidazole, pH 8.0) with 1x EDTA-free, cOmplete ULTRA 
protease inhibitor cocktail (Roche), stored at -20°C. For AIM media, the culture was 
left to grow overnight at 16°C with agitation. Then, the cells were harvested by 
centrifugation (4500 rpm for 45 min at 4°C), the supernatant was discarded and the 
cell pellets were then re-suspended in 1x binding buffer with 1x EDTA-free, 
cOmplete ULTRA protease inhibitor cocktail, stored at -20°C. 
2.18.4   Large scale protein expression  
For large-scale expression in LOBSTR E. coli, transformed cells were recovered 
from glycerol stock (section 2.18.2) by streaking a loopful onto LB agar containing 
ampicillin (100 µg/ml). A single colony was picked and used to inoculate a 10 ml 
overnight LB culture. The following day, the overnight culture was diluted 1/500 in 
fresh 500 ml of selective LB medium with ampicillin and incubated at 37°C in the 
shaker until an OD600 of 0.6 was reached. Adding IPTG induced protein expression. 
The culture was left to grow at 37°C for three hours. 1 ml was taken after each hour 
to optimize level of induction. Cell pellets were harvested and re-suspended in 
binding buffer containing proteinase inhibitor tablets and were ready for sonication, 
filtration, and purification by HisTrap
TM HP column. 
2.18.5  Cell lysis 
Cell stocks were left to thaw on ice before proceeding with purification; a pinch of 
lysozyme (SIGMA) and 10 µl of benzonase (Expedeon) was added to 
concentration of 250 unit/µl. Then, sample was sonicated for 5 min on ice (30 sec 
on: 30 sec off) with 85% amplitude. 500 µl of Triton 100x (Fisher) was added and 
samples were incubated on ice for 30-60 minutes. The samples were centrifuged at 
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4,500 rpm for 20 min at 4°C in falcon tube. The soluble fraction was filtered through 
a 0.8 µm or 0.45 µm syringe filter unit (Millipore Merck). The supernatant was 
ready for purification.  
2.18.6 Purification of protein  
Proteins was purified with a Ni
2+ affinity column (HisTrap
TM HP column; GE 
Healthcare), according to the manufacturers’ instructions’, the 5 ml column was 
equilibrated with 5 column volumes (CV) of binding buffer containing low imidazole 
concentration. The protein sample was loaded onto the column using a syringe. 
Then, the column was washed with 5 CV of binding buffer to remove unbounded 
materials. The sample was eluted with elution buffer (50 mM Tris-HCL, 150 mM 
NaCl, 400 mM imidazole, pH 8.0). The 5 ml fractions were collected in separated 
falcon tubes and those containing the protein of interest were concentrated using 
the vivaspin 10kDa molecular weight (GE Healthcare). SDS-PAGE (section 2.9) 
and coomassie staining (section 2.10) were used to check purification of protein at 
different stages. The column was immediately re-equilibrated with 5-10 CV binding 
buffer.  
2.18.7   Determination of protein concentration by Bradford Assay 
Bradford assays were used to measure protein concentrations. Bovine serum 
albumin (BSA) (Sigma) was dissolved in PBS buffer to prepare standard curve. 
The stock solution was diluted with PBS to obtain serial of dilutions.10 µl of each 
standard dilution was added into a 96 well plate in duplicate and 200 µl of Bradford 
reagent (BioRad) was added. 10 µl of unknown protein solution was combined with 
200 µl of Bradford reagent in duplicate. Two more different dilutions (1x, 5x) of 
unknown protein were added in duplicate and the absorbance of each sample was 
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measured at OD595. The unknown protein concentration is deterimed by blotting a 
BSA protein standard curve against the absorbance 595 nm.  
2.18.8  Statistical analysis 	  
The error bars represent the standard deviation of the mean. Statistical significance 
was determined using the t-test and differences were considered significant if the 
P-value was less than or equal to 0.05. 
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3 Cloning and expression of MHV genes and proteins 
in E. coli BL21(DE3)-pLysS competent cells and 
mammalian cells. 
3.1 Introduction 
Murine Hepatitis Virus (MHV) is used as a typical model system for the study of 
coronavirus replication and transcription (Snijder et al., 2003) and is closely related 
to SARS-CoV. MHV has historically served as a model system for studying 
infections caused by CoVs since it has the undeniable advantage of easy growth in 
cell culture in comparison to other CoVs such as human coronaviruses. Several 
MHV-A59 proteins have been investigated in the past two decades to clarify protein 
functions and protein-protein interaction. It has been observed in a number of 
studies that the presence of some coronavirus proteins and genes may alter the 
infectivity of the virus (Cui et al., 2015), some proteins stimulate other proteins, 
which is a common mechanism for coronaviruses as they form many protein-
protein complexes and targeting these proteins can suppress coronavirus 
replication (Wang et al., 2015). To investigate any potential inhibitory effect of 
different CoV proteins requires transient expression of these proteins in suitable 
mammalian cells. 
The expression of stable protein in mammalian cell requires several factors to be 
considered. For instance, selection of a proper vector is an essential factor that 
needs to be considered during experiment design. The plasmid pTriEx1.1 is 
designed to allow rapid characterization of target proteins in multiple expression 
systems (E. coli, insect and vertebrate). Expression of the gene of interest in 
mammalian cells is mediated by a hybrid promoter composed of the 
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cytomegalovirus (CMV) immediate early enhancer fused to the chicken β-actin 
promoter, termed a CAG promoter. In addition, pTriEx1.1 recombinant plasmids 
can be transferred into certain E. coli strains engineered to express the T7 
polymerase allowing IPTG induction of T7 promoter driven transcripts. Another 
critical factor is the selection of proper cloning method. Various techniques have 
been developed to introduce DNA into cultured prokaryotic and eukaryotic cells 
efficiently and selection of a suitable cloning system depends on several important 
numbers such as high fidelity, ease of use, less time consumption, low cost and 
high yield and solubility of any protein in a single batch (Marsischky and LaBaer, 
2004). Traditional cloning involves any DNA constructs that are joined by a ligation 
enzyme at restriction enzyme sites. However, the available unique sites in the 
vector and gene limit construct options. Such traditional DNA constructs are also 
undesirable for fusion proteins because this method sometimes includes undesired 
amino acids encoded by the restriction sites engineered to provide a joining point 
which can lead to reduced protein expression. In contrast, an In-Fusion enzyme 
reaction has the ability to join any two pieces of DNA that have 15 bp of identity at 
their ends. In addition, four or more pieces of DNA can be joined by In-Fusion in a 
single reaction (Zhu et al., 2007). 
The In-Fusion method is based on ligation independent cloning and depends on 
the unique properties of the 3′–5′ exonuclease activity of poxvirus DNA polymerase 
(Hamilton et al., 2007; Zhu et al., 2007). This system requires linear duplex DNAs 
with homologous ends that are incubated in the presence of Mg2+ and low 
concentrations of dNTP. The 3′–5′ proofreading activity of poxvirus DNA 
polymerase removes nucleotides from the 3′ end to produce single-stranded ends. 
Through base pairing, the complementary regions are annealed spontaneously to 
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generate a joined molecule that contains a hybrid region flanked by nicks, 1–5 
nucleotide gaps, or short overhangs. The low affinity of poxvirus DNA polymerase 
toward nicked or gapped DNA ends than for duplex ends permits the formation of 
metastable annealed structures. Finally, after transformation E. coli will repair any 
single-stranded gaps when introduced and the result is equivalent to a 
recombination event at the ends of the DNAs Figure 3.13. The In-Fusion cloning 
method was therefore selected as the most appropriate method to clone selected 
coding regions from the MHV-A59 genome into the pTriEx1.1 vector.  
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Figure 3.13. The In-Fusion system. The gene of interest is amplified with specific 
designed primers that contain 15bp extensions homologous to vector ends. The In-Fusion 
cloning reaction is set up for 15 minutes at 50°C. The Vaccinia virus DNA polymerase that 
has 3’ 5’ exonuclease activity will anneal the 15bp fragment of single stranded DNA. The 
In-Fusion mixture then, transformed into competent cell and transformed cells are grown 
on agar plate supplemented with antibiotic. Transformation of the construct into E. coli will 
repairs any gaps or nicks in the DNA sequence (Adapted from Zhu et al., 2007).  
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A gene delivery system is required to achieve cytoplasmic gene expression and the 
delivery of plasmid DNA by transfection reagents is one of the simplest and widely 
used methods. There are several protein transfection reagents that are 
commercially available however and a major key to success in protein delivery to 
cells is choosing the appropriate transfection reagent with high efficiency and low 
cytotoxicity. There are several factors that are important in selecting transfection 
reagent. Firstly, surface charge density, which is an important factor that can be 
related to the transfection efficiency. Several studies showed that the highest 
values of transfection occurred for the most positively charged complexes (Farrow 
et al., 2006), while other studies observed that the highest transfection efficiency 
was with negatively charged complexes. Secondly, some manufacturer’s protocols 
recommend serum-free medium for best results (Oba and Tanaka, 2012) as  size, 
chemical structure and mechanism for gene delivery are also factors to be 
considered when choosing protein transfection reagents for experiments.  
This aim of this chapter is to generate constructs for several MHV-A59 proteins in 
the pTriEx1.1 vector, demonstrate expression in E. coli and develop tranfection of 
17clone-1 mammalian cells, which are chosen as they are permissive for MHV-A59 
infection and so, by definition, contain any necessary cellular factors required by 
the virus.   
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3.2 Results 
 
In-Fusion cloning technology was used in this study. This technology ensures easy, 
directional cloning of DNA fragments into any vector with high cloning efficiency for 
any DNA fragment size. This strategy relies on recognition of 15 bp overlap 
sequences at the ends of each of the desired DNA fragments and linearized vector 
and then fuses these DNA fragments at these ends. These 15 bp overlap 
sequence can be simply generated by PCR amplification after addition them to the 
requisite primers for the genes concerned. The vector of choice, in this case 
pTriEx1.1, is linearized with NcoI and XhoI in such a way that the amplified ORF in 
the final construct will allow expression to include a C-terminal His tag already 
present in the pTriEx1.1 vector Figure 3.14. The His tag in the pTriEx1.1 vector 
enables detection of all expressed proteins using SDS-PAGE analysis and 
Western blot with a His tag specific antibody. Structural proteins such as N and M 
proteins, non structural proteins (5,6,7,8,9,10,16) from gene1, non-structural 
proteins PlPro, Y-domain from nsp3 and the N-terminus and RdRp from the C-
terminal region of nsp12 from MHV-A59 cDNA were PCR amplified with primers 
designed specifically for each coding region using the In-Fusion primer design tool 
Table 2.1. Each PCR product was mixed with linearized vector in the In-Fusion 
reaction mix. This cloning strategy should derive vectors that allow for expression 
of MHV-His tagged fusion proteins in both E. coli and 17clone-1 mammalian cells 
via the promoters present.  
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Figure 3.14. Cloning design using In-Fusion protocol. Cloning site located between 
NcoI and XhoI sites. 
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3.2.1   PCR amplification of DNA fragments from cDNA of MHV-A59 
 
The cloning process was carried out by amplifying the gene of interest by PCR. 
After amplifying with specific forward and reverse primers for each coding region 
Table 2.1, the PCR products were analyzed by agarose gel electrophoresis and 
the correct sizes of the PCR products (see Table 9.10) were compared against a 
1kbp DNA ladder, the results of which are shown in Figure 3.15, Figure 3.16 and 
Figure 3.17. The obtained products were purified using gel extraction kit and 
quantified by a Nanodrop spectrophotometer.  
 
Figure 3.15. Amplification of membrane gene, nsp3_Y-domain, nsp8 and nsp9 from 
cDNA of MHV-A59. cDNA of MHV-A59 was used as a template to amplify the M, nsp3_Y-
domain from nsp3, nsp8 and nsp9 coding regions. (A) Lane 1: Marker (1kb) DNA ladder, 
Lane 2: M protein (687bp), Lane 3: nsp3_Y-domain (1200bp). (B) Lane 1: Marker (1kb) 
DNA ladder, Lane 2: nsp8 (591bp), Lane 3: nsp9 (330bp). 
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Figure 3.16. Amplification of nsp12, nsp12_C-terminal, N protein, nsp5, nsp6 and 
nsp3_PlPro from cDNA of MHV-A59. cDNA of MHV-A59 was used as a template to 
amplify nsp12, nsp12_N-terminal, N protein, nsp5, nsp6 and nsp3_PlPro. (A) Lane 1: 
Marker (1kb) DNA ladder, Lane 2: nsp12 (2784bp), Lane 3: nsp12_C-terminal (1692bp), 
Lane 4: N protein (1365bp). (B) Lane 1: Marker (1kb) DNA ladder, Lane 2: nsp3Pro (744bp) 
Lane 3: nsp5 (909bp), Lane 4: nsp6 (861bp). 
 
  
Figure 3.17. Agarose gel electrophoresis of nsp10, nsp12_N-terminal and nsp16 
amplified by PCR from cDNA of MHV-A59. cDNA of MHV-A59 was used as a template 
to amplify nsp10, nsp12_N-terminal and nsp16 (A) Lane 1: Marker (1kb) DNA ladder, Lane 
2: nsp10 (393bp), (B) Lane 1: Marker (1kb) DNA ladder, Lane 2: nsp12_N-terminal 
(1092bp), (C) Lane 1: Marker (1kb) DNA ladder, Lane 2: nsp16 (900bp). 
 
The pTriEx1.1 plasmid was double digested with NcoI and XhoI restriction 
enzymes and visualized following gel electrophoresis as in Figure 3.18. Linearized 
vector was purified using a gel extraction kit according to the manufacturer’s 
instructions. Then, each amplified MHV PCR product was combined with the 
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linearized pTriEx1.1 vector through an In-Fusion cloning reaction to allow efficient 
and precise recombination of the vector and the desired DNA fragment. 
 
Figure 3.18. Double digest of pTriEx1.1. An agarose gel showing the digested 
pTriEx1.1. Marker (1kb) ladder, pTriEx1.1 plasmid digested with NcoI and XhoI restriction 
enzymes (5155bp). 
 
3.2.2 Transformation of In-Fusion products into competent E.coli cells 	  
The In-Fusion reaction mixes were transformed into chemically competent StellarTM 
E. coli cells and plated on LB agar containing ampicillin to select for transformants. 
About 30 colonies were selected randomly and screened by colony PCR using 
either T7 forward or TriExUP as a forward primer and either TriExDOWN or 
fragment specific primers as the reverse primer. The amplification products were 
analyzed following agarose gel electrophoresis; Figure 3.19 shows 13 colonies 
screened by colony PCR for the N protein gene using T7 forward and Rv_N 
primers (correct size 1546bp) where all but one of the screened colonies was 
positive for the correct sized insert.  
5000 
4500 
4000 
3500 
3000 
2500 
2000 
1500 
  
1000 
800 
  
600 
pTriEx1.1             Marker bp 
	  	   91 
 
Figure 3.19. N protein screened by PCR. 13 colonies were screened for the presence of 
N protein insert. Lane 1: Marker (1kb) DNA ladder, Lanes 2-14: colonies numbered from 1-
13. 
 
Two positive colonies were transferred into 10 ml LB broth supplemented with 
ampicillin and grown overnight at 37°C with shaking. Plasmid DNA was purified 
and a restriction digest performed using NcoI and XhoI as shown in Figure 3.20. 
Plasmid DNA from the transformants that contained the expected size insert were 
sequenced via Sanger sequencing at Source BioScience using T7 forward and 
TriExDOWN primers Table 2.2. Alignments were performed in Snapgene software 
to confirm the expected sequence of each insert and to check that the inserts were 
in frame with respect to the ATG start site and the C-terminal His tag. A glycerol 
stock of each positive transformant was prepared and stored at -80°C. 
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Figure 3.20. Gel electrophoresis of double digested pTriEx1.1 containing nsp16 and 
N protein. (A) Lane 1: Marker (1kb) DNA ladder, Lane 2: pTriEx1.1_nsp16 double digest 
with Ncol and Xhol (900bp), (B) Lane 1: Marker (1kb) DNA ladder, Lane 2: pTriEx1.1_ N 
protein double digest with Ncol and Xhol (1365bp). 
 
3.2.3 Correction of random mutation in nsp12_N-terminal  
 
All proteins sequences were identical to the sequences obtained from GeneBank 
(accession number AY700211.1) for MHV-A59 except for the nsp12_N-terminal 
coding region where the sequence analysis showed a C deletion at position 26. In 
order to correct this mutation in nsp12_N-terminal, which appeared to be a random 
error in the cDNA as it was present in all the transformants screened, additional 
forward (Fw_nsp12N-new) and reverse (Rv_nsp12N-new) primers Table 2.3 were 
designed to correct the mutation by overlapping PCR. One original nsp12_N-
terminal transformant was amplified by PCR with forward primer (Fw_SacII) and 
reverse primer (Rv_nsp12N-new) in reaction PCR1. Another PCR was carried out 
with forward (Fw_nsp12N-new) and reverse primer Rv_12N Table 2.1, reaction 
PCR2. The PCR products were analysed by agarose electrophoresis, and the 
correct sizes (396bp and 1070bp bp) were obtained for both PCR1 and PCR2 
respectively Figure 3.21.  
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Figure 3.21. Gel electrophoresis of PCR products following amplification of 
nsp12_N-terminal for one transformant using protein-specific primers. Lane 1: 
Marker (1kb) DNA ladder, Lane 2: PCR1 (396bp), Lane 2: PCR2 (1070bp). 
 
The DNA products were purified using a PCR purification kit and quantified by 
Nanodrop sectrophotometer, the concentrations were 195.6ng/µl for PCR1 and 
397.7ng/µl for PCR2. Then, 0.1ng/bp PCR from each product were mixed and 
subjected to PCR in a PCR reaction for five cycles without primers. Then, forward 
primer (Fw_SacII) and reverse primer (Rv_12N) were added and another thirty 
cycles were completed. The correct size 1466bp of overlap PCR product was 
analysed by agarose gel electrophoresis Figure 3.22, and extracted by gel 
extraction kit as before.  
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Figure 3.22. Agarose gel electrophoresis of two joined parts of nsp12_N-terminal 
amplified by PCR. Lane 1: Marker (1kb) DNA ladder, Lane 2: PCR1+PCR2 (1445bp).  
 
The purified product was quantified by Nanodrop spectrophotometer and the 
concentration was 216.8 ng/µl. The PCR product was first digested with SacII 
restriction enzyme for one hour at 37°C and then a clean up kit was used to purify 
the product. A second digest was applied to the PCR product with restriction 
enzyme XhoI for 45 minutes at 37°C. The new digested product was extracted by 
gel extraction kit after agarose gel electrophoresis and quantified by Nanodrop 
sectrophotometer, the concentrations was 35.2 ng/µl. Empty pTriEx1.1 plasmid 
was also digested with SacII and XhoI restriction enzymes as described previously. 
A T4 ligation kit was used for ligation according to the manufacturer`s instruction. 
The ligation mix was transformed into StellarTM E. coli competent cells with empty 
plasmid transformed as a control to check the efficiency of transformation. Colony 
PCR was performed using forward primer and reverse primer as in Table 2.1 to 
check for the presence of the nsp12N-terminal protein and three positive colonies 
with the most intense bands of the expected size were selected Figure 3.23.  
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Figure 3.23. Gel electrophoresis of colony PCR of Nsp12N in pTriEx1.1 plasmid. 
Lane 1: Hyperladder, Lanes 2-13: The colony PCR product corresponding to 1-12 
transformants, the correct size of Nsp12N is 1092bp. 
 
Transformants were grown at 37°C overnight in 10 ml LB broth with ampicillin and 
plasmid DNA extracted as before. Finally the three isolates were sent for 
sequencing to confirm the sequence correction. A glycerol stock was prepared and 
samples stored at -80°C freezer. 
3.2.4 Protein expression in E. coli BL21(DE3)-pLysS competent cells by 
IPTG induction 	  
All positive plasmids used in this study were transformed into E. coli BL21 (DE3)-
pLysS competent cells and plated on LB agar plates containing ampicillin. Two 
colonies selected randomly were grown in 10 ml LB broth with ampicillin (10 µg/ml) 
and chloramphenicol (34 µg/ml) at 37°C overnight in a shaking incubator. Of these 
cultures, 200 µl was transferred to a fresh 10 ml LB broth and grown to OD600 0.4-
0.6. Protein expression was induced by the addition of isopropyl-β-D-1-
thiogalactopyranoside (IPTG) and allowed to continue for 4 hours for optimal 
expression. Both before and after IPTG induction, aliquots of the bacterial culture 
were harvested for SDS-PAGE analysis. Western blots were performed and bands 
detected using anti His tag antibody. Cells only and E. coli BL21 (DE3)-pLysS 
carrying the empty pTriEx1.1 vector were used as controls. The induction was 
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successful for all proteins and the predicted sizes of each expressed protein were 
detected. Induction of Nsp16 protein showed a clear band (34.3kDa) after one hour 
induction with IPTG which became less distinct with time Figure 3.24. 
 
 
 
 
 	  	  	  
Figure 3.24. Western blot analysis of recombinant expression of nsp16 in E. coli 
BL21(DE3)-pLysS competent cells. Protein sample was extracted from E. coli prior to 
(non-induced; 0hr) and following induction of protein expression with IPTG at 37°C. Protein 
samples were subsequently taken after 1hr for 4 hours. pTriEx1.1 vector  was used as a 
control. 
 
Similarly, Western blot analysis showed a band of 50.8kDa for the N protein and 
nothing of the pTriEx1.1 vector used as a control Figure 3.25. 
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Figure 3.25. Western blot analysis of recombinant expression of N protein in E. coli 
BL21(DE3)-pLysS competent cells. Protein sample was extracted from E. coli prior to 
(non-induced; 0hr) and following induction of protein expression with IPTG at 37°C. Protein 
samples were subsequently taken after 1hr for 4 hours. pTriEx1.1 vector  was used as a 
control. 
 
Figure 3.26 and Figure 3.27 shows a clear band of 23kDa and 45.3kDa for nsp8 
and the Y-domain of nsp3 respectively in Western blot analysis.  
 
Figure 3.26. Western blot analysis of recombinant expression of nsp8 in E. coli 
BL21(DE3)-pLysS competent cells. Protein sample was extracted from E. coli prior to 
(non-induced; 0hr) and following induction of protein expression with IPTG at 37°C. Protein 
samples were subsequently taken after 1hr for 3 hours. Nsp8 protein size (indicated by an 
arrow) was detected after 1hr; C1 and C2 represent two colonies.  
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Figure 3.27. Western blot analysis of recombinant expression of nsp3_Y-domain in 
E. coli BL21(DE3)-pLysS competent cells. Protein sample was extracted from E. coli 
prior to (non-induced; 0hr) and following induction of protein expression with IPTG at 37°C. 
Protein samples were subsequently taken after 1hr for 4 hours. Nsp3_Y-domain protein 
size (indicated by an arrow) was detected after 1hr; C1 and C2 represent two colonies, 
pTriEx1.1 vector was used as a control. 
 
The nsp12_C-terminal showed a band of about 68.2kDa in Western blot analysis 
after one hour induction. Plasmid vector served as a control Figure 3.28. 
 
  
Figure 3.28. Western blot analysis of recombinant expression of nsp12_C-terminal in 
E. coli BL21(DE3)-pLysS competent cells. Protein sample was extracted from E. coli 
prior to (non-induced; 0hr) and following induction of protein expression with IPTG at 37°C. 
Protein samples were subsequently taken after 1hr for 4 hours. Nsp12_C-terminal protein 
size (indicated by an arrow) was detected after 1hr; C1 and C2 represent two colonies; 
pTriEx1.1 was used as a control. 
 
Similarly, Western blotting was performed to detect expression of nsp7 and the 
result showed a clear band (10.9kDa) after one hour induction in both 
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transformants analysed Figure 3.29. A stronger band at around twice the 
molecular weight appears to be an E. coli protein cross reacting with the antibody 
as it was also present in some control tracks (e.g. Figure 3.28). 
	  
Figure 3.29. Western blot analysis of recombinant expression of nsp7 in E. coli 
BL21(DE3)-pLysS competent cells. Protein sample was extracted from E. coli prior to 
(non-induced; 0hr) and following induction of protein expression with IPTG at 37°C. Protein 
samples were subsequently taken after 1hr for 3 hours. Nsp7 protein size (indicated by an 
arrow) was detected after 1hr; C1 and C2 represent two colonies. 
 
 
Another two MHV-A59 proteins, M protein and nsp3_PlPro were detected by 
Western blotting, showing the predicted sizes of 27.1kDa and 29kDa for M protein 
and nsp3_PlPro respectively Figure 3.30 and Figure 3.31 although the M protein 
migrated close to the E. coli contaminant making its identity tentative at this stage. 
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Figure 3.30. Western blot analysis of recombinant expression of membrane protein 
(M) in E. coli BL21(DE3)-pLysS competent cells. Protein sample was extracted from E. 
coli prior to (non-induced; 0hr) and following induction of protein expression with IPTG at 
37°C. Protein samples were subsequently taken after 1hr for 3 hours. Membrane gene 
size (indicated by an arrow) was detected after 1hr; C1 and C2 represent two colonies. 
	  
Figure 3.31. Western blot analysis of recombinant expression of nsp3_PlPro in E. coli 
BL21(DE3)-pLysS competent cells. Protein sample was extracted from E. coli prior to 
(non-induced; 0hr) and following induction of protein expression with IPTG at 37°C. Protein 
samples were subsequently taken after 1hr for 4 hours. Nsp3Pro protein size (indicated by 
an arrow) was detected after 1hr. 
 
Finally, the expression of nsp12_N-terminal and nsp9 were also successful in E. 
coli BL21(DE3)-pLysS and Western blot analysis for both proteins showed clear 
bands of 43.3kDa for nsp12_N-terminal and 13.3kDa for nsp9 after one hour 
induction with IPTG Figure 3.32 and Figure 3.33. 
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Figure 3.32. Western blot analysis of recombinant expression of nsp12_N-terminal in 
E. coli BL21(DE3)-pLysS competent cells. Protein samples were extracted from E. coli 
prior to (non-induced; 0hr) and following induction of protein expression with IPTG at 37°C. 
Protein samples were subsequently taken after 1hr for 4 hr. Nsp12_N-terminal protein size 
(indicated by an arrow) was detected after 1hr; C1 and C2 represent two colonies 
 
Figure 3.33. Western blot analysis of recombinant expression of nsp9 in E. coli 
BL21(DE3)-pLysS competent cells. Protein samples were extracted from E. coli prior to 
(non-induced; 0hr) and following induction of protein expression with IPTG at 37°C. Protein 
samples were subsequently taken after 1hr for 3 hours. Nsp9 protein size (indicated by an 
arrow) was detected after 1hr; C1 and C2 represent two colonies. 
 
 
3.2.5   Expression and optimization of transfection in mammalian cells 
 
17 clone-1 mammalian cell lines were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM). Transfections of the protein expressing constructs were carried 
out in 6 well plates using a range of different transfection reagents (FugeneHD, 
Fugene6, Mirus TransIT-LT1, Turbofect, Lipofectamine2000, Lipofectamine3000) 
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in accordance with the manufacturer’s instructions to determine the optimal 
conditions for plasmid transfection in this cell line. A control vector pTriEx1.1-GFP, 
which carries the Green Florescent Protein (GFP) gene inserted between the NcoI 
and Bsu361 sites in pTriEx1.1 was used to visualize the efficiency of transfection 
(O’Flynn, 2011).  
3.2.5.1 Optimization of transfection reagents  
 
Transfections of 17clone-1 with the selection of transfection reagents showed the 
best levels of GFP expression from the control vector were obtained using 
Lipofectamine2000, Lipofectamine3000 and Turbofect Figure 3.34. 
  
Figure 3.34. In vitro transfection of 17clone-1 cells with pTriEx1.1-GFP using 
different transfection reagents. Cells were grown in equal conditions and transfected 
with pTriEx1.1-GFP using different transfection reagents. The intensity of GFP was 
observed under fluorescence microscopy after 24 hours. 
 
A next step of optimization is determining the optimal DNA concentration for each 3 
transfection reagent that showed best level of GFP expression and results showed 
that Lipofectamine2000 and Lipofectamine3000 gave best result with low DNA 
concentration while Turbofect best result was with high DNA concentration. 
Mirus TransIT-LT1 Fugene6 
FugeneHD Lipofectamine2000 
Lipofectamine3000 
Turbofect 
	  	   103 
3.2.5.2 Optimization of cell density 
 
The initial cell density is an important variable to optimize transfection. Low cell 
density may result in poor transfection and a long time for expression, leading to a 
correspondingly low level of expression. Conversely, high cell density may lead to 
cell overgrowth, which may result in a plateauing of the signal that may obscure a 
true expression result. To determine the optimal cell density, 24 well plates were 
seeded with 17clone-1 mammalian cells so that the next day the confluence was 
50%, 60%, 70%, 80% and 90% in each well. At these stages of confluency plates 
were transfected with pTriEx1.1-GFP using Turbofect, Lipofectamine2000 and 
Lipofectamine3000 transfection reagents as before. The optimal cell density was 
found to be 60%, while higher cell densities increased the numbers of dead cells, 
particularly with Lipofectamine2000 and Lipofectamine3000 Figure 3.35. 
 
Figure 3.35. In vitro transfection of 17clone-1 cells with pTriEx1.1-GFP using 
different cells density. Cells were grown in different density and transfected with 
pTriEx1.1-GFP using Turbofect reagent. The intensity of GFP was observed under 
fluorescence microscopy after 24 hours. Figure (A) represent 50% cells density; figure (B) 
60% cells density; and figure (C) 90% cells density. The intensity of GFP was observed 
under fluorescence microscopy. 
 
3.2.5.3 Optimization of incubation time 
 
It was also necessary to optimize the incubation time with the three most promising 
transfection reagents, Turbofect, Lipofectamine2000 and Lipofectamine3000. 
17clone-1 mammalian cells were seeded in 24 well plates in DMEM containing 
A B C 
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10% FBS for 24 hours before transfection. For Lipofectamine2000 and 
Lipofectamine3000 transfection reagents, the DMEM media was changed to serum 
free opti-MEM and the transfecting reagent containing DNA was added and 
incubated for 24 and 48 hours at 37°C. For Turbofect transfection reagent, DMEM 
media was replaced by serum free DMEM media, then Turbofect reagent 
containing DNA in serum free DMEM media was added and incubated for 24 and 
48 hours at 37°C. The transfection efficiency was evaluated by fluorescence 
microscopy for GFP as before. pTriEx1.1-GFP showed a good expression signal  
with Turbofect, Lipofectamine2000 and Lipofectamine3000 after 24 hours 
incubation and these optimised conditions were then used for transfection of each 
of the expression positive clones obtained as above. However, disappointingly, 
when seeded 6 well plates at the optimum density were transfected under optimal 
consdtions as established using the GFP reporter plasmid, no MHV protein bands 
were detected for any of the clones tested except for the N protein following SDS-
PAGE and Western blot. The N protein was the only protein that showed a clear 
band of 50.8kDa with the His tag antibody, in this case using Turbofect as the 
transfection reagent Figure 3.36. 
 
 
  
 
 
 
	  	   105 
 
Figure 3.36. N protein expressed in mammalian cells. Cells were grown in equal 
conditions and transfected with the N protein construct using different transfection 
reagents, after 24 hours cells they were harvested and total cell extracts were prepared. 
Protein expression of total cell lysates was detected by Western blot using anti His tag-
conjugated antibody. N protein was detected only with Turbofect. Molecular weight marker 
in kDa is indicated on the left, while N protein in E. coli BL21(DE3)-pLysS competent cells 
was used as a positive control. 
 
The lack of product in Western blot may be due to poor expression or protein 
instability due to degradation by cellular proteases, either of which make it a 
challenge to detect the proteins after SDS-PAGE and Western blot. One option 
was to increase the sensivity of the Western blot using conjugated Anti-His versus 
unconjugated Anti-His antibody plus a secondary HRP labeled conjugate and to 
harvesting cell on ice to reduce protease enzyme activity prior to analysis. 
However, as before the results showed no bands after using conjugated and 
unconjugated antibody for all proteins except for N protein Figure 3.37.  
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Figure 3.37. Western blot analysis of MHV-A59 proteins using conjugated and 
unconjugated antibody. Cells were grown in equal conditions and transfected with 
membrane gene, N protein and nsp16 protein, after 24 hours cells were harvested then 
total cell extracts were prepared. (A) Protein expression of total cell lysates was detected 
by Western blot using anti-His tag-conjugated antibody. (B) Protein expression of total cell 
lysates was detected by Western blot using anti-His tag-unconjugated antibody. Molecular 
weight marker in kDa is indicated on the left, while cells, pTriEx1.1, pTriEx1.1-GFP were 
used as a control. 
 
It is possible that the presence of intracellular proteases could affect stability of 
MHV-A59 proteins in 17clone1 cell line and lead to their degradation following 
expression. A protease inhibitor, MG132, was used to try and improve the stability 
of expressed MHV proteins. MG132 protease inhibitor is a peptide aldehyde that 
has the ability to effectively block the proteolytic activity of the 26S proteasome 
complex. Mammalian 17clone-1 cells were treated with MG132 protease inhibitor 
(50 mM) four hours after transfection with pTriEx1.1-nsp3_Y-domain (as a test 
case) and incubated for 24 and 48 hours. Cells in another plate were treated with 
MG132 protease inhibitor four hours before transfection and cultured similarly. 
However, cells harvested from either experiment showed no improvement in the 
expression of nsp3_Y-domain at 24 or 48 hours post transfection Figure 3.38. The 
addition of MG132 was compatible with expression as a GFP control was positive 
throughout. A control E. coli extract showed a positive signal at the predicted 
molecular weight on this blot, indicating the nsp3_Y-domain could be detected by 
the His antibody used in this experiment.  
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Figure 3.38. Protein inhibitor does not stimulate protein expression. 17 clone-1 cells 
were grown in a 6 well plate for 24 hours and transfected using Turbofect and pTriEx-
nsp3_Y-domain or pTriEx_GFP as a positive control. After 24 and 48 hours cells were 
harvested then total cell extracts were prepared for analysis of protein expression via SDS-
PAGE and Western blot. Molecular weight marker in kDa is indicated on the left. Nsp3_Y-
domain in E. coli BL21(DE3)-pLysS competent cells was also used as a positive control. 
 
Since there was no improvement in protein expression signal in two optimisation 
experiments, a further approach assessed was to try using immunoprecipitation to 
concentrate any low level of expressed proteins present in the transfected lysates 
in order to increase the expression signal on the blot. However, while this method 
did improve detection of nsp16 (as an example) expressed in E. coli BL21 (DE3)-
pLysS it again failed to show any evidence of expression in 17clone-1 mammalian 
cells Figure 3.39.  
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Figure 3.39. Nsp16 protein is not detected by immunoprecipitation. 17 clone-1 cells 
were grown in a 6 well plate for 24 hours, transfected with Turbofect containing nsp16, 
after 24 hours cells were harvested then total cell extracts were prepared. Protein 
expression of total cell lysates was detected by immunoprecipitation method. Nsp16 could 
not be detected. Molecular weight marker in kDa is indicated on the left, while pTriEx1.1-
GFP and nsp16 in E. coli BL21 (DE3)-pLysS competent cells was used as a positive 
control. 
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3.3 Discussion 
 
This chapter reports the successful cloning of N protein, M protein, non structural 
proteins (7,8,9,10,16) from gene1, PlPro, Y-domain from nsp3, RdRp from C-
terminal of nsp12 and N-terminal from nsp12 from cDNA of MHV-A59 virus in the 
pTriEx vector using the In-Fusion cloning technique to generate clones capable of 
expression of His tagged fusion proteins. Protein expression was induced in E. coli 
BL21(DE3)-pLysS competent cells using IPTG and the MHV-His-tagged proteins 
were detected at the expected molecular weights in Western blots for all cloned 
constructs after one hour induction. The levels thereafter were variable, perhaps 
indicating issues of protein stability. By contrast with E. coli, transfections of the 
mammalian cell line 17clone-1 showed only a clear band for the N protein.   
 
As a first step to examining the effect of different proteins and genes on virus 
infectivity, this study set out to obtain expressed recombinant MHV proteins to 
determine whether the existing presence of these proteins in cells could affect virus 
infectivity or not. The In-Fusion technique was used to construct the necessary 
vectors and each amplified gene was cloned and inserted between the NcoI and 
XhoI restriction enzyme sites in the pTriEx1.1 vector. The In Fusion technique was 
very efficient with the majority of clones obtained showing positive inserts. The 
success of the cloning design was confirmed when all proteins were expressed in 
E. coli after one hour induction with IPTG. Clear bands were detected for most 
proteins and in some cases expression appeared stable even after 4 hours 
induction. In others however later expression was variable and in the cases of M 
protein the validation of expression was confounded by a host cross-reactive band 
at a similar molecular weight.  
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The preliminary sequence of the nsp12_N-terminal fragment showed a deletion of 
one nucleotide (C) at position 26. This mutation may be due to the framshifting 
events associated with this region, when the ribosome is directed to move into the 
−1, +1 or +2 reading frames from the reference “0” frame (Harger et al., 2002; Stahl 
et al., 2002) and N-terminal of nsp12 is the adjacent domain to the frameshift. An 
overlap PCR extension (Warrens et al., 1997) was utilized to correct this mutation 
to generate a bona fide sequence capable of expression of the nsp12_N-terminal 
protein. An overlap PCR technique was successfully employed to correct a 
mutation in a DNA fragment without the need to use a site directed mutagenesis kit.  
Although both ways provide correction for any mutation, including deletion, the 
overlap PCR provides a simple alternative giving the same result of site directed 
mutagenesis kits that are commercially available.  
In order to test whether MHV-A59 proteins interfere with virus replication, the 
detection of transient expression in 17clone-1 mammalian cells is required as a first 
step. One of the most critical features of expressing proteins in mammalian cells 
was establishing the most suitable conditions and in this study various conditions 
were optimized to provide the highest levels of expressed proteins. The first stage 
of optimization involved determining the best transfection reagent for this cell line 
and several different transfection reagents were tested. The transfection efficiency 
was evaluated by GFP expression, which showed the highest fluorescence 
profiling with Turbofect, lipofectamine2000 and lipofectamine3000. The next stage 
of optimization involved determining the proper DNA concentration for efficient 
expression with Turbofect, lipofectamine2000 and lipofectamine3000 transfection 
reagents. Then, cell density, which is essential to achieve accurate results with 
different transfection reagents were also tested, as low or high cells density will 
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affect protein yield, resulting in an unexpressed or low protein yield in mammalian 
cells. Increasing the incubation time for expression up to 48 hours was also tested. 
Results indicated that Lipofectamine2000 and lipofectamine3000 showed the 
highest fluorescence profiling with low DNA concentration but they also showed the 
highest toxic effect on cells. In contrast, Turbofect, which is a cationic polymer, 
showed less intensity but was the only reagent to express N protein in 17clone-1 
mammalian cells, a permissive cell line for MHV-A59 virus Figure 3.36.  
Western blot analysis was performed to detect the C-terminal His tag routinely 
using a directly conjugated anti His tag antibody. Western blot analysis revealed 
that only N protein was detectable. The undetectable proteins may due to the fact 
that these reagents were toxic to the cells and cause changes such as cell 
shrinking, reduced number of mitoses and vacuolization of the cytoplasm (Salvati 
et al., 2006) although no obvious effects were observed following transfection by 
any construct. Another possible explanation is that the CAG promoter poorly 
expressed these proteins, although the GFP control was expressed well during 
transfection reagents optimisiation and used the same promoter. A furthter 
possibility is that these proteins are inherently unstable. 
Conjugated versus unconjugated antibody use to detect any His tag proteins did 
not improve sensitivity to allow any additional bands to be visualised Figure 3.37 
leaving inherent instability the most likely explanation. In eukaryotic cells, proteins 
are degraded through the ubiquitin-proteasomal system, which is the major 
pathway of non-lysosomal proteolysis of intracellular proteins. It plays a critical role 
in cell cycling, division, differentiation and apoptosis (D. Voges et al., 1999; 
Orlowski, 1999). For better protein detection, tolerated protein inhibitors might have 
been an option in this study. MG132 was chosen to test whether the presence or 
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absence of this protein inhibitor would improve the protein expression of the 
reading frames cloned from MHV. This possibility was strengthened by the fact that 
proteasome inhibitor MG132 has been shown to block the proteolytic activity of 
proteasome complex in live cells (Lee and Goldberg, 1998). Transfected cells were 
treated with MG132 protease inhibitor both before and after 4 hour of transfection 
but the expressed proteins were again not detected by immunoblotting Figure 
3.38. However, additional experiment could have been performed as a positive 
control to confirm that MG132 was functional. 
This result suggests that the MHV proteins when expressed alone might be 
unstable. As noted in the introduction, many of CoV proteins form part of protein 
complexes in infected cells and may require another partner for stability. It is also 
notable that the one positive expression was of a structural protein (N protein). 
Proteins intended as non-structural may have intrinsically short half-lives as they 
are never required to accumulate to a high level. For example, SARS M protein is 
strongly detected until 1 h post synthesis but only weakly at 3 h, SARS S protein 
remains detectable at 12 h however, the E protein has a short half-life of 30 min 
when expressed in baby hamster kidney (BHK)-21 cell line (Nal et al., 2005). Nsp 
proteins have shorter half lives and some enzymatic activity of some nsp depends 
on other domains in gene 1. For example the activity of MHV-A59 PLP is affected 
by mutations to the adjacent ubiquitin-like domain (Ubl-2) and leading to the loss of 
enzymatic activity over time (half-life of ~30 min at 30°C) (Mielech et al., 2015).  
In this study, the immunoprecipitation was also performed from whole cell extract to 
improve the sensitivity of MHV-His tagged protein detection. Trace amount of 
positive protein are “pulled down” from a cytoplasmic extract that represents many 
more cells than could be analysed by direct gel electrophoresis. However, this 
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treatment did not improve detection of any MHV protein Figure 3.39 further 
suggesting that the expression was very low, consistent with degradation following 
translation or at certain steps in the protocol.  Concluding from these experiments, 
no clear explanation was found for the undetected proteins other than intrinsic 
instability.  
There are many challenges in delivering a foreign DNA to mammalian cells, both at 
the intracellular and extracellular level. In order for a gene or a protein of interest to 
show an effect on virus replication, they must be able to be in active form for the 
desired length of time, present in many copies inside the selected cell and not toxic 
on host cells. In order to overcome the problems in transfection/ infection several 
parameters of the transfection process were optimized however N protein was the 
only detected protein. Further experiments could be conducted to improve 
expression condition such as altering cell line or lysis method, use of 
immunofluorescence to look for protein expression and coomassie gel or PonceauS 
to check cellular protein loading and membrane transfer. 
In summary, all the genes cloned are expressed in E. coli, which indicates the 
success of the cloning strategy and the functional ability of the clones. However, 
the efficiency of recombinant protein expression in 17-clone1 mammalian cells 
depends on different parameters and was most likely thwarted by protein stability. 
Initial attempts were made to optimize transfection of the mammalian cells by 
varying the parameters affecting protein expression (cell density/ reagents/ time). 
However, the optimized conditions failed to increase the detection of any MHV 
proteins except the N protein. It is clear therefore that an alternative technique is 
required to increase protein stability, which will be discussed in the next chapter. 
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4 Inhibition of MHV-A59 infectivity by virus proteins in 
vitro 
 
4.1 Introduction 
 
Although all the MHV proteins selected in this study were expressed in the whole 
lysates of induced bacterial cells, the levels of expression was poor or not 
detectable in mammalian cells, with only N protein showing any indication of 
soluble expression. For maximizing soluble and functional protein yields in 
mammalian cells, the SUMO-based protein expression system was then selected 
to try and provide an improvement in the solubility and stability of each 
recombinant protein. To overcome problems of expressing proteins of interest in 
different systems like bacteria, yeast, insect and mammalian cells, a number of 
fusion tag technologies have been developed over the years, such as NusA, 
maltose binding protein (MBP), glutathione-S -transferase (GST), ubiquitin (UB), 
thioredoxin (Trx) and Small ubiquitin-related modifier (SUMO) (Catanzariti et al., 
2004; Malakhov et al., 2004; Nilsson et al., 1997). Fusion of target proteins to 
SUMO is used to enhance expression and protect against proteolytic degradation 
and so facilitate the purification of difficult to express proteins (Changsen et al., 
1999; De Marco et al., 2004; Pryor and Leiting, 1997). 
SUMO is a member of a group of proteins that are part of the ubiquitin-like protein 
family. SUMO and Ubiquitin are very similar in their three-dimensional 
conformation (Melchior, 2000) however, SUMO shares only ~18% similarity at the 
sequence level with Ubiquitin. SUMO is absent from prokaryotes (Hochstrasser, 
2000; Jentsch and Pyrowolakis, 2000; Müller et al., 2001) but present in all 
eukaryotes and is highly conserved from yeast to humans (Jentsch and 
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Pyrowolakis, 2000; Melchior, 2000; Müller et al., 2001). The first SUMO protein 
(SMT3) was discovered in 1995 in Saccharomyces cerevisiae, which has only one 
SUMO gene (SMT3) (Meluh and Koshland, 1995). A human homologue was 
discovered the following year (Mannen et al., 1996) and the mammalian SUMO 
family now has four members (SUMO-1, SUMO-2, SUMO-3 and SUMO-4) (Bohren 
et al., 2004; Saitoh and Hinchey, 2000). The SUMO protein is a 101 amino acid 
polypeptide (~10-20kDa) in mammals, slightly bigger than ubiquitin (8.5kDa). 
Although SUMO and Ubiquitin share similar structures and global folding, SUMO 
differs by the presence of a flexible N-terminal extension (Bayer et al., 1998; 
Skilton et al., 2009) and a different surface charge distribution (Gill, 2004).  
In use as an expression tag, the SUMO ORF is fused to the N-terminus of the 
target ORF and serves to generally protect the overall protein by acting in a 
chaperone like manner (Malakhov et al., 2004). The SUMO fusion system has 
been described to enhance both expression level and the solubility of proteins that 
are difficult to express in addition to protecting the protein of interest from 
proteolytic degradation (Butt et al., 2005). In eukaryotic cells, SUMO can be 
naturally conjugated to hundreds of protein species (Flotho and Melchior, 2013; 
Wilkinson and Henley, 2010) and is believed to participate in numerous 
protein/protein and protein/DNA interactions. However, the precise regulatory 
mechanisms it engenders via conjugation remains unknown in most cases (Flotho 
and Melchior, 2013).  
In eukaryotic cells, SUMO tags are recognized by endogenous SUMO proteases 
when expressed as fusions and the isopeptide bond formed between the carboxy-
terminal glycine of SUMO and the protein is cleaved (Li and Hochstrasser, 2000, 
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1999). This means that SUMO fusion proteins expressed in mammalian cells 
quickly have the SUMO domain removed, defeating the objective of the fusion 
construct. This limitation is eliminated with the development of the universal 
“SUMOStar” tag, which is a SUMO based tag that is double mutated (R64T/R71E) 
such that it will not be recognized or cleaved by the activity of cellular SUMO 
proteases (Peroutka et al., 2008).  
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4.2 Results 
4.2.1 Cloning strategy for SUMOStar-MHV fragments in pTriEx1.1 vector 	  
This section describes the strategy applied to generate stable expressed proteins 
in the pTriEx1.1 vector. The MHV-A59 genes encoding the M protein, the non-
structural proteins (5,6,7,8,9,10,16), nsp3_Y-domain and nsp12_C-terminal were 
inserted into pTriEx1.1 using SacII and XhoI restriction sites as described. A 
SUMOStar encoding fragment (Appendix Figure 9.78) was incorporated at the 5’ 
end of each MHV gene using overlap PCR extension. The amplified overlapped 
PCR fragments containing the SUMO and the MHV ORFs in-frame were digested 
using SacII and XhoI, and cloned into the pTriEx1.1 vector using T4 DNA ligase 
Figure 4.40. The ligation reaction was transformed into chemically competent 
StellarTM E. coli cells and colonies were selected randomly for screening by colony 
PCR using TriExUP as the forward primer and TriExDOWN as the reverse primer. 
The construction of each SUMOStar-MHV fusion protein is described in detail in 
the next section. 
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Figure 4.40. Cloning design. Overlap extension was used to incorporate a SUMOStar 
fragment into each MHV gene and the complete unit inserted between SacII and XhoI 
restriction sites in the pTriEx1.1 vector. 	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4.2.2 Amplification of MHV-A59 and SUMOStar fragments 
 
The first step was amplifying the protein coding regions of MHV-A59 virus by PCR 
using specific forward and reverse primers as described in Table 2.4. The results 
of these PCR reactions are shown in Figure 4.41. A SUMOStar fragment (795bp) 
was amplified from a donor plasmid pTriEx-SUMO kindly provided by Dr. Ian Jones 
with specific (0.5µM) Fw_SacII forward and Rv_SacII reverse primers Table 2.5 
Figure 4.42. After visualization by agarose gel electrophoresis, PCR products were 
extracted from the gel. 
 
	  
Figure 4.41. Gel electrophoresis of nsp7, nsp8, nsp9, nsp10, nsp16, nsp12_C-
terminal, nsp3_Y-domain amplified by PCR from cDNA of MHV-A59. cDNA of MHV-
A59 was used as a template to amplify nsp8, nsp16 , nsp3_Y-domain, nsp12_C-terminal, 
nsp7, nsp9 and nsp10. (A) Lane 1: Marker (1kb) DNA ladder, Lane 2: nsp8 (591bp), Lane 
3: nsp12_C-terminal (1692bp), Lane 4: nsp16 (900bp), Lane 5: nsp3_Y-domain (1200bp). 
(B) Lane 1: Marker (1kb) DNA ladder, Lane 2: nsp7 (267bp), Lane 3: nsp8 (591bp), Lane 
4: nsp9 (330bp), Lane 5: nsp10 (393bp). 
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Figure 4.42. Gel electrophoresis of SUMOStar PCR product following amplification 
of SUMOStar fragment. The SUMOStar fragment was amplified from pTriEx-SUMO 
vector by PCR. A 1kb DNA ladder molecular marker was used to confirm the correct 
fragment size. Lane 1: Marker (1kb) DNA ladder, Lane 2: SUMOStar fragment (795bp). 	  
4.2.3 Generation of SUMOStar-MHV fragments by overlap extension PCR.   
 
The PCR reactions were set up in a PCR tube by mixing each PCR product 
(0.1ng/bp) from each amplified protein coding regions, the SUMOStar fragment 
(0.1ng/bp), 1x Phusion® High-Fidelity PCR polymerease master mix (BioLabs) with 
dH2O to a final volume of 45µl. The mixture was placed in a thermal cycler with the 
PCR program consisting of five rounds without primers in order to combine the 
MHV encoding DNA fragment with the SUMOStar fragment. Then, (0.5 µM) 
Fw_SacII Table 4.5 and reverse primers for each gene Table 2.4 were added to 
the mixture in 2.5 µl volume for each primer. The program continued for 35 cycles 
and the PCR products were analysed on a 1% agarose gel and extracted using a 
gel extraction kit.  
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4.2.4 Ligation of SUMOStar-MHV fragments in pTriEx1.1 vector 
For the cloning of the SUMOStar-MHV fragments into the pTriEx1.1 vector it was 
necessary to treat the cloned fragments and vector with restriction enzymes to 
produce compatible sticky ends. The SUMOStar-MHV fragments and pTriEx1.1 
vector were first digested using SacII (37°C for 60 min) and purified with a clean up 
kit following the manufacturer’s protocol. They were then digested with XhoI (37°C 
for 30 min) and extracted from the agarose gel following gel electrophoresis. The 
SUMOStar-MHV fragments and linearized pTriEx1.1 vector were mixed at a molar 
ratio of 3:1 and ligated using T4 DNA ligase. 
4.2.5 Transformation in StellarTM E. coli competent cells and restriction 
digest with SacII and XhoI restriction enzymes  
 
The ligation product for each pTriEx1.1-SUMOStar-MHV construct was 
transformed into StellarTM competent cells. Colony PCR was performed with the 
Fw_SacII forward primer and specific reverse primers for each MHV gene  Table 
2.4 to check if the vector contained the overlapped PCR product. As an example 
Figure 4.43 shows that the SUMOStar-nsp7 fusion ORF was present in 70% of the 
20 randomly picked colonies.  
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Figure 4.43. Nsp7 screened by PCR. 20 colonies were screened for the presence of 
SUMOStar-nsp7 insert (1062bp). Lane 1: Marker (1kb) DNA ladder, Lanes 2-21: colonies 
numbered from 1-20. 
 
To confirm the insertion of the correct fragments, plasmid DNA was extracted from 
4 colonies that were positive for the correct sized insert and digested with Xbal and 
XhoI restriction enzymes for 30 min and then analysed by gel electrophoresis using 
a 1% agarose gel at 120v to confirm the expected size fragments Figure 4.44. Two 
plasmids for each transformation were sequenced with TriExUP and TriExDOWN 
primers to confirm the SUMOStar fusion was in-frame in all cases. Glycerol stocks 
were prepared for long-term storage at -80°C. In this way SUMOStar fusion 
constructs were generated for all the MHV target ORFs previously cloned for non-
fusion expression.  
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Figure 4.44. Gel electrophoresis of double digest pTriEx1.1 contains SUMOStar-nsp7 
fragment. Lane 1: Marker (1kb) DNA ladder, Lanes 2-5: selected pTriEx1.1-SUMOStar-
nsp7 transformants double digested with Xbal and Xhol, pTriEx1.1 (4789bp) and SUMO-
nsp7 (1062bp) 
 
4.2.6 Transfection and expression of SUMOStar-MHV fusion proteins in 
mammalian cells 
 
17clone-1 cells were seeded in 6 well plates at 1.5 x 10
5 cells/well and incubated in 
5% CO2 at 37°C. The next day, cells were transfected with each pTriEx1.1-
SUMOStar-MHV constructs as before. For DNA transfection, the optimal 
transfection reagents (see Chapter 3) Lipofectamine2000 or Turbofect were used 
according to the manufacture’s instructions. After transfection, 17clone-1 cells were 
incubated for 24 hr, plates were then placed on ice and cells were harvested, 
transferred into 1.5 ml microcentrifuge tubes and then centrifuged for 2 min. The 
pellets were either stored at -20°C or used immediately to verify expression of the 
proteins by Western blotting.  
Samples of the cell lysates transfected with Turbofect showed no bands for any of 
the SUMO tagged protein while cell lysate samples transfected with 
Lipofectamine2000 showed that fusion of the MHV ORFs to the SUMOStar tag 
enhanced gene expression in several cases. In particular, the result in Figure 4.45 
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shows that M protein, nsp9, nsp10 and nsp16 were detected for the first time while 
nsp7 and nsp8 were not detected. The plasmid pTriExSUMO was used as a 
control.   
 
Figure 4.45. Protein expression in mammalian cells using SUMOStar fusion tag. 
Cells were grown in equal conditions and each well was transfected with nsp7, nsp8, nsp9, 
nsp10, nsp16 and M protein using lipofectamine2000 transfection reagent, after 24 hours 
cells were harvested then total cell extracts were prepared. Protein expression of total cell 
lysates was detected by Western blot using anti-His tag ab. Nsp9, nsp10, nsp16 and 
membrane were detected. Molecular weight marker in kDa is indicated on the left, while 
pTriEx-SUMO was used as a control. 
 
4.2.7 Suppression of MHV infectivity by virus proteins 
 
The primary reason to express MHV ORFs in mammalian cells was to establish an 
assay for the detection of MHV proteins with the potential to interfere with MHV 
replication when produced in trans in infected cells. The M, nsp9, nsp10 and nsp16 
plasmid showed positive expression as a SUMO fusion was used to examine the 
effect on virus replication, based on its ability to protect cells from virus-induced 
cytopathic effects. The pTriEx1.1-SUMO vector, Lipofectamine2000 and virus only 
were used as acontrol. 17clone-1 cells were seeded in a 24 well plate and after 
incubation at 37°C in 5% CO2, each well was transfected with one protein encoding 
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construct for 18 hours. The next day, media was removed from each well and 
washed twice with PBS and the monolayers were infected with MHV-A59 virus at a 
MOI of 3. The MOI reflects the ratio of the number of virus particles that will enter 
the target cell, which is a statical process, and according to Poisson distribution, 
when MOI increase, the percentage of cells infected with at least one virus will 
increase also. With MOI of 3, there are a percentage of 95% of target cells will be 
infected with one virus. After incubation at 37°C for 45 min, the inoculums were 
removed and the monolayers were washed twice with PBS. Then, the plate was 
incubated with fresh DMEM media for 16 hr at 37°C. The plasmid pTriEx1.1-SUMO 
was used as a control. As shown in Figure 4.46, there was some general 
interference in virus induced killing by the assay design as the cytopathic effect 
caused by MHV infection of 17clone-1 mammalian cells in non-transfected cells 
was different from the cytopatic effect of the virus in the presence of transfected 
pTriEx1.1-SUMO. The virus yield from all transfections was used as a quantitative 
measure of replication inhibition by using plaque assay. 
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Figure 4.46. In vitro effect of transient expression of MHV-SUMO fusion proteins on 
MHV virus replication. Cells were grown in equal conditions and each well was 
transfected with nsp9, nsp10, nsp16 and membrane protein using lipofectamine2000 
transfection reagent, after 24 hours cells in each well were infected with MHV-A59 at 
MOI=3 except control. After 16 hours incubation, supernatants were collected and virus 
titre was measured by plaque assay. 
 
To do this, the supernatants were removed from each transfected/infected well and 
used for virus titre determination by plaque assay and this experiment was 
repeated in triplicate to ensure reproducability. 
The result of the plaque assay of three indepanant experimants shows that the 
expression of M protein, nsp9, nsp10 and of nsp16, as SUMOStar fusion proteins 
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did not reduce virus titre significantly when the replicates were taken into account. 
The p-value from each sample compared to the control (pTriEx1.1-SUMO vector) 
were >0.05 Figure 4.47. 
 
Figure 4.47. Effect of the MHV-A59 proteins on the virus replication in vitro. Plaque 
titrations were carried out on 17clone-1; monolayers were transfected with SUMOStar-
MHV-A59 plasmids, 24 hours after transfection, monolayers were infected with MHV-A59 
at MOI=3, 16 hours post infection, supernatants were collected and virus titers were 
measured with plaque assay. Lipofectamine2000, pTriEx-SUMO were used as a control. 
Error bar represent mean and SD from three independent experiments. 
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4.3 Discussion 
Coronavirus proteins are multifunctional and play a crucial role at different stages 
during the viral replication cycle. The data here show that transient expression of M 
and nsp16 MHV proteins in 17clone-1 cells appears to reduce the cytopathic effect 
caused by MHV-A59 in vitro but that a reduction in virus titre was not significant.   
As described in the previous chapter, the expression of functionally active forms of 
many MHV-A59 proteins in 17clone-1 mammalian cells was difficult to achieve at 
detectable levels, with the exception of the N protein. Yet to evaluate the potential 
inhibitory effect of MHV-A59 proteins expressed in trans in 17clone-1 mammalian 
cells requires the presence of the expressed proteins during a replication cycle. It 
was found that use of the SUMOStar tag was benefical to demonstrate expression 
of a number of MHV-A59 proteins. 
Non-structural proteins nsp9, nsp10, nsp16 and M protein of MHV-A59 were 
expressed at detectable levels using the SUMOStar system in this project Figure 
4.45. However, the SUMOStar system did not result in production of detectable 
levels of nsp3_PlPro, nsp5, nsp6, nsp7, nsp8, nsp12_C-terminal, nsp12_N-terminal, 
or nsp3_Y-domain in 17clone-1 mammalian cells. There is a possibility that the 
SUMOStar tag was not suitable for these proteins due to their poor solubility, slow 
folding or instability. As discussed, it may also be the case that these proteins are 
produced at low level in mammalian cells but are maintained below the detection 
threshold by proteolysis. It has been reported that SARS 3CL protease, N and S 
protein can be expressed with SUMO-fusion technology in E. coli strain BL21 
(DE3) (Zuo et al., 2005). The results here indicate that some MHV-A59 proteins 
can also be expressed in mammalian cells using the SUMOStar tag. Rescuing the 
expression of MHV-A59 proteins in mammalian cells, as presented in this study, is 
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a first step towards studying the effect of these proteins during the virus replication 
cycle. Preliminarly data suggested that some of the virus proteins might interfere 
with cytopathic effect although no consistent reduction in infectivity of the virus was 
demonstrable. 
The virus titre appeared to be unaffected by the presence of expressed MHV 
proteins, implying no effect on the viral replication cycle. A trend in all the replicated 
experiments was that transient expression of MHV M protein appeared to reduce 
virus induced cytopathic effect. Thus, it is possible that the constant presence of M 
protein may interfere with replication by interacting with other virus proteins in the 
early stages of the viral life cycle before virus encoded M is synthesised. Another 
possibility is that nsp16 and M protein may interact and bind with virus proteins that 
participate in virus formation. From the virus titre analysis Figure 4.47, the 
presence of M, nsp9, nsp10 and nsp16 protein had no signifinant inhibitory effect 
on MHV-A59 virus infectivity. 
 
M protein is the most abundant constituent of the virus outside the virion and is 
responsible for virus shape (De Haan et al., 2000), in association with other virus 
components. The expression of M protein and E protein alone are sufficient for 
the formation of virus-like particles (VLPs) in coronaviruses (Bos et al., 1996; 
Corse and Machamer, 2000; Vennema et al., 1996). M protein also interacts with 
N protein through its endodomain (Escors et al., 2001; Fang et al., 2005; Hurst et 
al., 2005; Kuo and Masters, 2002; Luo et al., 2006b; Verma et al., 2007, 2006). 
Cryo-EM and tomographic reconstructions studies found that the M protein 
endodomain of MHV and SARS-CoV virions are connected to the nucleocapsid via 
a single thread-like connection (Bárcena et al., 2009; Neuman et al., 2006). It has 
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also been reported that the M protein is a multifaceted molecule that interacts with 
diverse proteins such as S protein (de Haan et al., 1999; McBride and Machamer, 
2010), E protein (Corse and Machamer, 2003; Venkatagopalan et al., 2015) and 
also M-M interaction (Kuo and Masters, 2010). The interactions of M protein with 
other viral proteins and possibly cellular proteins may be consistent with the idea 
that an excess of this protein, especially at early times of the replication cycle, may 
bind with other proteins of the virus and slow virus growth or lead to the formation 
of defective viruses. It has been shown that SARS-CoV and MERS-CoV M protein 
could suppress type I IFN production in infected HEK293 cells (Lui et al., 2016; 
Siu et al., 2009), leading to evasion of the host innate antiviral response although 
this immunosuppressive activity was not observed for the M protein of HCoV-
HKU1 (Siu et al., 2014), implying that this inhibitory activity is not found in all 
coronaviruses.  
Another protein that is important in virus replication is the nsp16 protein. This 
protein is responsible for coronavirus capping (Snijder et al., 2003), interacts with 
nsp10 in SARS-CoV (Bouvet et al., 2010) and has other functions (reviewed in 
(Neuman et al., 2014)). It has been demonstrated that in some cases, the presence 
of exogenously expressed coronavirus proteins such as N protein can increase 
virus replication (Cui et al., 2015). However, evidence is lacking in regard to 
whether nsp16 can function as an inhibitory or stimulatory factor. No significant 
impact of nsp9 and nsp10 was observed on the virus titre. Although the data 
revealed no potential role for M, nsp9, nsp10 and nsp16 proteins as inhibitors, 
further experiments are required to confirm this and to clarify the mechanism 
involved. Using fluorescence and coomassie stain could be conducted to check 
whether these proteins are expressed or not and check also for half life of these 
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proteins. 
In conclusion, a revised recombinant expression strategy employed in this work 
was designed to express MHV-A59 proteins as SUMOStar fusion proteins, in order 
to rescue detectable levels of expression and enable an investigation of the 
potential inhibitory effect of these proteins on virus replication. Successful 
expression of nsp9, nsp10, nsp16 and M proteins in mammalian cells was used as 
the basis for inhibitory effects by transfection of each protein coding plasmid with 
infection by the wild-type MHV virus in 17clone-1 cells. The results showed no 
significant effect of these proteins on virus replication. 
In light of potential future studies, introducing reandom mutations by EP-PCR for 
M, nsp9, nsp10 and nsp16 proteins would be the next step for screening/selection 
for dominant negative variant(s). Another approach could be studying the effect of 
mutations introduced to nsp10 and nsp16 by using Gel-shift mobility assay since 
nsp10 and nsp16 interact with each other and this step is fundamental for the 
capping of the viral genome. The overarching aim of the work presented within this 
chapter was to investigate potential inhibitory effect MHV-A59 proteins on virus 
replication.  
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5 Fitness landscape of N protein variants 
5.1 Introduction 
 
Since N protein was the only protein well expressed in 17clone-1 mammalian cells 
(as described in chapter 3), it was the only real candidate to investigate the 
potentially inhibitory effects of non-mutated and mutated MHV protein on virus 
replication, based on their ability to protect cells from virus-induced cytopathic 
effects. The N protein is an important component for both replication and 
transcription by coronaviruses. It is a highly basic protein, encoded near the 3’ end 
of the coronavirus genome, with a molecular weight ranging from 45 to 60kDa 
among the coronavirus groups and is synthesized in large amounts during infection 
(Lai and Cavanagh, 1997; Stohlman and Lai, 1979). The N protein binds with the 
viral RNA and forms the nucleocapsid to protect the viral genome from degradation 
and, following S mediated fusion, the nucleocapsid enters the host cell to facilitate 
replication (Almazán et al., 2004; Baric et al., 1988; Grossoehme et al., 2009; Tylor 
et al., 2009). However, the exact mechanisms and role of N in replication are 
poorly defined. The N protein is an important diagnostic marker for coronavirus 
disease and induces host immune responses (Leung et al., 2004; Xiong et al., 
2004). Antibodies against N protein strongly inhibit RNA transcription in vitro 
(Compton et al., 1987), while coronavirus replication is strongly stimulated by 
inclusion of N protein at an early step of infection (Schelle et al., 2005). N protein 
was identified to be dynamically associated with the RTC (Verheije et al., 2010). 
This transient association may allow N protein molecules to change places with 
one another during transcription/replication and to carry out a variety of distinct 
functions. Reflecting its overall basic charge, N protein was also found to have 
nonspecific binding activity toward nucleic acids, including ssRNA, ssDNA, and 
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dsDNA (Takeda et al., 2008; Tang et al., 2005). At the level of amino acid 
sequences, coronavirus N proteins are quite diverse across the nidovirales, 
explaining their role as serospecific markers of infection. Coronavirus N proteins 
contain three domains: an N-terminal RNA-binding domain (NTD), a C-terminal 
dimerization domain (CTD), and a Ser/Arg (SR) rich linker (Chang et al., 2013; I.-J. 
Chen et al., 2013; Lo et al., 2013). The crystal structures have been solved for the 
N- terminal domain (NTD) of SARS (Saikatendu et al., 2007), infectious bronchitis 
virus (IBV) (Fan et al., 2005; Jayaram et al., 2006), HCoV-OC43 (I.-J. Chen et al., 
2013), and mouse hepatitis virus (MHV) (Grossoehme et al., 2009). The N-terminal 
domain (NTD) of coronavirus N protein contains several critical residues for RNA 
binding and virus infectivity (Keane et al., 2012; Saikatendu et al., 2007; Tan et al., 
2006) but the structural and mechanistic basis for RNA binding and 
ribonucleoprotein complex (RNP) formation remain unclear. The central region of 
the N (Hurst et al., 2013; Snijder et al., 2003) protein contains an RNA-binding 
region and the primary phosphorylation sites (Chang et al., 2006; Wootton et al., 
2002). Studies have identified that this region in MHV binds with the ubiquitin-like 
domain of nonstructural protein 3 (nsp3), and that this is an important interaction in 
early coronavirus replication (Hurst et al., 2013; Snijder et al., 2003). The C-
terminal domain (CTD) is known to be a critical determinant for recognition of the 
genomic RNA packaging signal in MHV N protein (Kuo et al., 2014), mediating N-N 
dimerization as well as longer-range interactions in the nucleocapsid (Chang et al., 
2013). The spacer B is a linker that joins the CTD with the N3 domain, this domain 
is an acidic domain which binds to the endodomain of the M protein during virion 
assembly (Hurst et al., 2005; Kuo et al., 2016; Verma et al., 2007, 2006). 
The N3 domain at the carboxy terminus is found to be a site for N-M interactions 
	  	   134 
suggested to be required to form virions (Hurst et al., 2005; Kuo and Masters, 
2002; Luo et al., 2006a; Verma et al., 2007, 2006) but other studies have disagreed 
with this conclusion (Fang et al., 2006; Hatakeyama et al., 2008; He et al., 2004). 
A library of variants is required to study any potentially inhibitory effect of mutated 
virus proteins and directed evolution can be used to generate and screen for such 
potential dominant negative variant(s). The term “directed evolution” or “in vitro 
evolution” refers to a general strategy that mimics natural evolution in the 
laboratory (Zhao et al., 2004). Selection of the most effective method to generate 
molecular diversity is an important step in an in vitro evolution experiment. Two 
evolutionary methods are used commonly for in vitro directed evolution 
experiments, gene recombination and random mutagenesis (Arnold, 2001; 
Bershtein and Tawfik, 2008; Chaput et al., 2008; Deshler, 1992; Fox and Huisman, 
2008; Hou, 2009; Jin et al., 2009; Johannes and Zhao, 2006; Kotzia and Labrou, 
2009; Xu et al., 2008; Yu et al., 2008). The first method depends on the exchange 
of any blocks of sequences among two or more DNA strands. By contrast, random 
mutagenesis depends on introducing random point mutations into the whole gene. 
Error-prone PCR (ep-PCR) has been widely used to generate libraries with random 
mutations by using the low fidelity of DNA polymerase and changing conditions in 
standard PCR experiments so that they favor error during the polymerization 
reaction. In bacteria there are three main polymerase families, A, B and C. Most 
family A and B bacterial polymerases are composed of a single subunit and have 
three domains: the 3’-5’ exonuclease (proofreading) domain, the 5’-3’ exonuclease 
domain and the polymerase domain. The combination of domains will affect the 
proofreading ability of the polymerase. Taq polymerase from Thermus aquaticus 
(Taq-Pol) lacks 3’-5’ exonuclease activity and exhibits a higher error rate than Pfu 
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polymerase from Pyrococcus furious (Pfu-Pol). As a result, the error rate of Taq 
DNA polymerase (measured at 2.0 x 10
-5 per nucleotide per cycle) is usually 
tenfold higher than the error rate of Pfu DNA polymerase (1.6 x 10
-6 per nucleotide 
per cycle). Because of its higher fidelity, Pfu DNA polymerase is often the preferred 
polymerase in PCRs used in molecular cloning experiments (Lundberg et al., 
1991). Early error-prone PCR experiments were proposed in 1989 (Leung et al., 
1989) and later modified by Cadwell and Joyce in 1992 (Cadwell and Joyce, 1992) 
who used Taq DNA polymerase to introduce random mutations at each PCR cycle. 
In standard PCR reactions, mutations occur at different places each time and the 
rate is usually reasonable but in error-prone PCR, the mutation rate becomes 
relatively higher and occurs earlier in the cycles.  
There are several ways to modify the mutation rate over and above the 
endogenous rate of the polymerase. One of the easiest ways is to decrease the 
fidelity of the DNA polymerase furhter by including Mn2+ in the PCR reaction 
mixture, which reduces base pairing specificity (Beckman et al., 1985; Lin-Goerke 
et al., 1997). For example, adding MnCl2 to 0.7 mM final concentration can 
increase the error rate up to 25-fold (Beckman et al., 1985). Another way to modify 
the mutation rate is to use different ratios of nucleotides in the reaction mixture 
leading the polymerase “hunting” for the correct nucleotide and so more likely to 
make a mis-incorporation (Fromant et al., 1995; Nishiya and Imanaka, 1994; 
Shafikhani et al., 1997). Increasing or decreasing the number of cycles can also 
generate a library of variants. Mutation frequencies from 0.11-2% are achieved by 
varying the nucleotide ratio and the amount of MnCl2 (Cadwell and Joyce, 1992; 
Zhao et al., 1999). Accurate estimation and control of the mutation rate during 
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error-prone PCR has become more and more exact (Wang et al., 2000), but there 
are few comparative studies of different random mutagenesis strategies for their 
efficiency in producing mutations for directed evolution experiments.  
Directed evolution also requires screening and selection methods for library 
analysis and these will depend on the new molecule(s)’ properties of interest. 
Mutation rate, population size and selection strategy are all parameters that can 
potentially effect and alter the outcome of directed evolution experiments and an 
additional consideration when developing strategies for antiviral drugs based on 
mutated virus proteins is their potential toxicity on the physiology and viability of the 
transduced cells. Non-mutated or mutated proteins can affect cellular properties 
and cell growth in an unpredictable manner and even subtle differences in cell 
growth rates can result in a major impact on different biological assays during in 
vitro experiments. The 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide 
(MTT) cell assay is a simple and convenient method to judge general toxicity. This 
assay is a colorimetric assay used to measure in vitro cytotoxicity and cell 
proliferation following exposure to test compounds. The MTT assay is used in 
mammalian cell studies to measure cell activation and viability (Gerlier and 
Thomasset, 1986; Price and McMillan, 1990), cell growth and survival (Ficken et 
al., 1991; Mosmann, 1983), the bactericidal activity of macrophages (Ferrari et al., 
1990; Peck, 1985) and fungal viability (Levitz and Diamond, 1985). The MTT assay 
is based on the ability of the mitochondrial enzyme, succinate-dehydrogenase, of 
viable cells to reduce the MTT tetrazolium salt to purple formazan crystals when 
added to the cell culture. The level of MTT formazan produced is therefore 
correlated with the viability of cells (Denizot and Lang, 1986), i.e. when there are 
live cells in the culture, active reductase enzymes will convert MTT tetrazolium salt 
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to MTT formazan. The absorbance of the formazan product can be measured with 
a spectrophotometer, high absorbance values result from more live cells in a 
culture over time.  
The aim of this chapter is to generate a library of variants using error-prone PCR, 
to test the effect of some variants on virus replication and to investigate mutated N 
protein toxicity on 17clone-1 cells by the MTT assay. 
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5.2 Results 
5.2.1  Plaque assay of virus yield in the presence of N protein expressed in 
trans 
 
As previously described in chapter 3, N protein was expressed following In-Fusion 
cloning of the N ORF into the pTriEx1.1 plasmid vector. Expression of N protein 
was detected in BL21 (DE3)-pLysS and in 17clone-1 cells by Western blotting 
Figure 3.25 and Figure 3.36. To examine the effect of N protein on virus 
replication, 17clone-1 cells were seeded in 24 well plates and transfected with the 
plasmid encoding N protein. The next day, monolayers were infected with MHV-
A59 virus at an MOI of 3; incubated for 45 min, washed with PBS and then 
incubated with fresh DMEM media. Images were taken at 18, 24 and 48 hours post 
infection Figure 5.48 before supernatants were removed to quantify viral yield by 
plaque assay. The empty plasmid was used as a control to check whether the 
presence of the plasmid affect virus replication irrespective of N expression. The 
data show that the observed cytopathic effect of the untransfected cells infected 
with MHV is different from the cytopathic effects caused by the virus in 17clone-1 
cells expressing MHV N protein Figure 5.48. 
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Figure 5.48. N protein effect on MHV-A59 virus replication. 17 clone-1 monolayers 
were transfected with N protein and empty vector. After 24 hours post transfection (0 hr), 
cells were infected with MHV-A59 virus MOI=3 and imaged at 18, 24 and 48 hours post 
infection. (A) Untransfected 17clone-1 cells, (B) 17clone-1 cells transfected with pTriEx1.1 
vector as a control, and (C) 17clone-1 cells transfected with pTriEx1.1-N protein.  
 
The result of the plaque assay showed that the presence of N protein increased 
virus infectivity when expressed whereas the plasmid vector only had no effect on 
virus replication Figure 5.49. The p-value was significant after 24 hrs post infection 
(0.00198936) confirming that N protein was expressed during that period and after 
48 hrs, the p-value was (0.00296086). As N protein expression has an observable 
effect on MHV replication, it was taken as the basis for library generation with a 
view to the isolation of mutants with increased interference in MHV replication 
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A 
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Figure 5.49. Affect of N protein expression on MHV replication in 17clone-1 
mammalian cells. Titrations were carried out on 17clone-1 cells; monolayers were 
transfected with N protein in triplicate, 24 hours after transfection, media was removed, 
washed twice with PBS, monolayers were infected with MHV-A59 at MOI=3, inoculums 
removed after 45min and monolayer washed with PBS twice, fresh media added, 
supernatants were collected after 18, 24 and 48 hours post infection, and virus titer was 
measured with plaque assay. Empty vector and cells were used as a control. The arrows 
represent p<0.05. 
 
5.2.2   Error prone PCR 
 
The first step in the construction of a library of N protein variants was to determine 
which PCR amplification protocol to use to achieve a low and evenly distributed 
rate of mutations in the N protein coding region. To do this error-prone PCR 
reactions were carried out using two different protocols in the presence of MnCl2. 
The first protocol was carried out with Taq polymerase; different concentration of 
nucleotides and MnCl2 were added immediately before the thermal cycling was 
initiated. This protocol has been reported to result in a mutation rate of ~0.66% of 
the nucleotide positions in the DNA template (Cadwell and Joyce, 1992). PCR 
products were analyzed by agarose gel electrophoresis Figure 5.50.  
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Figure 5.50. Gel electrophoresis of N protein amplified by first error-prone PCR 
protocol from cDNA of MHV-A59. cDNA of MHV-A59 was used as a template to amplify 
N protein using first error-prone protocol. Lane 1: Marker (1kb) DNA ladder, Lane 2: N 
protein (1365bp). 
 
To characterise the PCR products for the level of mutation, the amplified band was 
extracted from the gel and cloned into NcoI-XhoI digested pTriEx1.1 vector and 
transformed into Stellar competent cells (Clontech) as described in section 2.3. Ten 
randomly selected colonies were screened by colony PCR for the presence of the 
N protein coding region using T7 forward primer and Rev_N primer Table 2.1 the 
exact size predicted is 1546bp Figure 5.51.  
 
 
Figure 5.51. N protein screened by PCR. 10 colonies were screened for the presence of 
N protein insert. Lane 1: Marker (1kb) DNA ladder, Lanes 2-11: colonies numbered from 1-
10.	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The result showed that only two out of 10 colonies (colony 5 and colony 7) carried 
a band consistent with the expected size of the N protein ORF, the remainder were 
much smaller plasmids, consistent with deletions of the cloning vector. This result 
indicated that the efficiency of the ep-PCR reaction for single mutations within the 
N ORF was low and that many errors resulted in unclonable fragments or 
fragments that lost sequence once transformed into E. coli. However, a second 
error prone PCR protocol was carried out using reagents from the In-Fusion HD 
Cloning Kits (Clontech) mostly according to the manufacturer’s instructions but with 
slight modifications. Before the thermal cycling was initiated MnCl2 was added to 
the reaction in different concentrations (50 µM, 100 µM, 200 µM, 300 µM, and 400 
µM MnCl2). As previously described, section 2.1.5, the PCR protocol was 
completed in the normal way and the PCR products were analyzed by agarose 
electrophoresis as shown in Figure 5.52. 
 
Figure 5.52. Agarose gel electrophoresis of N protein amplified by second PCR 
protocol from cDNA of MHV-A59. cDNA of MHV-A59 was used as a template to amplify 
N protein using different concentrations of MnCl2. Lane 1: Marker (1kb) DNA ladder, Lane 
2: N protein with 0 µM MnCl2(control) ,Lane 3: N protein with 50 µM MnCl2, Lane 4: N 
protein with 100 µM MnCl2, Lane 5: N protein with 200 µM MnCl2, Lane 6 : N protein with 
300 µM MnCl2, Lane 7 : N protein with 400 µM MnCl2. 
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The PCR amplified band encoding N was clearer in these amplifications and so the 
bands amplified from error prone libraries of the 50 µM, 100 µM and 200 µM MnCl2 
conditions were all gel extracted, cloned by In-Fusion ligation-independent 
recombination, independently transformed into Stellar competent cells and cultured 
en masse in LB broth with ampicillin overnight. The next day, libraries were purified 
using a miniprep plasmid isolation kit. All libraries were double digested with NcoI 
and XhoI restriction enzymes as demonstrated in section 2.1.6. The results showed 
that as the MnCl2 concentration increased the intensity of the band encoding N fell 
suggesting a lower rescue rate for replication competent plasmids with an 
increased error rate Figure 5.53, a result, in principle, similar to that obtained with 
the initial ep-PCR conditions.   
	  
Figure 5.53. Gel electrophoresis of error-prone libraries double digest containing N 
protein. Error-prone libraries were double digested with Ncol and Xhol. Lane 1: Marker 
(1kb) DNA ladder, Lane 2: N protein with 0 µM MnCl2 library (control), Lane 3: N protein 
with 50 µM MnCl2 library, Lane 4: N protein with 100 µM MnCl2 library, Lane 5: N protein 
with 200 µM MnCl2 library. 
 
Colonies were selected randomly from platings of the error prone libraries (50 µM, 
100 µM and 200 µM MnCl2) on LB agar plates containing ampicillin and screened 
by colony PCR for presence of the full length N protein ORF. The result showed 
that a band expected of the N protein ORF was present in 10 colonies when 50 µM 
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MnCl2 was added to the PCR reaction and present in 9 colonies when 100 µM 
MnCl2 was added to the PCR reaction. However, in the 200 µM MnCl2 library a 
band consistent with the N protein sequence was absent in all 16 colonies. The In-
Fusion cloning reaction described in chapter 3 was also used as a control with a 
unmutated amplified N sequence to compare the effiency of N protein region 
cloning without MnCl2 and every colony screened had the expected band size 
Figure 5.54.   
 
Figure 5.54. Error-prone libraries screened by colony PCR. Randomly selected 
colonies were screened for the presence of N protein insert in error-prone libraries. (A) 
Lane 1: Marker (1kb) DNA ladder, Lanes 2-11: colonies numbered from 1-10 of 0 µM 
MnCl2 library (control), (B) Lane 1: Marker (1kb) DNA ladder, Lanes 2-11: colonies 
numbered from 1-10 of 50 µM MnCl2 library , (C) Lane 1: Marker (1kb) DNA ladder, Lanes 
2-11: colonies numbered from 1-10 of 100 µM MnCl2 library, (D) Lane 1: Marker (1kb) DNA 
ladder, Lanes 2-17: colonies numbered from 1-16 of 200 µM MnCl2 library.  
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5.2.3 Construction of library variant  
 
To know the mutation frequency of the 50 µM MnCl2 and 100 µM MnCl2 libraries 
plasmids were re-isolated from 2 colonies that had proved positive for the correct 
sized insert containing a N protein ORF insert from both libraries and sequenced 
Figure 5.55. 
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Figure 5.55. Distribution of amino acid mutations in 2 variants from 50µM MnCl2 and 
100µM MnCl2 libraries generated with error-prone PCR. Sequenced variants from 50 
µM MnCl2 and 100 µM MnCl2 libraries are aligned with wild-type using Jalview software. 0 
µM MnCl2 library is used as a control. 
	  	   147 
The results of the 50 µM MnCl2 library sequencing showed that, at the amino acid 
level, mutations present in the 50 µM MnCl2 library were less than those introduced 
into the 100 µM MnCl2 library and that higher MnCl2 concentration increased the 
percentage of protein truncation through the introduction of stop codons. Two 
colonies amplified without MnCl2 were used as a control and showed no error. 
Subsequently a further 10 colonies were sequenced to evaluate the complexity of 
the library generated by adding 50 µM MnCl2 into the PCR reaction. The results of 
sequencing showed that no less than 0.2% and no more than 0.6% mutations were 
introduced in a total of 1365 nucleotides sequenced Table 5.6.  
 
Table 5.6. Sequence analysis and mutation rate of 10 mutated colonies generated by 
error-prone PCR. 
Colony Mutations Total sequenced %Mut 
Colony 1 6 1365 0.4% 
Colony 2 7 1365 0.5% 
Colony 3 3 1365 0.2% 
Colony 4 3 1365 0.2% 
Colony 5 4 1365 0.3% 
Colony 6 8 1365 0.6% 
Colony 7 8 1365 0.6% 
Colony 8 8 1365 0.6% 
Colony 9 8 1365 0.6% 
Colony 10 6 1365 0.4% 
Total 61 13650 0.4% 
 
 
Similary, the mutations generated by the second ep-PCR protocol were mainly 
single base substitutions (Appendix Figure 9.79) with the level of A to G transitions 
36% and T to C 26% of the total number of mutations found since N protein consist 
more A (400bp) and less C (299bp) in N protein nucleotides distribution Table 5.7. 
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Table 5.7. Point mutations sequence analysis and mutation rates of variant library 
generated by ep-PCR.  
Mutation Number of the mutation Found Expected Difference 
A to C 1 2% 10% 8% 
A to G 22 36% 10% -26% 
A to T 5 8% 10% 2% 
C to A 0 0% 7% 7% 
C to G 0 0% 7% 7% 
C to T 6 10% 7% -3% 
G to A 6 10% 9% -1% 
G to C 0 0% 9% 9% 
G to T 2 3% 9% 5% 
T to A 2 3% 8% 4% 
T to C 16 26% 8% -19% 
T to G 1 2% 8% 6% 
Total  61    
 
 
At the amino acid level, the diversity created in the N protein sequence was an 
average of approximately 1% and one mutant was truncated Figure 5.56. 10 
colonies from 100 µM MnCl2 library were sequenced to compare number of 
truncation with 50 µM MnCl2 library. The results showed 4 mutants were truncated 
and rest of mutants had 3 to 5 mutations at amino levels (Appendix 9.80). Often, 
truncations of proteins have been found to be a source for dominant negative effect 
however this is not true in all cases. The higher truncation rates the higher non 
functional protein. For that reason the 50 µM MnCl2 library were chosen for further 
investigation for mutants that have a potential dominant negative effect. 
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Figure 5.56. Distribution of amino acid mutations in 10 variants generated with error-
prone PCR. Sequenced variants from 50µM MnCl2 library are aligned with wild-type using 
Jalview software. 
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5.2.4 Phylogenetic tree analysis 
 
Based on results obtained from the library generated in the presence of 50µM 
MnCl2, 100 more colonies were screened by colony PCR and then sequenced. As 
shown in Table 5.8, transition mutations were more frequent than transversion. The 
most frequent transition was A to G (33%), whereas GC to CG mutations occurred 
with a rate of 0.8%.  
 
Table 5.8. Point mutations sequence analysis and mutation rates of 100 variants 
library generated by error-prone PCR. 	  
Mutation No. of mutations Mut%     Average 
A to C 10 1.6% 1.8 
A to G 211 33.7% 4.6 
A to T 43 6.9% 2.2 
C to A 6 1.0% 1.7 
C to G 3 0.5% 1.5 
C to T 45 7.2% 2.5 
G to A 60 9.6% 2.7 
G to C 2 0.3% 1.3 
G to T 24 3.8% 2.1 
T to A 24 3.8% 2.3 
T to C 169 27.0% 4.3 
T to G 9 1.4% 1.8 
Deletion 19 3.0% 2.4 
Insertion 2 0.3% 1.3 
Total 627   
 
Phylogenetic analysis showed a substantial diversity had been created in the N 
protein, except for 3 sequences, which were identical to the wild type sequence 
Figure 5.57. The average rate of nucleotides mutation was 1.7% mutations per 
copy. Transition mutations (A to G and T to C) were commonest. The mutation 
G18T appeared in 20% of selected mutants, suggesting that this mutation 
happened in the early rounds of the mutagenic PCR reaction, a “jackpot” mutation 
that was carried through the subsequent rounds. The mutations A20G, A64G and 
A148T also appeared in selected mutants. 
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Figure 5.57. Phylogenetic analysis between non-mutated and mutated N protein. The 
N protein sequences from 100 clones were aligned by CLUSTAL omega alignment for the 
analysis and the tree was constructed using MEGA6.06 software based on analysis of 
nucleotides.	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At the amino acid level, 33.3% of the mutated N proteins were truncated proteins. 
Truncated mutants varied from 16 aa (mut33) variant in length to 405 aa (mut82) 
variant in length while the overall diversity in the complete set of mutants was 
random and there was no specific type of mutation or site of mutation when the 
tested library was considered as a whole. This library of 100 variants was therefore 
considered suitable as a moderately diverse source of N protein variants with 
which to explore the possibility of selection of a trans-dominant negative inhibitor of 
MHV replication.  
5.2.5 Effect of mutated N proteins on virus replication 
 
To study the effect of mutated N proteins on virus replication in 17clone-1 cells, 24 
well plates were seeded with 17clone-1 cells and the next day all plates were 
transfected with a different transformant selected from the screening of the 50 mM 
MnCl2 library described, that is 100 individual transfections, and incubated 24 hr at 
37°C in 5% CO2. After incubation, each well was infected with MHV-A59 at a MOI 
3. After 16 hours incubation, when the cytopathic effect in the control infections 
was extensive, the supernatants were removed for storage and the cell monolayers 
were fixed with formalin and stained with crystal violet. Some wells showed a cell 
density equal to the density of the control (cells transfected with empty plasmid 
vector) while other wells showed cell densities that varied when compared to the 
density of the control. 
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Figure 5.58. Effect of mutated N protein on MHV-A59 virus replication. 17clone-1 cells 
were cultured, seeded at 1 x 104 cells/well using 24 well plates, after 24 hours incubation, 
each well was transfected with 100 variants, then incubated for 24 hours at 37°C in 
atmosphere of 5% CO2. Cells were infected with mHV-A59 at MOI=3. After 16 hours 
incubation, supernatants were collected and each well was stained with crystal violet stain. 
Virus only, Turbofect and wild type were used as a control. 
 
These monolayers were considered as candidates that had received potential 
dominant negative variants and the stored supernatants from these wells along 
with control supernatnats were subjected to plaque assay to measure virus titre as 
a quantitative measure of any effect. From this visual screen, 37 variants were 
selected for plaque assay from the original 100 transfections. As before it was 
observed that the replication of MHV increased when parental N protein was 
expressed in trans, while some mutated N protein variants decreased infectious 
virion production and were graded for comparison by the extent of the decrease in 
titre Figure 5.59. The distribution of the amino acid mutations in the 37 variants 
subjected to plaque assay was aligned with the wildtype sequence using Jalview 
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software Figure 9.81. Interestingly, the result indicated that all the mutants that 
showed a clear inhibitory activity, that is mut74 (222 amino acids), mut66 (120 
amino acids), mut1 (290 amino acids), mut2 (149 amino acids) and mut38 (374 
amino acid) were truncated except mut94 was not truncated with 3 amino acid 
mutations (Q251R, Q294R and G298D). Mutants with a similar activity to the wild 
type protein were point mutations and were not truncated. 
 
 
Figure 5.59. Inhibitory activity of different mutated N protein on virus replication 
tested by plaque assay. Plaque titrations were carried out on 17clone-1; monolayers 
were transfected with different mutated N protein, 24 hours after transfection, monolayers 
were infected with MHV-A59 at MOI=3, 16 hours post infection, supernatants were 
collected and virus titer was measured with plaque assay. Empty plasmid was used a 
control. The error bars represent mean and SD. The experiment has been repeated once.  
 
The plaque assay was repeated for mut38, the most active inhibitor Figure 5.60, 
confirming the result obtained from the previous experiment that mut38 inhibited 
virus growth.   
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Figure 5.60. Inhibition of MHV-A59 infectivity by mut38. Monolayers of 17clone-1 cells 
were transfected with mut38, 24 hours after transfection, monolayers were infected with 
MHV-A59 at MOI=3, 16 hours post infection, supernatants were collected and virus titer 
was measured with plaque assay. The error bars represent mean and SD. The experiment 
has been repeated in triplicate 
 
Although the presumed mode of action would be via the truncation protein, the 
mut38 variant sequence was analyzed at the nucleotide level Figure 5.61. The 
result showed that the mutant had 8 mutations, 3 of the mutations were G to A at 
sites 232,303 and 1098 while the remaining mutations were T950C, A1006G, 
G1120T, T1252C and A1310G. 
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Figure 5.61. Comparison of wild type and mut38 nucleotides sequences. Sequenced 
mut38 are aligned with wild type using Jalview software. Black arrow represents stop 
codon sequence. 
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The mut38 variant was also aligned with the wild type at the protein level. The 
result revealed that the mut38 protein has 3 amino acid mutations (G78R, L317S 
and N336D) when compared to the wild type. However the predominant change 
was mutation of G1120T nucleotide, which resulted in a stop codon introduced at 
residue 374 instead of glutamate. This mutation therefore results in the production 
of a truncated N protein of 373 amino acids, compared to the 454 amino acids of 
the wild type MHV N protein Figure 5.62. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.62. Comparison of wild type and mut38 amino acid sequences. Sequenced 
mut38 are aligned with wild type using Jalview software. 
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5.2.6 MTT assay 
 
In order to test whether mut38 was exerting a specific effect on MHV replication or 
was generally cytotoxic through an unknown mechanism in 17clone-1 cells, so 
reducing virus yield non-specifically, a MTT assay was performed. 17clone-1 cells 
were seeded in two 24 wells plates (1×10
4 cells/well) and the adherent cells were 
grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine 
serum, NEAA, L-Glutamine, 100 U/ml penicillin and 0.1 µg/ml streptomycin and 
incubated in the incubator at 37°C and 5% CO2. When the 17clone-1 cells had 
reached approximately 75% confluence, wells were transfected in triplicate with 
plasmids expressing the wild type N protein or mut38 along with empty plasmid as 
control. 18 hours after transfection, a solution of MTT reagent was added to each 
well, and incubation continued further for 4 hours with observation every hour until 
a clear purple precipitate had become visible. The media was removed and DMSO 
was added to each well. One plate was incubated for one hour at 37°C and the 
optical density (OD) was measured at wavelength 595nm using a microplate 
reader. The other plate was incubated for 24hr at 37°C and 5% CO2 and the optical 
density measured again at the same wavelength. The assay included wells 
containing transfection reagent only, DMSO as well as untreated control cells. This 
experiment was also repeated as described with the cells at approximately 60% 
confluence. The MTT assay revealed an absence of cytotoxicity for mut38 on 
17clone-1 cells Figure 5.63. 
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Figure 5.63. Cytotoxicity of wild type and mut38. 17clone-1 cells were cultured, seeded 
at 1 x 104 cells/well using 24 well plates, after 24 hours incubation, each well was 
transfected with wild type and mut38, then incubated for 18 hours at 37°C in atmosphere 
of 5% CO2. Cells were treated with MTT solution, incubated for 4 hours, after appearance 
of purple precipitant, media removed and DMSO added. The optical density measured with 
a plate reader set at wavelength 595nm after 1 and 24 hours incubation. Three replicates 
were performed. (A) 17 clone-1 cells were transfected with wild type, mut38, empty 
plasmid and Turbofect only for 24  h and subjected to MTT assay. (B) Cell viability was 
measured by MTT assay. The error bars represent mean and SD.	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5.3 Discussion 
 
N protein is a key protein involved in coronavirus replication. N protein binds with 
viral RNA to form the ribonucleoprotein complex (RNP), which protects the RNA in 
an ordered conformation that is necessary for replication and transcription. In 
addition, N protein is involved in many viral processes. As a result, the N protein of 
coronaviruses is a logical target for the development of antiviral compounds 
because such compounds would have the potential to target many crucial functions 
during the viral life cycle. A similar study had demonstrated previously that N 
protein increased SARS replication when provided in trans (Pan et al., 2008) 
suggesting that an assay could be established. In another study mutated HCoV-
OC43 N protein, when transfected into 293T cells, was shown to significantly 
decrease the level of viral RNA encoding M protein compared with cells transfected 
with plasmids encoding the wild type N (Lin et al., 2014). Transfected mRNA 
encoding MHV N protein increases the PFU up to 40-fold but this enhancement 
was not found when the MHV N protein mRNA contained knockout mutations that 
inactivated translation of a functional protein (Hurst et al., 2010). A further recent 
study has shown that N protein increases the infectivity of MHV-A59 (Cui et al., 
2015). 
Directed evolution has become a powerful tool both for altering and improving the 
properties of many proteins, by harnessing Darwinian principles to generate 
proteins with new or improved properties. The first step in a directed evolution 
experiment is to introduce mutations randomly into copies of the target gene, 
resulting in a large and diverse library of variants. Error prone-PCR is a simple and 
common method for introducing such random mutations into an entire gene. Such 
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random mutagenesis has been shown to be important for studying the structure, 
function and evolution of proteins (Tindall and Kunkel, 1988) as well as in the 
development of novel proteins with desired properties. It is important to decide the 
level of mutagenesis that is best to create a large library of variants. If the mutation 
rate is too low it may not be possible to find the variants of interest. If the mutation 
rate is too high, nearly all the library variants will carry multiple mutations and the 
protein of interest therefore may be in an inactive form. For the work described 
here, the first protocol for ep-PCR was based on the protocol of Cadwell and Joyce 
(1992), which was basically optimized for a 400bp sequence. This protocol 
introduces errors at a frequency of 0.66% per nucleotide position over the course 
of the PCR by adding Mn2+ ions and unbalanced ratios of dNTPs, nearly all of 
which are base substitutions. However, the efficiency of cloning was found to be 
low Figure 5.51. The second protocol for library construction took advantage of 
generating a low frequency of mutations by the addition of only Mn2+. With slight 
modification the ep-PCR reactions were carried out with 0, 50, 100, 200, 300 and 
400µM of MnCl2 with the aim of controlling of the mutation frequency during 
amplification of N protein. Error prone libriaries generated using 0, 50, 100, 200 µM 
MnCl2 were gel extracted, but the addition of 300 and 400µM MnCl2 in the PCR 
reaction produced no clear band and were not used for further investigation Figure 
5.52. The 0, 50, 100, 200 µM MnCl2 libraries generated were transformed into 
Stellar competent cells and sequenced to determine the mutation frequency. By 
sequencing 2 of the isolated clones from the 50 µM MnCl2 and 100 µM MnCl2 
reactions, the results indicated that a higher concentration of MnCl2 increased the 
number of mutations and that the frequency of protein truncations was also higher. 
Sequencing 10 more clones from the 50 µM MnCl2 library demonstrated that the 
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mutated sites spanned the entire N protein in keeping with the desired complexity 
of an N protein library. Substitution of Mg2+ by Mn2+ affects base pairing specificity 
and the Mn2+ ion may interact with the DNA polymerase, either reducing the 
accuracy of base selection prior to insertion or inhibiting an "exonuclease-like" 
proofreading function (Beckman et al., 1985). It has been reported that the 
presence of 200 µM, 300 µM, or 400 µM MnCl2 results in a nucleotide error rate of 
2.2, 4.36, and 5.6 per kilobase, retaining protein function by up tp 83% in 200 µM 
MnCl2 whereas higher MnCl2 concentrations decreased protein functionality 
(McIsaac et al., 2014).  
To further demonstrate the diversity of the final mutant library, 100 clones were 
sequenced and the resulting sequences aligned. A phylogenetic tree was built on 
the basis of grouping of sequences with similar characteristics with the branches of 
the tree representing the distance from a common origin. The phylogenetic tree 
constructed from the 100 sequences using MEGA0.06 software revealed that only 
3 mutants were identical to the wild type although several additional mutants 
showed close homology to the wild type. 
At the nucleotide level, 627 mutations were found in 96 mutants, 211 of these 627 
mutations were A to G, 169 T to C, 19 deletion mutations and insertion were 
detected in 2 clones. The data from Table 5.8 showed that transition mutations 
(AG and TC) occur much more frequently than other types of mutation and that 
certain types of mutation like A→G or T→C occur more frequently than others. The 
N protein consists of 1365bp with a distribution of A 400bp (29%), T 316bp (23%), 
G 350bp (26%) and C 299bp (22%) and the cumulative total diversity for the 50µM 
MnCl2 library was a mutation frequency of ~0.4%.  
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The 100 N protein mutants generated by ep-PCR in this study were transfected in 
17clone-1 cells and at 24 hours post-transfection, cells were infected with MHV-
A59.  Monolayers that appeared to survive the effects of cytopathic effect better 
than cultures that were not transfected, or were transfected only with empty vector, 
were selected for quantitative measurement by plaque assay. The results 
confirmed that replication of MHV increased when the wild type N protein was 
expressed but that some mutated N protein decreased infectious virion production. 
An amino acid analysis showed that the majority of mutants that showed an 
inhibitory effect were truncated and that the length of the truncated mutants varied 
from 120 aa (mut66), 290 aa (mut1) to 373 aa (mut38). Non-truncated mutants that 
showed some effect had 3 mutations or more. For example mut2, which contained 
a 6 amino acids substitution and mut98, a 5 amino acid substitution, but these were 
not investgated further.  
    
The inhibitory effect of the most effective mutant, mut38, was confirmed by 
repeated plaque assay with the data confirming that a mutated N protein can 
interfere with virus replication and that a decrease in infectivity is possible by a 
mutation that changes relatively few of the residues in the virus N protein. The 
mut38 is truncated due to introduced stop codon, with only 373 residues and so 
lacks the N3 and B spacer domains. In SARS CoVs, the C-terminal domain is 
responsible for oligomeriziation and removal of 40 amino acids apparently 
decreased the ability of the N protein to oligomerize (Luo et al., 2006a). The lack of 
13 amino acid (residues 377–389) from the C-terminus of the HCoV-229E N 
protein has been also found to impair higher-order oligomerization and the virus 
titre is decreased by the presence of an excess of a peptide based on the 
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sequence of the C-terminal tail, which interferes with oligomerization of HCoV-
229E C-terminal domain (Lo et al., 2013). Improvement could be made to this work 
by conducting further experiments such as confiming which of the mutations in 
mut38 were responsible for the effect seen on virus infectivity by investigating 
truncation without mutations, each mutation individually and one mutation with the 
truncation. A computer algorithm can be applied to examine the role of the mutated 
proteins’ structure. No general cytotoxic effect was noted by MTT assay for mut38 
suggesting a specific effect in MHV infected cells. Accordingly, these results 
confirm that the wild type N and selected mutated N proteins have an effect on 
MHV-A59 replication when supplied in trans. 
In summary, this chapter demonstrated that presence of some N protein mutants 
could decrease virus infectivity and that the most effective variant, mut38 is not 
generally toxic to cells. Based on the results obtained from this study, there is 
evidence that coronavirus replication might be inhibited by a mutated N protein if 
present in cells at the time of infection. Since N protein a genetically stable protein 
and shows least variation in the gene sequence, therefore indicating it to be an 
efficient drug target candidate. 
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6 Directed evolution 
6.1 Introduction 
 
Previous chapters indicated that some mutated N proteins derived from MHV N 
can have potentially inhibitory effects on virus replication. These mutants were 
found by individual transfection of a large number of singly isolated mutants but it is 
reasonable to suppose that these mutants, and other potentially more potent 
variants, would be also present in a library of many thousands of random mutants. 
To select such mutant(s), which have an inhibitory effect on replication, from 
various complex libraries a directed evolution approach (also called in vitro 
laboratory evolution) can be useful (Jürgens et al., 2000; May et al., 2000; Zaccolo 
and Gherardi, 1999). This approach does not require an understanding of protein 
structure or function and is predicated on evolutionary paradigms. Directed 
evolution is a powerful method for generating enzymes and even entire genomes 
with desired properties. A library of variants is screened for a desired outcome, 
resulting in an enriched library of perhaps hundreds or thousands of variants from 
an original much more complex pool. This enriched library is recovered and used in 
a second round of enrichment, selecting again for a desired trait. The combination 
of randomness in the initial library and iterative selection results in the selection of 
a function based purely on phenotype, but when the complexity is reduced to only 
a few members each can be characterized genotypically and the genetic basis of 
the new trait determined. The capacity to screen depends on the size of the library 
for, although limited library diversity can be easily screened, a large library requires 
a high selectivity in order to be screened effectively, so for each new application, 
screening and selection are generally re-invented. The outcome of a directed 
evolution experiment can be also altered by the mutation rate and population size 
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in addition to the selection strategy. During a directed evolution experiment the 
frequency of variants in a population changes; the diversity of the variants pool is 
reduced and the frequency of the desired variants is increased.  
With its diverse functionality N protein may be considered an ideal target for the 
development of an antiviral drug and based on the data presented in previous 
chapters it can be hypothesized that mutated N may have an inhibitory effect on 
virus replication and may be considered a dominant negative. As such, the directed 
evolution of N protein could be considered to develop increasingly effective 
dominant negative N variant(s), which in turn could lead small molecule 
development Figure 6.64. 
 
Figure 6.64. Work flow for directed evolution of MHV N protein in 17clone-1 cells. N 
protein of MHV-A59 is amplified by ep-PCR, library of variants are cloned and transformed 
into E. coli. After transfecting 17clone-1 with N variants, cells will be infected with the virus. 
Selected clones is extracted from live cells, amplified, cloned, transformed, transfected and 
infected. Evolution cycle is repeated for several rounds. 
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In this chapter, a new expression and screening system is developed to select the 
evolution of mutated N protein variants with the potential to inhibit MHV replication. 
Libraries were generated by the second protocol ep-PCR protocol previously 
discussed (50 µM MnCl2) as described in chapter 5, and the resulting library was 
cloned into the pTriEx expression vector and transformed en masse into E. coli. 
Unlike earlier experiments, no colonies were picked, instead the whole library was 
prepared as DNA and transfected into mammalian cells which were subsequently 
infected with MHV-A59 virus. Variants that might have exhibited a dominant 
negative property were isolated from those live cells that survived the infection and 
subjected to further rounds of selection, purification, re-cloning and transfection. 
This process was applied for several rounds with the aim of developing a protein 
inhibitor based on the N protein capable of MHV replication inhibition, but the 
principle of the method could be applied to any mutated component of the 
coronavirus genome.  
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6.2 Results 
6.2.1 Directed evolution for N protein and mut38 
 
As a first step to test that selection of potential dominant negative variant(s) by in 
vitro directed evolution, a small mixture containing only the wild type and mut38 
was constructed. The wild type and vector containing N mut38 were mixed in a 
ratio of 1:1 from stored stocks and used as a library that contains only two variants 
to prove the principle of competition between these two variants. The wild type N, 
which increased virus production and mut38 variant which decreased virus 
production. 
 
6.2.1.1  Round 1: wild type and mut38 
Mammalian 17 clone-1 cells were grown in a T25 flask, representing a population 
of about 5 x 106 cells. Assuming a transfection efficiency of about 50% then 
something over 106 variants could be sampled using a culture of this size. When 
the cell confluence reached ~70% the monolayer was transfected with the plasmid 
mixture which contained equal copies from both wild type and mut38 using 
Turbofect transfection reagent according to the manufacture’s instruction. After 
incubation for 24 hours the flasks were washed twice with PBS and the monolayers 
infected with MHV-A59 at an MOI 3 by incubation at 37°C on a low speed platform 
rotator for 45min. After incubation, the inoculum was discarded and the monolayer 
again washed with PBS. Fresh media was added and the flask was incubated at 
37°C for 16 hours, by which time cytopathic effect was clearly extensive. The 
media was removed gently by aspiration and the flask was washed carefully with 
PBS 3 times to eliminate all dead cells. Intact cells were recovered by scraping and 
low speed centrifugation at 4°C and any plasmid DNA present in the surviving cells 
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was extracted using a plasmid miniprep kit (Thermo Fisher SCIENTIFIC). The DNA 
product was amplified with N protein ORF specific forward and reverse primers 
(see Table 1) as described in section 2.1.5 and the PCR product was analyzed by 
agarose gel electrophoresis Figure 6.65. The result showed a high intensity band 
with the correct size for the N encoding fragments indicating that the N protein ORF 
(wild type and/or mut38) was present in rescued cells. 
 
Figure 6.65. Gel electrophoresis of N protein extracted from survived cell. The 
recovered error-prone library representing N sequence of both wild type and mut38 was 
amplified using N protein forward and reverse primers. Lane 1: Marker (1kb) DNA ladder, 
Lane 2: N protein library (1365bp).  
 
The amplified N sequence, which represents an enriched library of variants was 
purified by a PCR reaction clean up kit and the pool of DNA fragments was cloned 
into a NcoI/ XhoI digested pTriEx1.1 plasmid through the In-Fusion protocol. The 
reaction was transformed into Stellar competent cells (500 µl) and each 100 µl of 
the transformed mix was inoculated into to 10 ml LB broth with 100 µg/ml of 
ampicillin and incubated at 37°C for 16hr in the shaker. The last 100 µl from the 
transformation mix was plated onto LB agar plate supplemented with ampicillin and 
colonies isolated to provide a snapshot of the mutants present in the rescued 
1               2       
N library 
1st  round 
A 
1500 
  
1000 
800 
600 
400 
  
bp 
	  	   170 
population of N sequences. An enriched library was purified from the overnight 
culture using a miniprep kit (Thermo Fisher SCIENTIFIC) and used, as before, for a 
second round of transfection and selection.  A sample of the recovered library was 
also double digested with XbaI and XhoI to confirm the presence of an insert 
consistent with the ORF for wild type N protein and/or mut38 Figure 6.66. 
  
Figure 6.66. Gel electrophoresis of error-prone library double digest containing 
variants (wild type and mut38) of N protein. The recovered error-prone library 
representing N sequences following a single round of selection was double digested with 
XbaI and Xhol. Lane 1: Marker (1kb) DNA ladder, Lane 2: N protein library (1662bp) (wild 
type/mut38).  
 
Of the colonies from the plated transformation, 25 were picked randomly and 
screened by colony PCR for the presence of N sized inserts using primers T7 
forward and Rv_N Table 2.1. The N insert was found in 15 isolate from a total of 25 
isolated that were subjected for colony PCR Figure 6.67. 
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Figure 6.67. N protein (wild type and mut38) screened by PCR. 25 colonies were 
screened for the presence of N protein insert. Lanes 1-25: colonies numbered from 1-25, 
Lane 26: Marker (1kb) DNA ladder. 
 
Of the 15 isolates that were positive for the correctly sized insert, ten isolates 
(2,3,4,6,8,10,12,13,15 and 17 in Figure 6.67) were cultured in LB broth with 
ampicillin and purified in the next day by using miniprep kit (Thermo Fisher 
SCIENTIFIC). All 10 isolates were sequenced using primers T7 forward and 
TriExDOWN from SourceBiosinences. The result showed that 6 isolate were 
identified carrying sequence of the wild type and the remaining 4 isolates carried 
the mut38 sequence (i.e mut38 was present in 40% of the total sequenced 
isolates) as shown in Figure 6.68. This round was considered 1st round of 
selection. 
 
 
Figure 6.68. Sequence alignment of 10 isolates with wild type. Sequence of 10 
isolates was aligned with wild type using snapgene software. Red box represent G to A 
mutation at position 303 which occurred in mut38.  
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6.2.1.2 Round 2: wild type and mut38 
 
The library products from the 1st round as described above were transfected again 
in a T25 flask containing a ~70% 17clone-1 cell monolayer using Turbofect reagent 
and incubated for 24hr at 37°C with 5%CO2. The flask was washed with PBS twice 
and the cells were infected with MHV-A59 at MOI 3, incubated for 45 min at low 
speed platform rotator. After incubation, inoculum was removed, washed twice with 
PBS, new fresh media was added and the flask incubated at 37°C with 5%CO2. 
The next day, the media was aspirated gently, the flask washed with PBS and the 
plasmids present in surviving cells were rescued by using a plasmid miniprep kit. 
The DNA product was amplified with Fw_N and Rv_N primers Table 2.1 and 
analyzed by gel electrophoresis. The result showed a clear band with of N protein 
ORF size (1365bp) Figure 6.69.  
 
Figure 6.69. Gel electrophoresis of N protein extracted from survived cell (2nd round 
of selection). The recovered error-prone library representing N sequence of both wild type 
and mut38 from 2nd rounds of selection that was amplified using N protein forward and 
reverse primers. Lane 1: Marker (1kb) DNA ladder, Lane 2: N protein library (1365bp). 
 
As before the reaction was cloned and transformed into Stellar competent cells 
(500 µl) and divided as described in section 6.2.1.1. The last 100 µl from 
transformed mix was transformed onto LB agar plate containing ampicillin. 
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Screening was done by colony PCR and 10 isolates grown in LB broth, purified by 
miniprep kit and sent for sequencing with primers T7 forward and TriExDOWN. The 
sequencing result showed that 7 of the isolated plasmids had the wild type 
sequence and the remaining 3 isolates were mut38. This round was considered the 
2nd round of selection. 
6.2.1.3 Round 3: wild type and mut38 
 
A third round of selection was performed in 17clone-1 cells using the library from 
2nd round, also transfected in a T25 flask containing 17clone-1 monolayer and all 
steps were repeated as described above. The results from 10 sequenced colonies 
showed that wild type N protein sequence was identified in 6 isolates while the 
mut38 sequence was present in 4 isolates. The purified library was considered the 
3rd round of selection and was ready for a next round of selection.  
6.2.1.4 Round 4: wild type and mut38 
 
The purified library from the 3rd round of selection was transfected into T25 flask 
and all steps were repeated in this round as described previously.  The results from 
10 sequenced colonies showed that wild type N protein sequence was present in 5 
isolates while mut38 sequence was present also in 5 isolates. After the 4th round of 
selection the result revealed that both WT and mut38 were present in equal 
numbers. At this stage we stopped the selection experiment since strategy applied 
in this method can check for selection but the result obtained didn’t show any 
significant in the selection after 4th rounds and we were not sure how many rounds 
are required for success of this selection method. Another approach maybe 
developed in the future to gain more accurate results. The next step is to start the 
selection in a bigger library. 
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6.2.2 Directed evolution for 10 variants 
 
Despite the lack of selection in the experiments described in section 6.2.1 a 
directed evolution experiment was designed for a pool of N variants that were more 
complex, that is the type N protein and 10 of the selected variants as described in 
Chapter 5. Accordingly, a mixture was generated from plasmids encoding the wild 
type, mut38, mut1, mut2, mut6, mut59, mut65, mut66, mut90, and mut94 by 
preparing plasmid stocks from each variant and mixing them equally to form the 
final sample for transfection, that is, a total of 8 µg for a T25 flask. The ability to 
select from this pool of variants depended on their effect on virus titre as shown in 
Figure 5.59. The pool included variants that showed a potential inhibitory effect 
(mut1, mut2, mut66, mut38, and mut94), three variants that showed the same 
effect of the control (mut90, mut6 and mut59) and mut65, with the same effect as 
wild type N. In addition the wild type was included in the library. This plasmid 
mixture was assumed to contain ~40-50% of its members as potential dominant 
negative variants. According to results in chapter 5 it was assumed that 2nd error 
prone protocol (50 µM MnCl2) can provide less than 50% dominant negative 
variants.  
 A T25 flask containing ~70% 17clone-1 cell monolayer was transfected with the 
constructed library using Turbofect reagent and incubated for 24hr at 37°C with 
5%CO2. The next day, the flask was washed with PBS twice and cells were 
infected with MHV-A59 at MOI 3. After 16hr incubation, DNA was extracted from 
the surviving cells using a miniprep kit, the N coding DNA product was amplified 
with Fw_N and Rv_N primers Table 1 and analysed by gel electrophoresis Figure 
6.70.	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Figure 6.70. Gel electrophoresis of N protein extracted from survived cell. The 
recovered error-prone library representing N sequence of 10 variant was amplified using N 
protein forward and reverse primers. Lane 1: Marker (1kb) DNA ladder, Lane 2: N protein 
library (1365bp).  
 
The amplified N sequence was purified by a PCR reaction clean up kit and the pool 
of DNA fragments was cloned into pTriEx1.1 plasmid previously digested with 
NcoI/XhoI through the In-Fusion protocol. The reaction was transformed into Stellar 
competent cells (500 µl) and divided as described for the wild type/mut38 library. A 
sample of the mix was double digested with XbaI and XhoI for confirmation of 
suitably sized inserts Figure 6.71. 	  
	  
Figure 6.71. Gel electrophoresis of error-prone library (10 variants) double digest. 
The recovered error-prone library representing N sequences of 10 variants following a 
single round of selection was double digested with XbaI and Xhol. Lane 1: Marker (1kb) 
DNA ladder, Lane 2: N protein/mut38 library (1662bp). 
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For screening, 24 colonies were selected randomly and screened by colony PCR 
and N sized insert was found in 9 isolates only. Another 24 colonies were screened 
by colony PCR Figure 6.72 and from this screen 10 randomly picked colonies were 
prepared as plasmid DNA and sent for sequencing with T7 forward and 
TriExDOWN primers. 
 
Figure 6.72. N protein (10 variants library) screened by colony PCR. 48 colonies were 
screened for the presence of N protein insert. Lane 1: Marker (1kb) DNA ladder, Lanes 2-
25: colonies numbered from 1-24. Lane 26: Marker (1kb) DNA ladder, Lanes 27-50: 
colonies numbered from 25-48. 
 
The purified plasmid product from the tissue culture transformation, derived as 
above, was transfected again to a T25 flask and this process was repeated for 3 
rounds. As before, a representative 10 colonies were picked from each round of 
transfection and selection and the distribution of variants from each of these 10 
sequenced isolates from each round is illustrated in Table 6.9. The result indicated 
little overall selection. The data from the 2nd round of selection indicated that the 
wild type was the predominant species although it was expected that the wild type 
N would be outcompeted by potentially dominant negatives.  In the 3rd round it 
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appeared that mut65, which showed an increase in virus titre when screened 
alone, appeared less frequently but this was also true for mut6, which previously 
had the same inhibitory effect as the control. However, the results across the 
rounds of selection revealed essentially random recovery and no significant 
selection for dominant negative variants. Sequencing 10 isolates from each round 
was helpful in showing the distribution of mutants from the selection procedure, 
that is that plasmid DNA was successfully re-isolated at each round despite the 
complexity of the methodology, but it can be concluded that the experiment was 
too lacking in complexity to demonstrate a clear effect and that many thousands of 
clones may have to be tested to observe a rising variant among many other equally 
competing variants.   
Table 6.9. Screening of N protein variants after 3 rounds of directed evolution. 10 
randomly isolates were selected and sent for sequencing from each round.  
 
 
 
6.2.3 Directed evolution of a complex N protein library 
 
In vitro error prone libraries generate a population of many thousands of different 
variants and screening and selection is a key factor for successful evolution 
especially from a pool that contains mainly unknown or inactive form of mutants. In 
directed evolution, the library size to be screened is ultimately limited by the screen 
itself and a combination of selection approaches can be more useful with big 
libraries.    
Variant Wild  
type 
Mut1 Mut2 Mut6 Mut38 Mut59 Mut65 Mut66 Mut90 Mut94 
Round1 2 1 1 2 0 1 1 1 0 1 
Round2 3 2 1 1 1 0 1 1 0 0 
Round3 2 0 1 1 1 1 0 2 1 1 
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Therefore, accepting that the data with limited plasmid mixtures of know N variants 
did not satisfactorily demonstrate clear selection, all the steps used previously for 
the wild type/mut38 and the 10 variants libraries were performed for a library 
containing a random pool of N protein variants.  The second error prone protocol 
(50 µM MnCl2) as described in chapter 5 was used to generate the library of N 
variants for this experiment. After amplification under error prone conditions, the 
DNA product was analysed by gel electrophoresis Figure 6.73.  
Figure 6.73. Gel electrophoresis of N protein generated by error prone PCR (50 µM 
MnCl2). N protein was amplified using second error prone PCR. Lane 1: N protein library 
(1365bp), Lane 2: Marker (1kb) DNA ladder.  
 
The whole error prone N band, representing a random library of N variants, was 
purified by a clean up kit, cloned by In-Fuison reaction as described and 
transformed in Stellar competent cell. The transformation mix was cultured en 
masse in LB broth and the next day the culture was extracted using a miniprep kit. 
A T25 flask was transfected with the library using Turbofect transfection reagent 
according to manufacturer’s instruction and the selection procedure repeated. That 
is, after 24 hr incubation the 17clone-1 cells monolayer was washed twice with 
PBS and infected with MHV-A59 at an MOI 3. The inoculum was removed after 
45min, monolayer washed with PBS and fresh media added. After 16 hours 
incubation, media was aspirated gently; the monolayer washed with PBS and DNA 
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was extracted from the cells that had survived the MHV infection. All these steps 
were repeated for 4 rounds and the supernatants from each round of selection 
were stored and titrated for the level of virus replication by plaque assay. The 
results of plaque assay showed that the virus titre slightly decreased after the first 
round of transfection and selection but that virus infectivity slightly increased in the 
2nd round. In the 3rd and 4th rounds virus titre again decreased slightly Figure 6.74 
although in all cases the error bars of the assays overlapped so no significant 
overall trend was apparent. It was hoped that the plaque assay result could be 
used to assess which round might be used to screen for individual clones that 
could exhibit a dominant negative effect but it is clear that the data do not support 
such a strategy and other selection methods will be needed to screen for true 
dominant negatives. 
 
Figure 6.74. Inhibition of virus replication tested by plaque assay. Supernatants from 
four rounds were subjected for plaque assay to measure virus titre. Cells infected with 
virus only at MOI=3 is used as a control. The error bar represent mean and SD. 	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6.3 Discussion 
 
The success of any directed evolution experiment hinges on generating libraries 
with significant size and diversity and with appropriate methods for 
screening/selection. As demonstrated in previous chapter, ep-PCR was titrated for 
its ability to introduce random errors into the N protein sequence and was used and 
here those libraries were used to try and select dominant negative N variants from 
different pools of N protein. 
In order to screen for potential dominant negative N variants, cell survival was 
assessed with different pools. For wild type N protein and mut38 screening, mut38 
was found in live cells after 4 rounds with the same numbers as the wild type. This 
stability in numbers after 4 rounds selection suggested that selection was not 
working efficiently to provide a good starting point for evolution selection/screening. 
Although disappointing there were many possible explanations for this, which 
prevented a clear conclusion. For example, WT and mut38 plasmids could both be 
entering the same cells during transfection and their effects of stimulation (WT) and 
inhibition (mut38) on MHV replication cancelling each other out. The extensive 
washing of the surviving cells was assumed to have removed input plasmid DNA 
but it cannot be ruled out that this too provided a background that obscured any 
selection taking place, although this would have been expected to decrease with 
increasing rounds of selection. A technical improvement in future experiments may 
be to include a DNAse step before the cells are disrupted to remove any loosely 
bound DNA. Notwithstanding this data an evolution experiment with a bigger pool 
of variants, the 10 variants isolated in previous experiments, was attempted. Here 
too, selection was not obvious although it with a more complex mixture the effects 
at each round might have been expected to be slower. Again, multiple plasmid 
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entry into single cells may provide an explanation of why selection was not more 
apparent.  In a final and much more complex library selection experiment, a true 
epPCR library created under conditions known to generate suitable diversity, the 
virus titre decreased after the 1st round of selection, possibly consistent with the 
presence of variants that might exhibit dominant negative properties. However, the 
virus titre recovered in the 2nd round and was variable in the 3rd and 4th rounds 
indicating no significant trend in selection overall. The possible explanations for the 
failures above also apply to these results, and are in fact more plausible as the 
library was highly diverse and high numbers of positive WT-like variants could 
obscure any dominant negative variants.  
In directed evolution experiment, it is important to consider the time and path of 
evolution that may be required to select a gene of interest with desired properties. 
Several mutations may be required to switch the N protein from a protein which 
enhances MHV replication to a dominant negative protein and these may be only a 
small proportion of the total library used. It may be necessary to perform an 
incremental approach to N protein evolution by combining low error rate libraries, 
which include many non-desired variants, with high error rates that are more likely 
to contain a desired function but will also include many non-functional variants. 
Therefore, large libraries or mixtures of several thousand mutants should be 
screened at each round and for many rounds in order to find suitable dominant 
negative variant(s). Adaptation in the experiments described here were stopped 
after a few rounds of selection as a result of technical and consumable limitation 
but the data in earlier chapters suggests such variants do arise although the data in 
the later chapters suggest their isolation from random libraries is challenging.  
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In conclusion, this chapter demonstrated that checking for success of directed 
evolution protocol in selecting dominant negative variant(s) in three different size 
libraries was inadequate. The precise mechanism for this selection was not clear 
and more optimization such as sequencing more variants from each round or using 
different approach may improve selection protocol. Next-generation sequencing 
(NGS) technologies has been applied for RNA virus detection in recent years 
(Capobianchi et al., 2013; Shan et al., 2011; Yu et al., 2013; Zhang et al., 2014) 
which help in revealing a huge number of sequences of nucleic acids (DNA or 
RNA) and can detect various kinds of RNA viruses. The use of next generation 
sequencing approach could provide more a detailed analysis and scan throughout 
the library generated by random mutagenesis. A deeper understanding of the 
mechanism by which dominant negative variant (s) interfere with WT may help in 
selection stage. 
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7 Expression and purification of MHV-A59 Mtase protein 
7.1 Introduction 
 
The primary goal for any research studying protein characteristic, function, drug 
development or production of antibodies against these proteins is obtaining a 
suitbale yield of purified protein. This challenge requires research to select 
appropriate vectors, purification tags, expression host and many other parameters. 
Since there is a continued need to study and develop treatments for coronavirus 
infections including infections by significnat viruses such as SARS and MERS, 
understanding key coronavirus protein structure, function and interactions will be 
the cricital to develop novel therapies for current and future coronavirus outbreaks 
and to improve control strategies. One of the attractive targets for coronavirus drug 
development is the viral RNA capping enzymes and the recent connection between 
the requirement for viral RNA capping and evasion of the host cell innate immunity 
is a promising research field for the development of anti viral interventions. Put 
simply, an inhibitor of the capping reaction would lead to viral RNA being detected 
by the innate RNA sensors RIG-I or MDA-5 and the induction of a signalling which 
could avert a full infection as the success of any viral infection depends on the 
ability of viruses to evade the host immune response. Viruses have evolved means 
to deactivate host sensing through either direct antagonism of pathway 
components, for example by the NS1 protein of influenza virus (Mibayashi et al., 
2007), or by molecular mimicry of host processes so that detection is avoided. The 
duplication of capping elements for viral mRNAs is an important example of the 
molecular mimicry approach (Decroly et al., 2012). Higher eukaryotes uses a 5′-
terminal capping system to protect mRNA from degradation by 5’ 
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exoribonucleases, ensures efficient mRNA translation, mRNA stability, and helping 
to distinguish between self/non-self RNA that will lead to initiation of the host 
immune response (Gu and Lima, 2005; Shuman, 2002, 2000; Yoneyama and 
Fujita, 2010). This capping system includes methylation of the first one or two 5’ 
nucleotides at the ribose 2’-O position by a distinct host 2’-O methyltransferases 
(MTases) (Bélanger et al., 2010; Werner et al., 2011). The vast majority of viruses 
that replicate in the cytoplasm including coronaviruses (Daffis et al., 2010; Szretter 
et al., 2012; Züst et al., 2011) have evolved a strategy to cap their RNAs and the 
coronavirus MTase (nsp16) activity is therefore important for coronavirus virus 
replication/transcription and an obvious target to develop antivirals for control of 
coronaviruses infection. In addition, an nsp16/nsp10 interaction is involved in the 
capping of coronavirus RNA (Bouvet et al., 2010; Chen et al., 2011; Debarnot et 
al., 2011; Decroly et al., 2011, 2008; Lugari et al., 2010) and can be used in the 
future as an additional attractive site for the design of antiviral drugs, rather than 
targeting the nsp16 active site only.  
MTase has become an attractive target to develope inhibitors known to act on viral 
RNA capping and block the cap formation. Several inhibitors have been reported 
that bind to either the S-adenosylmethionine (SAM)/ S-adenosylhomocysteine 
(SAH) binding pocket or the Guanosine-5'-triphosphate  (GTP) binding pocket in 
different viruses such as Dengue and West Nile viruses (Benarroch et al., 2004; H. 
Chen et al., 2013; Coutard et al., 2014; Lim et al., 2011; Stahla-Beek et al., 2012). 
In coronavirus, different screening assays have been used toward the identification 
of viral cap-methyltransferase inhibitors (Aouadi et al., 2017b; Sun et al., 2014), 
which provide a platform toward developing more specific inhibitors against 
coronavirus methyltransferases. 
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Protein purity is of key importance for development of much viral biochemistry such 
as immunodiagnostic assays, viral pathogenesis and structural studies (EM, SAXS, 
NMR, and crystallography).  Expression hosts (mammalian, insect, yeast, bacterial, 
algal, and cell-free systems), media and expression time may affect any protein 
expression experiment and optimizing conditions for purification is the initial and 
major step to obtain a high yield of any protein of interest. The expression and 
purification of recombinant proteins is valuable for both clinical and investigational 
purposes. In comparison to other systems, bacterial systems are simple, easy to 
use and can give good protein yields (Baneyx and Mujacic, 2004). However, well 
studied expression hosts, such as E. coli, lack most of the posttranslational 
modification apparatus, which may results in poor folding or non-functional 
proteins, depending on the protein of interest. Recently, several modified strains 
have been developed that contain additional chaperones to assist the proper 
folding of proteins (e.g. BL21 (DE3) GroES/L) (Caspers et al., 1994; Endo et al., 
2006; Luo and Hua, 1998). Other Strains contain rare tRNAs to help external 
eukaryotic proteins to express better (e.g. B834 (DE3) pRARE, BL21 (DE3) 
CodonPlus, Rosetta series). The type of media used for bacterial growth also has a 
signficant effect and both Luria Bertani (LB) and Auto induction media (AIM) media 
are used for bacterial growth for expression purposes. The first media is a simple 
media in which expression is induced by addition of IPTG while the auto induction 
system depends basically on a natural turn on of the lac promoter achived through 
a suitbale balance between the glucose and lactose in the media. Glucose 
depletion from the media results in cAMP increase in media and allows higher-level 
expression (Studier 2005). This technique for automated induction of cells does not 
require IPTG addition. One other main factor is the fusion tag(s), for facilitation of 
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purification. The polyhistidine (His) tag is the most common tag used for protein 
purification purposes. This tag is relatively small tag, with minor effect on the 
overall structure and does not interfere with the protein structure in most of the 
cases (Mason et al., 2001). Proteins are purified by a HisTrapTM column in a 
process of immobilized metal ion chromatography (IMAC). An immobilsied metal 
ion in the matrix, usually nickel, preferably binds to the poly histidine residues on 
the protein surface and then can be eluted competitively with free imidazole, which 
essentially competes the nickel ion from the imidazole ring of the histidine residues. 
In this chapter several parameters affecting the expression and purification of the 
MHV nsp16 protein expressed in E. coli were assessed. The ultimate goal of the 
work was in keeping with the other chapters of this thesis, that is, to focus on areas 
that might lead to the development of antiviral strategies. The immediate need 
however was to increase levels of expression and to develop rapid purification for 
nsp16 with a high level of purity and yield. 
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7.2 Results 
7.2.1 Optimizing conditions of nsp16 expression and purification  
 
As described in chapter 3, nsp16 was amplified from cDNA of MHV A59 and 
cloned into the pTriEX expression vector followed by transformation of E. coli BL21 
(DE3)-pLysS competent cells and induction and screening for product Figure 3.24. 
Nsp16 was also expressed in LOBSTR (low background) competent cells as 
described in section 2.17.2. Since the nsp16 was successfully expressed in both 
strains, the next step was to optimize expression conditions for purification. One 
colony from each strain, that is, E.coli BL21 (DE3)-pLysS and LOBSTR cells 
previously shown to express nsp16 was inoculated into 10 ml LB media containing 
ampicillin and chloramphenicol and incubated at 37°C with shaking for 16hr. The 
following day, the starting culture was inoculated in Luria Bertani (LB) media with 
ampicillin, incubated in the shaker at 37°C until an OD600nm of 0.6 was reached and 
protein expression induced by the addition of IPTG to 0.1mM final concentration. 
Cells were harvested by centrifugation after 3 hours induction with IPTG and the 
cell pellets were resuspended in binding buffer containing a proteinase inhibitor 
cocktail, sonicated, filtered and applied to a HisTrap
TM HP column. The column was 
washed to background OD280 with binding buffer and the bound protein eluted 
using a linear gradient of imidazole from 0.02 to 0.5 M in binding buffer. The SDS-
PAGE gel results showed a higher expression of nsp16 in LOBSTR cells compared 
to E. coli BL21 (DE3)-pLysS and the background was noticeably cleaner Figure 
7.75 and Figure 7.76. When the LOBSTR extracts were subjected to Western blot 
using an anti His antibody, nsp16 presence was confirmed in the crude, lysates, 
the soluble column load and the eluted fractions Figure 7.76B.     
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Figure 7.75. Expression and purification of nsp16 protein from BL21 (DE3)-pLysS 
competent cells.	   The SDS PAGE gel was stained with coomasie blueTM. Nsp16 protein 
was transformed with vector pTriEX and induced by 1 mM IPTG for 3 hours at 37°C in LB 
media. Nsp16 expression culture was run through a Ni-affinity column designed for 
purification of 6x His tag bound recombinant proteins and eluted with an imidazole. Lanes 
represent different stages of nsp16 purification. 1: Marker; 2:total lysate (uninduced); 3: 
total lysate (after 1 hour induction); 4: total lysate (after 2 hours induction); 5: total lysate 
(after 3 hours induction); 6: soluble extract; 7: Ni column flow through; 8: Ni column elute 
fraction 1; 9: Ni column elute fraction 2; 10: Ni column elute fraction 3. The black arrow 
represents where a band of 34.5 kDa would run, representing the predicted weight of 
nsp16. 
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Figure 7.76. Expression and purification of nsp16 protein from LOBSTR competent 
cells. Nsp16 protein was transformed with vector pTriEX and induced by 1 mM IPTG for 3 
hours at 37°C in LB media. Nsp16 expression culture was run through a Ni-affinity column 
designed for purification of 6-His-tag bound recombinant proteins and eluted with an 
imidazole. Lanes represent different stages of nsp16 purification. 1: Marker; 2:total lysate 
(uninduced); 3: total lysate (after 1 hour induction); 4: total lysate (after 3 hours induction); 
5:soluble extract; 6:Ni column flow through; 7: Ni column after wash; 8: Ni column eluate 
fraction 1; 9: Ni column eluate fraction 2; 10: fraction 1 (concentrated). The black arrow 
represents where a band of 34.5 kDa would run, representing the predicted weight of 
nsp16. (A: The SDS PAGE gel was stained with coomasie blueTM; B: Western blot). 
 
Two media were also compared to choose best one for nsp16 protein purification. 
As before starting cultures were grown overnight and then inoculated into either 
Luria Bertani (LB) or Auto induction media (AIM) culture media with ampicilin and 
incubated with shaking at 37°C until an OD600nm of 0.6 was reached. The 
autoinduction (AIM) culture was left to grow overnight at 20°C before cells were 
harvested by centrifugation while cells in LB media were harvested at 3 hours post 
IPTG induction. Cell pellets were resuspended in binding buffer containing a 
proteinase inhibitor cocktail, sonicated, filtered and again purified to a HisTrap
TM 
HP column. 
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Figure 7.77.	  Expression and purification of nsp16 protein from LOBSTR competent 
cells in AIM media. Nsp16 protein was transformed with vector pTriEX and grown at 20°C 
in AIM media in the shaker. Nsp16 expression culture was run through a Ni-affinity column 
designed for purification of 6-His-tag bound recombinant proteins and eluted with an 
imidazole. Lanes represent different stages of nsp16 purification. 1: Marker; 2: total lysate 
(uninduced); 3: total lysate (after 3 hour induction); 4: soluble extract; 5: Ni column flow 
through; 6: Ni column eluate fraction 1; 7: Ni column eluate fraction 2. The black arrow 
represents where a band of 34.5 kDa would run, representing the predicted weight of 
nsp16.  
 
The protein yield of nsp16 was found to be higher following growth in LB media 
Figure 7.76 than in the AIM media Figure 7.77. Nsp16 protein concentration was 
estimated using a Bradford Assay, according to the manufacturer’s protocol (Bio-
Rad) and Nsp16 protein fractions were concentrated and stored frozen at -80°C for 
subsequent analysis. 
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7.3 Discussion 
 
Pure and functionally active forms of coronavirus proteins are critical to the 
development of anti-viral drugs and vaccines. This chapter presents the work 
carried out for optimizing conditions required for coronavirus nsp16 purification. 
The nsp16 protein was shown to be best expressed from LOBSTR cells in LB 
media after 3 hours induction with IPTG which allowed for successful purification 
by HisTrap
TM HP column chromatorgraphy.  
To achieve this, trial experiment using two different bacterial strains were 
performed, with LOBSTR and E.coli BL21 (DE3)-pLysS. The nsp16 from both 
strains was found in the soluble fraction following sonication so either strain was 
suitable for the purification procedure. The results showed higher expression when 
nsp16 was grown in LOBSTR cells. The E. coli BL21 (DE3)-pLysS cells carry 
pLysS for toxic protein expression. It encodes T7 lysozyme which is a natural 
inhibitor of the T7 RNA polymerase. This gene can inactivate leaky expression of 
RNA polymerase efficiently but has no direct effect on the levsl of expression 
following induction. By contrast, LOBSTR cells are designed for the purification of 
low expressing proteins in E. coli by means of lowering the background 
contamination by two E. coli proteins with naturally high levels of His residues, 
ArnA and SlyD which bind to the resin during immobilized metal-affinity resins. 
LOBSTR is engineered to carry genomically modified copies of arnA and SlyD 
which encode these proteins and so abolish this histidine rich surface (Andersen et 
al., 2013).  
A second experiment was performed to compare the expression level of nsp16 
using two different media. Auto induction depends on ability of certain media to 
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induce protein expression in E. coli strains when cells reach saturation (Studier, 
2005). Adjusting levels of glucose/lactose in media can regulate auto-induction but 
one of potential problems is that the expressed protein can be degraded. It is 
normal to obtain less amount of protein when the protein is expressed in AIM 
media since the nutrients provided by this media are limited unlike the nutrients 
provided by LB media. The temperature for expression was also different for both 
media. Nsp16 was successfully expressed at 37°C in LB media whereas nsp16 
was expressed at 20°C in the AIM media. In the optimized protocol, nsp16 protein 
expression started after one hour of induction at 37°C with maximum soluble 
amount after 3 hours while harvesting of the culture after an overnight induction 
(16hr) at 20°C resulted in reduced amount of eluted protein. One reason for this 
maybe that nsp16 protein is degraded during the extended incubation period. 
Degradation by E. coli indigenous systems or by autolysis could be other reasons 
for target protein declining.  
In conclusion, the optimal expression and purification of the target nsp16 protein 
was in E. coli LOBSTR in LB media with 3hr induction with IPTG at 37°C.  
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8 General discussion 
 
It has been almost two decades since the first human coronavirus outbreaks were 
described and, despite progress in our understanding of the coronavirus genome 
and replication process; there are still no effective antivirals for this group of viruses 
(Graham et al., 2013; Perlman and Netland, 2009). Coronaviruses continue to 
emerge and cause great losses for both humans and animals (Choudhury et al., 
2016; Weng et al., 2016; Zhang, 2016). To investigate the inhibitory role of 
coronavirus non mutated and mutated proteins on virus replication, it was 
necessary to express coronavirus proteins in mammalian cells that were 
compatible with coronavirus infection. First, In-Fusion cloning was used to produce 
DNA constructs encoding expressed proteins. Recombinant proteins were 
expressed in bacterial cells and 17clone-1 mammalian cells. Early attempts to 
express the coronavirus proteins using the bacterial expression system were 
successful in obtaining consistent and stable proteins, proving that the expression 
vectors produced were functional; successful cloning into the pTriEx vector was 
verified by sequencing, and Western blotting demonstrated bands of appropriate 
sizes for each protein following the induction of expression. However expression of 
these proteins in mammalian cells was rather difficult. Despite several attempts, it 
was not possible to detect MHV-A59 proteins in 17clone-1 mammalian cells with 
the exception of the N protein. At this stage it was not determined whether these 
proteins were not expressed, expressed in low level or affected by protease 
enzymes. Attempts to increase expression signal and reduce the effect of protease 
enzyme activity were tested but the proteins were not detected, and therefore an 
alternative strategy was explored (described in chapter 3).  
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Changing the expression strategy could increase the stability of the selected 
coronavirus proteins and for that, the SUMOStar tag was used.  The covalent 
attachment of SUMOStar to cellular proteins constitutes a widespread mechanism 
that rapidly regulates protein function in response to a changing cellular 
environment. The coronavirus proteins (M protein, nsp9, nsp10, nsp16) were 
expressed in mammalian cells using this strategy Figure 4.45 but despite many 
attempts, it was not possible to express proteins nsp7 and nsp8. Alternative tags 
or/and vectors may need to be considered to acheive expression of all targeted 
MHV proteins. Any inhibitory effect of non-mutated coronavirus proteins on virus 
replication was investagted by plaque assay to measure virus titre. Judging from 
this Figure 4.47 the presence of some virus proteins could have been interfering 
with the virus replication but the mechanism by which they may inhibit virus 
infectivity is not clear. Several key questions remain to be answered: (i) why some 
coronavirus proteins are inhibiting virus infectivity and other proteins are increasing 
infectivity? (ii) why this effect is different between different viruses in the same 
family? For example, why M protein of SARS-CoV can suppress type I IFN (Lui et 
al., 2016) while M protein of HKU-1 does not (Siu et al., 2014) yet both are from the 
beta group in the coronaviridae family (iii) How can this be taken advantage of in 
developing antivirals? (described in chapter 4). 
Information pertaining to how the presence of coronavirus proteins at the time of 
infection interfers with virus replication has been limited but in the last few years’ 
studies has described the inhibitory and stimulatory effects of coronavirus proteins. 
N protein is well studied comparing with other coronavirus proteins in this respect. 
N protein is a multifunctional protein that can act as a RNA chaperone (Luo et al., 
2004; Zeng et al., 2008; Zhao et al., 2008; Zúñiga et al., 2007) and interact with 
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other proteins (Chen et al., 2002). Several studies have shown that presence of 
coronavirus N protein could increase infectivity of the virus (Cui et al., 2015; Pan et 
al., 2008). In this study, the hypothesis was based on this data in that if mutated 
coronavirus N proteins, selected by directed evolution, could have diverse effect 
and inhibit virus replication they may lead to their consideration as antiviral models. 
In order to select proposed dominant negative variants a library of variants was 
required. Directed evolution hasn’t proved to be a successful method to solve 
problems in protein engineering and metabolic engineering only, but also a 
powerful research tool for problems in protein structure, function and protein 
folding. In vitro directed evolution accelerates the process of natural selection 
however it requires the development of powerful high-throughput screening or 
selection methods. One of the most popular random mutagenesis methods is ep-
PCR. Ep-PCR is based on increasing of the overall error frequency of Taq DNA 
polymerase by changing some PCR conditions that can increase this error rate, 
e.g. the addition of Mn2+ can reduce the base pairing specificity (Beckman et al., 
1985). Two different ep-PCR protocols were tested here. The first protocol 
depended on combining different dNTP concentrations with the presence of Mn2+ 
but had the disadvantage of limited cloning efficiency. The second protocol 
depended on generating a library of variants by using different concentrations of 
Mn2+ to the PCR reaction buffer. The error rate was estimated for each library by 
sequencing and the library produced using 50 µM MnCl2 achieved 1-2 mutations 
per individual amino acid within the whole N sequence and had high cloning 
efficiency. Thus, a strategy was developed for rapidly generating a library of 
variants with high cloning efficiency, suitable for studying active sites for any MHV 
protein. This library was used to screen for trans-dominat mutations of the N 
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protein but preliminary data was first obtained on the role of singly selected N 
mutations as proof of principle. Investigation of the inhibitory effect of a set of 
mutated (including deleted) N variants, supplied in trans, showed a variety of 
effects on MHV replication from stimulation to inhibition. However, the mechanism 
by which mutated N protein may inhibit and block virus infectivity, which may be 
important for designing better screens, remains to be determined (described in 
chapter 5). 
Based on the data obtained by screening single mutations attempts at selection 
from libraries of N proteins with differing complexities was done. The initial “library” 
was a mixture of only two members, wild type N and mut38. After four rounds of 
selection with the two variants library, both the variant mut38 and WT N were still 
found in more or less equal numbers in 10 randomly selected clones. A second 
library was constructed from ten variants, all presvioulsy characterised at the 
individual level and examination of the complexity after 3 rounds of selection still 
showed a high diversity with little evidence of consistent selection occurring. It may 
be that effective selection requires many more rounds of selection than was 
possible in this study. A final attempt to select from a truly diverse ep-PCR library 
similarly failed to consistently demonstrate an emerging variant from this library 
after 4 rounds of selection and although changes in virus titre were observed albeit 
transiently, they were not significant (described in chapter 6). 
A last chapter detailed work on the more general topic of MHV protein purification, 
especially for proteins for which limited structural data exists as purified 
recombinant proteins with high solubility and stability are a prerequisite for any 
structure based antivirial strategy. In the field of protein expression several 
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previous attempts have been made to express reasonable amounts of the nsp16 
protein. An evaluation was done of the ability to express nsp16 protein with 
different expression hosts, media and induction times. The data improved on any 
previous work described but was still insufficient to progress this protein as a 
meaningful target for furhter study in this thesis (described in chapter 7). 
This thesis study illustrates that significant effect of coronavirus proteins acting in 
trans on virus infectivity can be observed. The individual steps of applying this 
finding to the isolation of new trans dominnat mutants were also put in place, that is 
creating sequence diversity by using ep-PCR, showing transfection into target 
cells, demonstrating co-infection with MHV and showing recovery of library variants 
from transfected and infected cells. However combining these parameters failed to 
achive the desired goal of a randomly selected mutant and the reagents and 
techniques established will required further work. The goal, if achieved, could lead 
the way to the desiegn of pan-coronavirus inhbiting agents with great potential for 
the control of the diseases caused by coronaviruses, both currently circulating and 
emerging.    
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Table 9.10. Coronavirus MHV-A59 protein sizes 
 
Protein Size  
(bp) 
Size  
(a.a) 
Size (kDa) 
With his tag 
Size (kDa) 
With SUMO tag 
Nsp3Pro 774 248 29 43.5 
Y-domain 1200 400 45.7 59.8 
Nsp5 909 303 34.2 48.7 
Nsp6 861 287 30.3 44.8 
Nsp7 267 89 10.9 25.4 
Nsp8 591 197 23 37.5 
Nsp9 330 110 13.3 27.8 
Nsp10 393 131 15 29.5 
Nsp12 2784 924 106 120 
Nsp12N 1902 364 43.3 57.8 
Nsp12C 1692 564 68.2 82.7 
Nsp16 900 300 34.3 48.8 
M protein 687 229 27.1 41.6 
N protein 1365 455 50.8 65.3 
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Figure 9.78. The sequence of SUMOStar tag protein. The SUMOStar tag contains a 6x 
His tag at the N-terminus. 
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Figure 9.79. Distribution of nucleotide mutations in 10 variants generated by ep-
PCR. Sequenced variants from 50µM MnCl2 library are aligned with wild type using 
Jalview software. 	  
 
	  	   201 
 
Figure 9.80. Distribution of nucleotide mutations in 10 variants generated by 
ep-PCR. Sequenced variants from 100µM MnCl2 library are aligned with wild type 
using Jalview software. 	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Figure 9.81. Distribution of amino acid mutations in 37 variants generated with ep-
PCR and subjected to plaque assay. Sequenced variants are aligned with wild type 
using Jalview software.	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